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   1	  
Summary	  
The	  effect	  of	  mesenchymal	  stem	  cells	  (MSC)	  on	  cancer	  progression	  is	  still	  a	  matter	  of	  debate.	  It	  is	  
increasingly	   appreciated	   that	   MSC	   can	   migrate	   towards	   the	   site	   of	   the	   primary	   tumor	   and	  
participate	   in	   tumor	   stroma	   formation,	   supporting	   tumor	   growth	   and	   priming	   cancer	   cells	   for	  
dissemination.	   Less	   is	   known	   about	   MSC	   or	   other	   stromal	   cells	   at	   the	   site	   of	   metastasis.	   Some	  
cancers	   show	   a	   strong	   tendency	   to	   metastasize	   to	   bone,	   a	   tissue	   of	   mesenchymal	   origin	   and	   a	  
prominent	  site	  of	  MSC.	  Recent	  reports	  have	  suggested	  that	  bone-­‐metastasizing	  cancers	  may	  mimic	  
the	  process	  of	  homing	  of	  hematopoietic	  stem	  cells	  to	  their	  bone	  niche,	  in	  which	  MSC	  play	  a	  crucial	  
role.	  With	   regard	   to	   the	   fact	   that	  MSC	   play	   an	   important	   role	   in	   cancer	   progression,	   I	   aimed	   to	  
dissect	  the	  interactions	  and	  the	  dynamics	  between	  tumor	  cells	  and	  MSC	  in	  metastasis	  formation.	  	  
In	  order	  to	  understand	  the	  role	  of	  MSC	  in	  metastasis	  formation,	  I	  investigated	  primary	  human	  bone	  
marrow	  MSC	  with	  established	  cancer	  cell	  lines	  able	  to	  metastasize	  to	  bone	  in	  a	  transwell	  migration	  
assay.	   Combining	   this	   experimental	   set	   up	   with	   impedance	   measurements	   allowed	   quantitative	  
analysis	   of	   cancer	   cell	   migration	   towards	   MSC	   in	   a	   time-­‐resolved	   fashion	   and	   high-­‐throughput	  
format.	   This	   enabled	   an	   unbiased	   approach	   taking	   the	   complete	   secretome	   of	   MSC	   into	  
consideration.	  	  
The	  results	  showed	  that	  MSC	  induced	  a	  rapid	  migration	  response	  of	  prostate	  and	  breast	  cancer	  cell	  
lines.	  In	  contrast	  to	  this	  finding,	  fibroblast	  cell	  lines	  were	  not	  able	  to	  induce	  a	  comparable	  migration	  
response	  indicating	  specific	  MSC	  –	  cancer	  cell	  crosstalk.	  In	  order	  to	  identify	  the	  factors	  stimulating	  
cancer	   cell	   migration,	  MSC	   cell	   culture	   supernatant	   was	   then	   purified	   by	   size	   exclusion	   and	   ion	  
exchange	   chromatography.	   This	   was	   followed	   by	   mass	   spectrometry	   as	   well	   as	   antibody	   array	  
analysis	   of	   the	   chromatographic	   fractions	   inducing	   migration.	   With	   this	   approach	   I	   identified	  
extracellular	  matrix	  proteins	  to	  be	  the	  main	  drivers	  of	  rapid	  cancer	  cell	  migration	  requiring	  as	  little	  
as	  two	  hours	  for	  a	  full	  migration	  response.	  These	  factors	  included	  type	  I	  and	  III	  collagen,	  fibronectin	  
and	   Laminin	   421,	   which	   were	   confirmed	   using	   recombinant	   proteins.	   RNAi	   experiments	   showed	  
that	  the	  response	  to	  these	  molecules	  required	  the	  extracellular	  matrix	  receptor	  β1	   integrin	   in	  the	  
migrating	  cancer	  cells.	  
This	  study	  shows	  that	  MSC	  are	  very	  potent	  mediators	  of	  cancer	  cell	  migration,	  based	  on	  diffusible	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Zusammenfassung	  
Welche	   Rolle	   mesenchymale	   Stammzellen	   (MSC)	   in	   Krebserkrankungen	   spielen,	   ist	   weitgehend	  
ungeklärt.	  Es	  wird	  jedoch	  zunehmend	  davon	  ausgegangen,	  dass	  MSC	  zu	  Tumoren	  wandern	  können,	  
dort	   an	   der	   Bildung	   des	   Tumorstromas	   beteiligt	   sind	   und	   dadurch	   Tumorwachstum	   und	   die	  
Streuung	   der	   Tumorzellen	   unterstützen.	   Wie	   MSC	   konkret	   am	   Ort	   der	   Metastasen	   wirken,	   ist	  
dagegen	   weniger	   bekannt.	   Manche	   Krebserkrankungen	   bilden	   besonders	   häufig	   Metastasen	   in	  
Knochen,	   einem	   Gewebe	  mesenchymalen	   Ursprungs	   und	   wichtiger	   Sitz	   zahlreicher	  MSC.	   Zudem	  
mehren	   sich	   die	   Vermutungen,	   dass	   metastasierende	   Krebszellen	   den	   physiologischen	  
Einnistungsprozess	   hämatopoetischer	   Stammzellen	   in	   das	   Knochenmark	   nachahmen	   könnten.	   Da	  
dieser	   Einnistungsprozess	   von	  MSC	   beeinflusst	   wird	   und	   auf	   Grund	   ihrer	   Rolle	   in	   Tumor-­‐Stroma	  
Interaktionen,	   habe	   ich	   die	  Wechselwirkungen	   zwischen	  MSC	   und	  metastasierenden	   Krebszellen	  
untersucht.	  	  
Um	  zu	  verstehen,	  welche	  Rolle	  MSC	  bei	  der	  Entstehung	  von	  Metastasen	  spielen,	  wurden	  primäre	  
MSC	  aus	  dem	  Knochenmark	  isoliert	  und	  in	  einem	  Migrationsassay	  analysiert,	  wie	  sie	  Migration	  von	  
Krebszelllinien,	   von	   denen	   bekannt	   ist,	   dass	   sie	   Knochenmetastasen	   bilden,	   auslösen.	   Die	  
Verwendung	  eines	   impedanzbasierten	  Assay	   erlaubte	  quantitative	  und	   zeitaufgelöste	  Messungen	  
in	  einem	  Hochdurchsatzformat	  zur	  funktionalen	  Analyse	  des	  gesamten	  MSC	  Sekretoms.	  	  
Meine	   Ergebnisse	   zeigen,	   dass	   MSC	   eine	   schnelle	   Migration	   von	   Brust-­‐	   und	   Prostatakrebszellen	  
auslösen	   können.	   Im	   Gegensatz	   hierzu	   waren	   Fibroblastenzelllinien	   dazu	   nicht	   in	   der	   Lage,	   was	  
darauf	  schließen	  lässt,	  dass	  die	  beobachteten	  Wechselwirkungen	  MSC	  spezifisch	  sind.	  
Um	   diejenigen	   Faktoren	   zu	   identifizieren,	   die	   für	   die	   Induzierung	   der	   Krebszellmigration	  
verantwortlich	   waren,	   wurde	   der	   MSC	   Zellkulturüberstand	   mittels	   Größen-­‐	   sowie	  
Ionenaustauschchromatographie	   aufgereinigt.	   Chromatographiefraktionen,	   die	   Krebszellmigration	  
auslösten,	   wurden	   anschließend	   mittels	   Massenspektrometrie	   und	   Antikörper-­‐Array	   analysiert.	  
Dieses	   Verfahren	   erlaubte	   es	   mir,	   extrazelluläre	   Matrixproteine	   als	   diejenigen	   Faktoren	   zu	  
identifizieren,	   welche	   die	   beobachtete	   Krebszellmigration	   auslösten.	   Zu	   diesen	   Matrixproteinen	  
zählten	   Typ	   I	   Kollagen	   und	   Typ	   III	   Kollagen,	   Fibronektin	   und	   Laminin	   421,	   deren	  
migrationsinduzierende	  Wirkung	   mittels	   rekombinanter	   Proteine	   bestätigt	   werden	   konnte.	   RNAi	  
Experimente	   konnten	   zudem	   aufzeigen,	   dass	   die	   beobachtete	   Migration	   der	   Krebszelllinien	  
abhängig	  war	  vom	  Zellrezeptor	  β1	  Integrin.	  
Meine	   Studien	   konnten	   somit	   belegen,	   dass	   MSC	   mittels	   extrazellulärer	   Matrixproteine	   und	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1. Introduction	  
1.1. Cancer	  progression	  and	  the	  tumor	  microenvironment	  
Cancer	  describes	  a	  pathology	  in	  which	  normal	  cells	  acquire	  the	  characteristics	  of	  uncontrolled	  and	  
chronic	  proliferation.	  During	   the	  progression	  of	   cancer,	   the	   cancerous	   cells	  undergo	  an	  evolution	  
from	  proliferative	  to	  tumorigenic	  and	  finally	  malignant	  state.	  Malignant	  cells	  then	  grow	  beyond	  the	  
regular	  tissue	  boundaries,	  invade	  surrounding	  tissue	  and	  finally	  spread	  throughout	  the	  body.	  	  
Although	   there	   are	   a	   large	   variety	   of	   different	   types	   of	   tumors,	  most	   forms	   of	   cancers	   seem	   to	  
undergo	   similar	   changes	   in	   cellular	   characteristics.	   These	   have	   been	   termed	   the	   hallmarks	   of	  
cancer1,2.	  They	  include	  self-­‐sufficiency	  in	  growth	  signals,	  insensitivity	  to	  anti-­‐growth	  signals,	  evasion	  
of	  programmed	  cell	  death,	  sustained	  angiogenesis,	  limitless	  replicative	  potential,	  tumor	  promoting	  
inflammation,	   reprogrammed	   energy	  metabolism	   and,	   lastly,	   tissue	   invasion	   and	  metastasis.	   The	  
reason	   why	   cancer	   pathologies	   do	   differ	   and	   form	   the	   complexity	   observed	   when	   comparing	  
different	  cancer	  types	  or	  cancer	  patients	  is	  that	  although	  most	  cancers	  undergo	  these	  hallmarks	  of	  
cancer,	   they	   do	   so	   based	   on	   different	   genetic	   or	   environmental	   reasons	   and	   in	   varying	  
chronological	  order.	  	  
Additional	  complexity	  of	  the	  disease	  arises	  from	  the	  fact	  that	  a	  tumor	  is	  not	  a	  homogenous	  tissue	  
but	  comprises	  a	  heterogeneous	  cell	  population	  with	  differing	  plasticity,	  including	  cancer	  stem	  cells.	  
Furthermore,	   tumors	   are	   surrounded	   by	   a	   complex	   tumor	   microenvironment,	   which	   is	   build	   up	  
during	  the	  course	  of	  the	  multistep	  tumorigenesis	  described	  above3.	  This	  tumor	  microenvironment,	  
also	  called	  tumor	  stroma,	  is	  made	  up	  of	  numerous	  cells	  that	  are	  recruited	  by	  and	  interact	  with	  the	  
tumor	   cells.	   These	   cellular	   interactions	   are	   reciprocal,	   allowing	   both	   the	   tumor	   cells	   and	   the	  
surrounding	   tissue	   to	   transform	   from	  normal	   tissue	   to	  high-­‐grade	  malignancies4.	   The	   cells	   of	   the	  
tumor	  stroma	  include	  endothelial	  cells	  and	  mesenchymal	  pericytes	  aiding	  in	  angiogenesis,	  immune	  
inflammatory	   cells	   facilitating	   tumor	   promoting	   inflammation	   and	   various	   stromal	   cells	   of	  
mesenchymal	  origin,	  such	  as	  cancer	  associated	  fibroblasts	  (CAF).	  These	  stromal	  cells	  supply	  growth	  
factors	   and	   cytokines	   to	   the	   cancer	   cells	   as	  well	   as	   extracellular	  matrix	   proteins	   to	   facilitate	   the	  
framework	  of	  the	  tumor	  microenvironment.	  	  
The	  final	  step	  of	  cancer	  progression	  is	  the	  spread	  of	  tumor	  cells	  from	  the	  primary	  tumor	  to	  distant	  
metastatic	   sites.	   This	   step	   is	   normally	   responsible	   for	   most	   of	   cancer	   lethality	   with	   metastatic	  
tumor	  growth	  disrupting	  the	  function	  of	  vital	  organs	  such	  as	  lungs,	  liver	  and	  bone	  marrow.	  
In	   order	   for	   cancer	   cells	   to	   successfully	   metastasize	   to	   distant	   organs	   they	   need	   to	   invade	   the	  
surrounding	   tissue	  of	   the	  primary	   tumor	  and	  then	   intravasate	   into	   lymphatic	  or	  blood	  vessels	   for	  
dissemination	   throughout	   the	  body.	  Once	   the	   circulating	   cancer	   cells	   have	   reached	   the	  potential	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site	  of	  metastasis	  they	  need	  to	   interact	  successfully	  with	  the	  microenvironment	  at	  the	  metastatic	  
site.	   Paracrine	   factors	   from	   the	   microenvironment	   facilitate	   adherence	   to	   the	   vessel	   wall	   and	  
extravasation	  into	  the	  surrounding	  tissue.	  The	  microenvironment	  also	  helps	  facilitate	  proliferation,	  
evasion	   of	   apoptosis	   and	   angiogenesis;	   all	   contributing	   to	   the	   formation	   of	   a	   new	   tumor5.	   This	  
essential	   requirement	   for	   cancer	   cells	   to	   closely	   interact	  with	   their	  metastatic	   surrounding	   is	   the	  
reason	  why	  metastasis	  formation	  is	  a	  non-­‐random	  event	  and	  why	  cancers	  differ	  in	  their	  propensity	  
to	  metastasize	  to	  certain	  organs.	  This	  phenomenon	  has	  been	  termed	  the	  ‘seed	  and	  soil’	  hypothesis,	  
describing	  that	  metastasizing	  cancer	  cells	  and	  the	  site	  of	  metastasis	  need	  to	  match	  and	  contradicts	  
the	  opposing	  view	  that	  metastatic	  dissemination	  occurs	  solely	  through	  mechanical	   factors	  caused	  
by	  the	  anatomical	  structure	  of	  the	  vasculature6-­‐8.	  	  
1.2. Breast	  and	  prostate	  cancer	  metastasize	  to	  bone	  
Breast	   and	   prostate	   cancer	   are	   both	   the	   second	   most	   common	   cancer	   in	   females	   and	   males	  
respectively.	  For	  both	  cancers	  the	  skeleton	  is	  the	  preferred	  site	  of	  metastasis	  in	  over	  70%	  of	  breast	  
and	  prostate	  cancer	  patients.	  The	  majority	  of	  bone	  metastases	  are	  found	  in	  the	  highly	  vascularized	  
metaphyseal	   bone	   at	   the	   end	   of	   long	   bones,	   ribs	   and	   vertebrae9.	   Once	   the	   tumors	   have	  
metastasized	  to	  the	  bone	  they	  cause	  severe	  morbidity	  and	  are	  considered	   incurable,	  because	  the	  
homeostasis	  of	  bone	  formation	  and	  bone	  degradation	  becomes	  out	  of	  balance	  leading	  to	  a	  loss	  of	  
bone	  integrity	  resulting	  in	  skeletal	  complications10.	  
The	  healthy	  bone	  microenvironment	  is	  made	  up	  of	  mineralized	  extracellular	  matrix	  and	  the	  two	  key	  
cell	   types,	   osteoclasts	   and	  osteoblasts	   (Figure	  2).	  Osteoclasts,	  which	   are	  of	   hematopoietic	   origin,	  
are	  able	  to	  secrete	  acid	  and	  a	  number	  of	  proteases	  demineralizing	  and	  degrading	  the	  bone	  matrix.	  
Osteoblasts	  on	  the	  other	  hand	  are	  of	  mesenchymal	  origin	  and	  are	  responsible	  for	  the	  secretion	  of	  
the	   organic	   matrix,	   which	   is	   then	   calcified	   to	   form	   the	   mineralized	   bone	   tissue.	   Not	   only	   do	  
osteoblasts	  and	  osteoclasts	  counteract	  each	  other	   functionally,	  but	   they	  also	   regulate	  each	  other	  
with	  osteoblasts	  enhancing	  osteoclast	  maturation	  and	  activation.	  This	  occurs	  via	  the	  secretion	  of	  a	  
number	  of	  factors	  including	  macrophage	  colony	  stimulating	  factor	  (M-­‐CSF)	  aiding	  in	  maturation	  of	  
progenitor	   cells	   as	  well	   as	   receptor	   activator	   of	   nuclear	   factor	   (NF)-­‐κB	   ligand	   (RANKL)	   leading	   to	  
activation	  of	  osteoclasts11.	   In	  contrast,	  osteoclast	  maturation	  can	  also	  be	   inhibited	  by	  osteoblasts	  
via	  osteoprodegrin	  (OPG)12.	  Osteoblast	  maturation	  is	  also	  tightly	  regulated	  by	  transforming	  growth	  
factor	  β	  (TGF-­‐β)	  or	  bone	  morphogenetic	  proteins	  (BMP),	  which	  are	  stored	  in	  the	  mineralized	  bone	  
matrix	  and	  can	  be	  released	  from	  it	  upon	  osteoclast	  activity.	  	  
This	  finely	  tuned	  cycle	  of	  osteoblast	  as	  well	  as	  osteoclast	  maturation	  and	  function	  is	  disrupted	  upon	  
metastasis	  formation.	  In	  general,	  bone	  metastasis	  can	  be	  classified	  as	  predominantly	  osteolytic	  or	  
osteoblastic13.	   Breast	   cancer	   induces	   mainly	   osteolytic	   lesions	   in	   which	   bone	   tissue	   is	   lost	   and	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patients	   experience	   severe	   pain,	   pathological	   fractures	   and	   spinal	   cord	   compression.	   Prostate	  
cancer	   on	   the	   other	   hand	   induces	  mainly	   osteoblastic	   lesions	   with	   excessive	   bone	   formation	   of	  
poor	  quality,	  causing	  pathological	  fractures14.	  	  
The	   progression	   of	   tumor	   growth	   in	   bone	   metastasis	   depends	   on	   the	   reciprocal	   interaction	  
between	   the	   metastasizing	   cancer	   cells	   with	   osteoblasts	   and	   osteoclasts	   in	   the	   bone	  
microenvironment.	   Cancer	   cells	   can	   secrete	   stimulating	   factors	   such	   as	   parathyroid	   hormone	  
related	   peptide	   (PTHRP),	   enhancing	   osteoclast	   activity15,	   or	   endothelin-­‐1,	   inducing	   osteoblast	  
proliferation16.	  This	  leads	  to	  enhanced	  bone	  turnover	  and	  therefore	  an	  enhanced	  release	  of	  potent	  
growth	  factors	  from	  the	  bone	  matrix.	  These	  can	  then	  feed	  back	  to	  the	  tumor	  to	  increase	  cancer	  cell	  
proliferation.	  This	  phenomenon	  has	  been	  termed	  the	  ‘vicious	  cycle	  of	  bone	  metastasis’10.	  	  
Bone	  tissue	  together	  with	   immobilized	  growth	  factors	  are	  an	  extremely	  fertile	  soil	   for	  tumor	  cells	  
once	   they	   have	   gained	   a	   foothold	   in	   the	   bone	  microenvironment,	   rendering	   this	   stage	   of	   cancer	  
incurable.	   The	   focus	   must	   therefore	   lie	   on	   understanding	   how	   initial	   metastases	   are	   formed	   in	  
order	  to	  prevent	  them	  in	  a	  clinical	  setting.	  The	  problem	  is	  that	  although	  the	  processes	  occurring	  in	  
bone	  metastasis	  growth	  are	  understood	  to	  a	  certain	  degree,	  the	  question	  of	  how	  tumor	  cells	  gain	  
an	   initial	   foothold	   in	  the	  bone	  remains	  unresolved.	  One	   idea	  which	   is	  currently	  being	  discussed	  is	  
the	  concept	  of	  the	  pre-­‐metastatic	  niche17.	  It	  describes	  a	  phenomenon	  in	  which	  the	  primary	  tumor	  is	  
able	   to	   prepare	   the	   site	   of	   metastasis	   for	   subsequent	   colonization.	   This	   could	   be	   potentially	  
mediated	  by	  endocrine	  factors	  secreted	  by	  primary	  tumor	  cells	  rendering	  the	  bone	  marrow	  more	  
susceptible	   for	   circulating	   tumor	   cells.	   PTRHP,	   for	   example,	   is	   produced	   by	   a	   number	   of	   primary	  
tumors	   and	   at	   the	   distant	   site	   of	   the	   bone	   it	   enhances	   bone	   resorption	   and	   the	   release	   of	   the	  
chemokine	  CCL2	  by	  osteoblasts	  and	  endothelial	  cells18.	  CCL2,	  in	  turn,	  is	  known	  for	  its	  proliferative19	  
and	   chemotactic20	   effect	   on	   prostate	   cancer	   cells.	   Another	   potential	   mechanism	   through	   which	  
cancer	   cells	   could	   initiate	   colonization	   of	   the	   bone	   is	   by	   mimicking	   the	   homing	   process	   of	  
hematopoietic	  stem	  cells	  (HSC)	  21,22.	  This	  process,	  in	  which	  HSC	  present	  in	  the	  blood	  circulation	  are	  
guided	   into	   their	   stem	   cell	   niche	   in	   the	   bone,	   is	   regulated	   by	   chemotactic	   gradients	   secreted	   by	  
MSC	  also	  residing	  in	  the	  HSC	  stem	  cell	  niche21,22.	  Although	  these	  mechanisms	  appear	  to	  play	  a	  role,	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Figure	  1:	  Steps	  in	  cancer	  progression	  and	  bone	  metastasis	  formation.	  
A:	   DNA	   damage	   induces	   cellular	   transformation	   of	   normal	   cells	   to	   cancerous	   cells	   leading	   to	   unbalanced	  
cancer	   cell	   growth.	   B:	   During	   tumor	   growth,	   MSC	   are	   recruited	   to	   the	   primary	   tumor,	   participate	   in	   the	  
formation	  of	  the	  tumor	  stroma	  and	  differentiate	  into	  numerous	  stromal	  cells.	  C:	  These	  stromal	  cells	  enable	  
enhanced	   growth	   and	   vascularization	   of	   the	   tumor	   through	   secretion	   of	   growth	   and	   angiogenic	   factors.	  
D:	  Invasion	   of	   tumor	   cells	   into	   the	   surrounding	   tissue	   is	   a	   three-­‐step	   process	   requiring	   attachment	   of	   the	  
cancer	  cells	  to,	  proteolytic	  digestion	  of	  and	  locomotion	  through	  the	  extracellular	  matrix	  of	  the	  tumor	  stroma	  
and	   the	   adjacent	   tissue.	   This	   is	   enhanced	   by	   MSC-­‐derived	   chemokines.	   Tumor	   cells	   can	   then	   enter	   the	  
circulation	   through	   thin-­‐walled	   venules	   of	   the	   blood	   or	   lymphatic	   system.	   E:	   Transport	   of	   tumor	   cells	  
throughout	  the	  body.	  F:	  Tumor	  cells	  become	  entrapped	  in	  capillaries	  and	  sinusoids	  of	  the	  bone	  marrow	  and	  
adhere	   to	   endothelial	   cells.	  G:	   Adhered	   cancer	   cells	   extravasate	   past	   the	   endothelial	   cells	   into	   the	   bone	  
marrow	   space	   along	   gradients	   of	   chemotactic	   factors	   secreted	   by	   cells	   of	   the	   bone	   marrow	   niche.	   This	  
extravasation	  might	  be	  very	  similar	  to	  the	  homing	  process	  of	  hematopoietic	  stem	  cells	  into	  the	  bone	  marrow	  
niche.	   In	   this	   process	   (described	   in	   more	   detail	   in	   Figure	   2)	   the	   chemotactic	   gradient	   attracting	   the	  
hematopoietic	  stem	  cells	   is	  formed	  by	  the	  chemokine	  CXCL12.	  CXCL12	  is	  secreted	  by	  various	  MSC	  including	  
CXCL12	  abundant	   reticular	   cells	   (CAR)	   and	  Nestin+	  MSC.	   It	   is	   still	   a	  matter	  of	   debate	  which	   further	   factors,	  
secreted	  by	  MSC	  or	  other	   cells,	   are	   also	   involved	   in	   cancer	   cell	   extravasation	   into	   the	  bone	  marrow	  niche.	  
H:	  Once	  the	  metastasizing	  cancer	  cells	  have	  gained	  a	  foothold	  in	  the	  bone,	  metastatic	  tumor	  growth	  induces	  
enhanced	   remodeling	   of	   bone	   tissue	   by	   bone	   degrading	   osteoclasts	   and	   bone	   forming	   osteoblasts.	   This	  
causes	  the	  release	  of	  growth	  factors	  previously	  entrapped	  in	  the	  calcified	  bone	  matrix	  further	  driving	  tumor	  
growth.	  This	  phenomenon	  is	  called	  the	  ‘vicious	  cycle	  of	  bone	  metastasis’.	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1.3. Mesenchymal	  stem	  cells	  in	  cancer	  
1.3.1. Mesenchymal	  stem	  cells	  	  
Mesenchymal	  stem	  cells	  (MSC),	  also	  called	  mesenchymal	  stromal	  cells,	  were	  initially	  isolated	  from	  
human	  bone	  marrow23	  and	  later	  on	  from	  multiple	  tissues	  including	  synovia,	  muscle,	  fat,	  dermis	  and	  
amniotic	   tissue.	   MSC	   are	   best	   known	   for	   their	   ability	   to	   differentiate	   into	   many	   tissues	   of	  
mesodermal	   origin,	   such	   as	   bone,	   cartilage	   or	   connective	   tissue24,	   as	   well	   as	   for	   their	  
immunomodulatory	   characteristics25.	   Due	   to	   their	   diverse	   differentiation	   potential,	   the	   relative	  
ease	  of	  their	   isolation	  from	  multiple	  tissues	  and	  the	  fact	  that	  they	  can	  be	  expanded	   in	  vitro,	  MSC	  
are	  regarded	  as	  a	  promising	  tool	  for	  clinical	  applications.	  This	   is	  why	  MSC	  are	  currently	  subject	  of	  
over	  300	  clinical	  trials	  (www.clinicaltrials.gov)	  although	  their	  true	  identity	  is	  still	  a	  matter	  of	  debate.	  
MSC	  cultivated	  in	  vitro	  are	  currently	  defined	  by	  their	  plastic	  adherent	  growth,	  their	  differentiation	  
potential	  under	  specific	  conditions	   in	  vitro,	  and	  a	  panel	  of	  surface	  markers	  which	  should	  either	  be	  
expressed	   	   (CD73,	  CD90,	  CD105)	  or	  not	  expressed	   (CD34,	  CD45,	  CD14	  or	  CD11b,	  CD79a	  or	  CD19,	  
HLA-­‐DR),	  as	  proposed	  by	  the	  International	  Society	  of	  Cell	  Therapy26.	  Nonetheless,	  these	  criteria	  are	  
not	  sufficient	  and	  fail	  to	  clearly	  define	  MSC	  and	  distinguish	  them	  from	  other	  stromal	  cells	  such	  as	  
fibroblasts.	  Furthermore,	  the	  in	  vivo	  identity	  of	  MSC	  remains	  unknown27-­‐29.	  	  
Not	   only	   are	   MSC	   elusive	   regarding	   their	   true	   identity,	   but	   they	   also	   show	   a	   high	   degree	   of	  
complexity	  regarding	  their	  functional	  properties,	  of	  which	  their	  differentiation	  ability	  is	  only	  part	  of	  
their	  capabilities.	  
First	  and	  foremost,	  MSC	  have	  the	  ability	  to	  exit	  their	  niche	  and	  migrate	  to	  sites	  of	  inflammation	  or	  
tissue	   damage	   allowing	   them	   to	   participate	   in	   tissue	   regeneration29.	   Once	   at	   the	   site	   of	   tissue	  
damage,	  MSC	  can	  differentiate	  into	  a	  number	  of	  potentially	  required	  cell	  types.	  More	  importantly,	  
MSC	  act	  as	  trophic	  mediators	  via	  the	  secretion	  of	  bioactive	  factors;	  initiating,	  aiding	  and	  enhancing	  
the	   regeneration	   process.	   This	   is	   achieved	   by	   the	   inhibition	   of	   apoptosis	   and	   fibrosis,	   immune	  
modulation,	  chemoattraction	  of	   immune	  cells	   to	   the	  site	  of	  damage,	  enhancing	  angiogenesis	  and	  
finally	   stimulation	   of	   mitosis	   as	   well	   as	   differentiation	   of	   tissue	   specific	   progenitor	   cells30.	   Anti-­‐
apoptotic	  effects	  of	  MSC	  were	  described	   in	  mouse	  models	  of	   ischemia	  or	  acute	  kidney	   injury	  and	  
the	   authors	   of	   these	   studies	   could	   show	   that	   these	   effects	   were	   based	   on	  MSC-­‐derived	   factors	  
including	   VEGF,	   HGF,	   bFGF	   or	   TGF-­‐β	   amongst	   others31,32.	   HGF	   and	   bFGF	   not	   only	   have	   an	   anti-­‐
apoptotic	   effect	   but	   also	   are	   important	   in	   the	   inhibition	   of	   fibrosis33,34.	   The	   immune	  modulatory	  
properties	  of	  MSC	  were	  initially	  shown	  in	  studies	  describing	  the	  inhibition	  of	  T-­‐cell	  proliferation35.	  
Since	   then,	  MSC	  were	   shown	   to	  modulate	  B-­‐cell	   proliferation36,37,	   inhibit	  NK	   cell	   activation38	   and	  
alter	   the	   cytokine	   secretion	   profile	   of	   macrophages39	   and	   dendritic	   cells40.	   All	   of	   these	   studies	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showed	  an	  important	  role	  of	  prostaglandin	  2	  as	  well	  as	  TGF-­‐β	  and	  HGF	  in	  regard	  to	  T-­‐	  cells	  and	  TGF-­‐
β	   in	   regard	   to	  NK	  cells.	   It	   is	   known	  as	  well	   that	  MSC	  can	   secrete	  a	  vast	  array	  of	   chemoattractive	  
factors	  which	  allow	  MSC	  to	  further	  aid	  in	  tissue	  regeneration	  or	  remodeling	  by	  attracting	  other	  cells	  
such	   as	  monocytes	   or	   hematopoietic	   and	   endothelial	   progenitor	   cells	   to	   the	   site	   of	   injury29,41.	   In	  
addition	   to	   attracting	   endothelial	   precursor	   cells,	  MSC	  were	   also	   shown	   to	   secrete	   a	   number	   of	  
angiogenic	   factors	   including	   bFGF,	   VEGF,	  MCP-­‐1,	   IL-­‐642.	   Finally,	   studies	   have	   described	   that	  MSC	  
stabilize	   vasculature	   formation	   in	   vitro43	   and	   in	   vivo44.	   Based	   on	   their	   abilities	   and	   complex	  
secretome,	   MSC	   can	   therefore	   be	   seen	   as	   powerful	   mediators	   in	   processes	   related	   to	   tissue	  
inflammation	  and	  damage.	  
1.3.2. Mesenchymal	  stem	  cells	  in	  tumor	  stroma	  formation	  and	  cancer	  progression	  
Studies	  have	  shown	  that	  bone	  marrow	  MSC	  migrate	  towards	  different	  types	  of	  primary	  tumors	  and	  
integrate	   into	   the	   tumor	   microenvironment45-­‐47.	   These	   tumors	   have	   been	   described	   as	   sites	   of	  
chronic	   inflammation,	   constant	   tissue	   remodeling	   and	   wound	   healing.	   Indeed,	   many	   of	   those	  
inflammatory	   factors	   found	   at	   sites	   of	   tissue	   damage	   can	   also	   be	   localized	   to	   tumors.	   Hence	   it	  
seems	   plausible	   that	   the	   same	   tropism	   that	   guides	   MSC	   to	   the	   sites	   of	   tissue	   damage	   and	  
inflammation	  is	  also	  believed	  to	  initiate	  the	  observed	  migration	  of	  MSC	  towards	  tumors48,49.	  
There	  has	  been	  an	  ongoing	  discussion	  what	  effects	  the	  MSC	  exert	  once	  they	  reach	  the	  site	  of	  the	  
tumor.	   Although	   there	   are	   studies	   showing	   anti-­‐tumor	   effects	   of	   MSC50,51,	   a	   growing	   body	   of	  
evidence	  suggests	  that	  MSC	  promote	  cancer	  progression	  in	  many	  cases.	  They	  potentially	  do	  so	  by	  
immune	   response	   suppression52,	   stimulation	   of	   angiogenesis46	   and	   proliferation53,	   inhibition	   of	  
apoptosis54	  as	  well	  as	  enabling	  enhanced	  extravasation,	  migration	  and	  metastasis4.	  Based	  on	  their	  
multi-­‐lineage	   differentiation	   potential,	   they	   can	   furthermore	   differentiate	   into	   tumor	   stroma	  
associated	   cells	   including	   pericytes,	   cancer	   associated	   fibroblasts	   and	   myofibroblasts	   which	  
themselves	   can	   effect	   cancer	   progression55-­‐57.	   Often,	   these	   described	   interactions	   between	   the	  
tumor	  and	   its	  stroma	  are	  reciprocal,	  with	  cancer	  cells	  and	  MSC	  regulating	  each	  other	  and	  by	   this	  
further	  driving	  the	  progression	  of	  cancer4,58	  
Introduction	  
	  
	   9	  
1.3.3. Mesenchymal	  stem	  cells	  and	  their	  bone	  marrow	  niche	  
Although	  the	  in	  vivo	  identity	  of	  MSC	  is	  still	  a	  matter	  of	  debate29,	  it	  is	  believed	  that	  MSC	  found	  in	  the	  
bone	  marrow	  reside	  in	  a	  niche	  termed	  the	  bone	  marrow	  stem	  cell	  niche	  or	  hematopoietic	  stem	  cell	  
niche.	   What	   this	   niche	   actually	   looks	   like	   and	   how	   it	   functions	   is	   still	   not	   fully	   understood.	  
Regardless	   of	   the	   unanswered	   questions,	   this	   commonly	   accepted	   concept	   of	   a	   bone	   stem	   cell	  
niche	  describes	  an	  area	  in	  the	  bone	  marrow	  in	  which	  mesenchymal	  and	  hematopoietic	  stem	  cells	  
localize	  and	  interact59.	  HSC	  are	  multi-­‐potent	  progenitor	  cells	  that	  give	  rise	  to	  all	  mature	  blood	  and	  
various	   immune	   cells60.	   Tracing	   experiments	   with	   HSC	   revealed	   that	   they	   localize	   to	   the	   bone	  
endosteum	  lined	  by	  osteoblasts	  and	  additionally	  localize	  close	  to	  sinusoidal	  endothelium61,62.	  These	  
findings	   initiated	   the	   idea	   of	   multiple	   niches	   in	   the	   bone,	   including	   a	   so-­‐called	   endosteal	   and	   a	  
perivascular	   niche.	   Nonetheless,	   a	   clear	   distinction	   of	   separate	   niches	   seems	   problematic	   as	  
multiple	  cellular	  components	  of	  either	  niche	  are	  found	  in	  the	  other63.	  It	  also	  needs	  to	  be	  noted	  that	  
HSC	  are	  believed	  to	  change	  their	  localization	  in	  the	  niche	  in	  response	  to	  stress,	  making	  the	  concept	  
of	  the	  HSC	  niche	  even	  more	  complex64.	  For	  the	  sake	  of	  simplicity,	  here	  the	  bone	  marrow	  niche	  will	  
be	  considered	  as	  one	  entity	  (Figure	  2).	  	  
The	   bone	   marrow	   stem	   cell	   niche	   contains	   a	   number	   of	   cell	   types	   with	   functional	   importance.	  
Among	  these	  are	  osteoblasts	  which	  line	  the	  bone	  endosteum	  and	  can	  be	  found	  in	  close	  proximity	  
to	   HSC	   under	   physiological	   conditions65	   and	   after	   bone	   marrow	   transplantation66.	   Osteoblasts	  
secrete	  several	  factors	  including	  the	  extracellular	  matrix	  (ECM)	  protein	  osteopontin,	  binding	  to	  HSC	  
via	   β1	   integrin	   resulting	   in	   enhanced	  HSC	   quiescence
67.	   Furthermore,	   they	   secret	   CXCL12	   and	  N-­‐
cadherin	   involved	   in	  HSC	  maintenance	  and	   retention	  as	  well	   as	   angiopoetin	  1,	  membrane	  bound	  
stem	  cell	  factor	  and	  thrombopoietin	  which	  aid	  in	  regulation	  of	  HSC	  quiescence68,69.	  
The	  vasculature	  of	  the	  bone	  marrow	  is	  comprised	  of	  sinusoids,	  which	  are	  lined	  by	  a	  special	  type	  of	  
endothelial	  cells	  termed	  bone	  marrow	  sinusoidal	  endothelial	  cells	  (BMSEC).	  These	  are	  fenestrated	  
and	  have	  a	  marginal	  basement	  membrane	  with	  minimal	  pericyte	  coverage.	  Sinusoids	  are	   in	  close	  
proximity	   to	   mesenchymal	   reticular	   cells	   and	   are	   embedded	   in	   extracellular	   matrix	   proteins	  
secreted	   by	   this	   subpopulation	   of	   MSC.	   In	   addition	   to	   acting	   as	   a	   barrier	   between	   niche	   and	  
vasculature,	   it	   has	   been	   suggested	   that	   BMSEC	  might	   influence	   HSC,	   based	   on	   co-­‐localization	   of	  
these	  cells70.	  Nonetheless,	  it	  is	  still	  not	  clear	  whether	  BMSEC	  have	  a	  direct	  influence	  on	  HSC,	  which	  
is	  distinct	  from	  the	  reticular	  cells	  and	  the	  general	  surrounding71.	  	  
MSC	  are	  the	  major	  player	  in	  the	  bone	  marrow	  stem	  cell	  niche.	  For	  one,	  MSC	  in	  the	  endosteum	  can	  
act	  as	  progenitor	  cells	  of	  the	  functionally	  important	  osteoblasts.	  This	  could	  be	  shown	  for	  a	  subclass	  
of	   MSC	   termed	   Nestin+	   MSC.	   Furthermore,	   these	   cells	   not	   only	   have	   osteogenic	   differentiation	  
potential	  but	  also	  express	  high	  levels	  of	  HSC	  maintenance	  factor	  transcripts	  including	  CXCL12,	  SCF,	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angiopoetin	   1,	   IL-­‐7,	   vascular	   cell	   adhesion	   molecule	   1	   (VCAM1)	   and	   osteopontin63.	   A	   further	  
subclass	  of	  MSC	  found	  residing	  close	  to	  sinusoids	  and	  expressing	  high	  amounts	  CXCL12	  are	  termed	  
CXCL12	   abundant	   reticular	   (CAR)	   cells.	   CAR	   cells	   actively	   regulate	   HSC	   mobilization	   into	   the	  
bloodstream	  and	  homing	  back	  into	  the	  bone	  niche	  by	  secretion	  of	  CXCL12	  and	  SCF,	  with	  elevated	  
concentrations	   in	   the	   niche	   supporting	   HSC	   retention	   and	   homing	   or	   reduced	   concentrations	  
allowing	  the	  exit	  of	  HSC	  from	  the	  niche71,72.	  	  
Interestingly,	  MSC	  do	  not	  necessarily	  execute	  their	  functions	  in	  an	  isolated	  fashion	  but	  interact	  with	  
and	   are	   regulated	   by	   their	   environment.	   Nestin+	   MSC	   undergo	   crosstalk	   with	   adrenergic	   nerve	  
fibers	  of	  the	  sympathetic	  nervous	  system	  which	  has	  been	  shown	  to	  play	  a	  role	  in	  mobilization	  and	  
release	  of	  HSC	  by	  secreting	  noradrenaline,	  targeting	  the	  β3-­‐adrenergic	  receptor	  of	  MSC	  and	  altering	  
the	  secretion	  of	  CXCL12	  by	  MSC72.	  Macrophages,	  also	  present	  in	  the	  bone	  marrow	  stem	  cell	  niche,	  
were	  found	  to	  be	  key	  regulators	  of	  HSC	  mobilization	  from	  the	  niche73,74.	  Previous	  studies	  suggested	  
that	   this	   macrophage-­‐triggered	   HSC	   mobilization	   is	   also	   mediated	   via	   altering	   the	   secretion	   of	  
CXCL12	  by	  MSC75.	  
	  
	  
Figure	  2:	  Cellular	  components	  of	  the	  bone	  marrow	  niche.	  
The	   bone	  marrow	   stem	   cell	   niche	   is	   home	   to	   the	   hematopoietic	   stem	   cells	   (HSC),	   a	   place	   in	   which	   their	  
proliferation	  and	  differentiation	   is	  tightly	  regulated.	  Main	  regulators	  of	  HSC	  function	  and	  cellular	  status	  are	  
different	   subtypes	   of	   mesenchymal	   stem	   cells	   (MSC)	   including	   CXCL12	   abundant	   reticular	   cells	   (CAR)	   and	  
Nestin+	  MSC	  as	  well	  as	  MSC-­‐derived	  osteoblasts	  secreting	  various	  growth	  factors.	  Furthermore,	  MSC	  secrete	  
CXCL12,	  enabling	  retention	  of	  HSC	  in	  and	  homing	  of	  HSC	  into	  the	  niche.	  	  
The	   spatial	   composition	   and	   the	   physical	   integrity	   of	   the	   bone	   is	   enabled	   by	   a	   balanced	   activity	   of	  MSC-­‐
derived	   bone	   forming	   osteoblasts	   and	   HSC-­‐derived	   bone	   degrading	   osteoclasts.	   ANGPT1,	   angiopoietin-­‐1;	  
BMP,	   bone	  morphogenic	   protein;	   Il-­‐7,	   interleukin-­‐7;	  M-­‐CSF,	   macrophage	   stimulating	   factor;	   RANKL,	   RANK	  
ligand;	  SCF,	  stem	  cell	  factor;	  TGF-­‐β,	  transforming	  growth	  factor-­‐β.	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1.3.4. Extracellular	  matrix	  proteins	  in	  the	  bone	  marrow	  niche	  
Despite	  progress	  on	  understanding	   the	  cellular	   components	  of	   the	  bone	  marrow	  stem	  cell	  niche,	  
the	   extracellular	   matrix	   of	   this	   niche,	   synthesized	   by	   non-­‐hematopoietic	   stromal	   cells,	   remains	  
poorly	   understood.	   This	   stands	   in	   contrast	   to	   the	   suspected	   relevance	   of	   ECM	  molecules	   in	   the	  
bone	  marrow	  niche	  as	  hematopoietic	  progenitor	  cells	  express	  over	  20	  different	  adhesion	  receptors	  
which	  enable	  the	  cells	  to	  interact	  with	  a	  multitude	  of	  ECM	  proteins76.	  
Among	  these	  are	  a	  number	  of	  fibrous	  ECM	  proteins	  which	  are	  present	  in	  the	  niche	  and	  secreted	  by	  
cells	  of	  mesenchymal	  origin.	  These	  fibrous	  ECM	  proteins	  include	  type	  I,	  III,	  IV	  and	  VI	  collagen	  as	  well	  
as	  fibronectin77.	  Matrix	  proteins,	  acting	  as	  structural	  components,	  make	  up	  the	  three-­‐dimensional	  
framework	  of	  the	  niche	  and	  define	  physical	  properties	  such	  as	  topography,	  porosity,	  stiffness	  and	  
rigidity.	   These	   physical	   properties	   of	   the	   environment	   can	   influence	   general	   biological	   processes	  
such	   as	   cell	   division,	   polarity	   or	   migration78	   as	   well	   as	   stem	   cell	   specific	   processes	   such	   as	   the	  
equilibrium	   between	   quiescence,	   self-­‐renewal	   and	   differentiation79,80.	   In	   addition	   to	   the	   physical	  
cues,	   ECM	   proteins	   can	   bind	   growth	   factors	   and	   act	   as	   a	   reservoir,	   thereby	   regulating	   their	  
availability	  and	  even	  establishing	  gradients81.	  In	  an	  environment,	  such	  as	  the	  bone	  stem	  cell	  niche,	  
in	   which	   the	   distribution	   of	   growth	   factors	   requires	   spatial	   and	   temporal	   regulation,	   it	   seems	  
plausible	  that	  ECM	  proteins	  may	  play	  a	  functional	  role	  in	  this	  context.	  
Besides	  their	  passive	  role	  as	  structural	  components	  and	  growth	  factor	  reservoir,	  ECM	  proteins	  also	  
actively	  participate	  in	  the	  organization	  of	  the	  bone	  marrow	  stem	  cell	  niche.	  Homing	  of	  HSC	  into	  the	  
bone	  marrow	  niche	   is	  primarily	   guided	  by	  growth	   factors	  and	   chemokines	   such	  as	  CXCL12.	  None	  
the	   less,	   studies	   have	   also	   shown	   that	   after	   transplantation,	   the	   ECM	   glycosaminoglycan	  
hyaluronan	   is	  required	   in	  the	  niche	  as	   it	  cooperates	  with	  CXCL12	  guiding	  the	  HSC	   into	  their	  niche	  
via	  the	  hyaluronan	  receptor	  CD4482.	  	  
A	   similar	   study	   using	   osteopontin	   knockout	   mice	   showed	   that	   osteopontin	   was	   required	   for	  
successful	   engraftment	   and	   localization	   of	   HSC	   to	   the	   endosteum	   after	   transplantation,	   further	  
emphasizing	   the	   functional	   importance	  of	  ECM	  proteins	   in	  HSC	  homing	  and	  engraftment	   into	   the	  
bone	  marrow	  stem	  cell	  niche67.	  	  	  
The	   glycoprotein	   tenascin-­‐C	   is	   an	   ECM	   protein	   restricted	   to	   sites	   of	   tissue	   damage83	   or	  
inflammation84	   in	  an	  adult.	  Experiments	   in	   tenascin-­‐C	  knockout	  mice	  showed	  that	   tenascin-­‐C	  was	  
not	  required	  for	  steady	  state	  hematopoiesis	  but	  was	  up-­‐regulated	  in	  the	  bone	  marrow	  stroma	  and	  
endothelial	   cells	   during	   hematopoietic	   recovery	   after	   bone	   myeloablation.	   These	   mice	   showed	  
increased	   lethality	   and	   reduced	   hematopoietic	   regeneration	   as	   well,	   emphasizing	   the	   role	   of	  
tenascin-­‐C	  in	  hematopoietic	  regeneration85.	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The	   heterotrimeric	   laminins,	   in	   particular	   laminin	   411,	   421,	   511	   and	   521,	  were	   also	   identified	   in	  
human	  bone	  marrow	  and	  were	  shown	  to	  exert	  adhesive	  interactions	  with	  CD34+	  cell	  lines86.	  
All	  in	  all,	  ECM	  proteins	  are	  an	  essential	  component	  of	  the	  bone	  marrow	  stem	  cell	  niche	  providing	  a	  
spatial	  scaffold	  for	  cells	  as	  well	  as	  influencing	  these	  by	  physical	  cues	  and	  regulation	  of	  growth	  factor	  
availability.	  
1.3.5. Mesenchymal	  stem	  cells	  in	  bone	  metastasis	  
MSC	   are	   an	   essential	   cellular	   component	   of	   the	   HSC	   niche	   in	   the	   bone	   marrow	   making	   it	   a	  
hospitable	   environment.	   This	   not	   only	   assures	   the	   maintenance	   of	   the	   HSC	   progenitor	   pool	  
throughout	   life,	  but	  could	  also	  make	  the	  bone	  marrow	  niche	  a	  perfect	   ‘soil’	   for	  circulating	  cancer	  
cells	   leading	   to	   cancer	   cell	   attachment	   and	   subsequent	   metastatic	   growth	   in	   the	   bone	   marrow	  
niche.	  	  
In	  line	  with	  this	  hypothesis	  are	  observations	  describing	  the	  co-­‐localization	  of	  transplanted	  HSC	  and	  
prostate	  cancer	  cells	   to	   the	  bone	  marrow	  after	   lethal	   irradiation	  of	  mice.	  These	   results	   suggest	  a	  
competition	   between	   homing	   HSC	   and	   cancer	   cells	  metastasizing	   into	   the	   bone	  marrow	   niche21.	  
Homing	  into	  the	  niche	  is	  orchestrated	  by	  different	  subtypes	  of	  MSC,	  secreting	  a	  number	  of	  factors	  
including	   the	   chemokine	   CXCL12.	   Like	   HSC,	   breast	   cancer87	   and	   prostate	   cancer87,88	   cells	   are	  
reported	  to	  respond	  to	  CXCL12	  gradients	  from	  the	  bone	  marrow	  niche,	  as	  neutralizing	  antibodies	  
against	   the	   CXCL12	   receptor	   CXCR4	   or	   CXCR7	   show	   a	   significant	   reduction	   in	   engraftment	   and	  
growth	   of	   tumor	   cells	   in	   bone.	   In	   addition	   to	   CXCL12,	   prostate	   cancer	   cells	   are	   also	   known	   to	  
respond	  to	  CCL2	  gradients	   formed	  by	  MSC-­‐derived	  osteoblasts	   in	  the	  niche,	  enabling	  homing	  and	  
stable	   integration	   into	   the	   niche18,19.	   The	   struggle	   between	   cancer	   cells	   and	   HSC	   for	   niche	  
predominance	   is	   not	   limited	   to	   the	   homing	   process.	   Cancer	   cells	   gaining	   a	   foothold	   in	   the	   bone	  
marrow	   niche	   have	   also	   been	   shown	   to	   push	   HSC	   out	   of	   their	   niche,	   affecting	   HSC	   homeostasis	  
which	   results	   in	   peripheral	   blood	   changes	   including	   infection	   or	   anemia	   during	   late	   stage	  
progression	  of	  prostate	  cancer88.	  
MSC	   are	   also	   being	   discussed	   in	   the	   concept	   of	   a	   pre-­‐metastatic	   niche.	   This	   describes	   a	  
phenomenon	   in	   which	   the	   primary	   tumor	   prepares	   the	   site	   of	   metastasis	   for	   subsequent	  
colonization89.	   In	   this	   context,	   bone	  marrow-­‐derived	   hematopoietic	   cells	   have	   been	   reported	   to	  
migrate	   to	   sites	   of	   future	   metastasis	   and	   initiate	   fibronectin	   production90	   and	   inflammatory	  
chemokine	  secretion91,	  facilitating	  successful	  homing	  of	  cancer	  cells	  to	  the	  primed	  metastatic	  site.	  
In	   the	   bone,	   similar	   processes	   can	   be	   witnessed	   with	   endocrine	   factors	   such	   heparanase92	   or	  
PTHRP15	  being	  secreted	  by	  the	  primary	  tumor	  and	  altering	  functional	  behavior	  of	  bone	  marrow	  cells	  
in	   the	   bone	   marrow	   stem	   cell	   niche.	   With	   MSC	   exerting	   key	   regulatory	   functions	   in	   the	   bone	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marrow	   niche,	   it	   seems	   plausible	   that	   they	   could	   also	   be	   involved	   in	   the	   priming	   of	   the	   bone	  
marrow	  niche	  for	  metastasis	  growth.	  	  
In	   addition	   to	   initial	   cancer	   cell	   homing,	   the	   cellular	   compartment	  of	   the	  bone	  marrow	   stem	  cell	  
niche	  enables	   tumor	  dormancy	   in	   the	  bone.	  Dormancy	  describes	  a	  cellular	  state	  of	  growth	  arrest	  
which	  allows	  the	  tumor	  cells	  to	  remain	  in	  the	  bone	  marrow	  for	  years	  and,	  most	  importantly,	  survive	  
chemotherapeutic	  treatment,	  as	  this	  targets	  only	  the	  fast	  cycling	  cancer	  cells93.	  Tumor	  dormancy	  is	  
therefore	  a	  major	  cause	  for	  cancer	  relapse	  after	  treatment	  and	  initial	  remission	  and	  occurs	  in	  about	  
20	   to	  40%	  of	  breast	  and	  prostate	  patients	   in	  a	  matter	  of	  years	  or	  even	  decades94,95.	  The	   topic	  of	  
tumor	  dormancy	  is	  still	  in	  need	  of	  a	  large	  investigative	  effort.	  Nonetheless,	  initial	  accomplishments	  
in	   understanding	   this	   phenomenon	   have	   been	   achieved.	  Whether	   HSC	   in	   the	   bone	  marrow	   are	  
found	   in	   a	  quiescent	  or	  proliferative	   state	  depends	  on	   signals	   from	   the	  niche	  microenvironment.	  
This	   key	   function	   of	   the	   HSC	   niche	   ensures	   the	   supply	   of	   blood	   and	   immune	   cell	   progenitors	  
throughout	   life68.	   Cancer	   cells	   metastasizing	   to	   bone,	   seem	   to	   respond	   to	   the	   niche	  
microenvironment	   similarly	   to	   HSC.	   Annexin	   II,	   for	   example,	   supplied	   by	   the	   niche	  
microenvironment	  has	  been	  shown	  to	  induce	  growth	  arrest	  in	  prostate	  cancer	  cells	  and	  is	  believed	  
to	  be	  a	  facilitator	  of	  tumor	  dormancy	  in	  bone96.	  The	  role	  of	  MSC	  in	  this	  context	  remains	  unknown.	  
The	   fact	   that	  cancer	  cells	  metastasize	   to	   the	  bone	  marrow	  stem	  cell	  niche,	  has	  become	  common	  
ground	   in	   the	   field	   of	   bone	  metastasis	   research.	   The	   progression	   of	  metastatic	   disease	   has	   also	  
been	  studied	  for	  some	  time	  and	  considerable	  insight	  has	  been	  gained	  into	  how	  cancer	  cells	  interact	  
with	  the	  bone	  marrow	  niche.	  Nonetheless,	  the	  complete	  picture	  of	  how	  cancer	  cells	  interact	  with	  
the	  bone	  marrow	  niche	  and	  its	  stromal	  constituents	  remains	  unclear,	  especially	  when	  it	  comes	  to	  
the	  processes	  occurring	  during	  initial	  colonization	  of	  the	  bone	  by	  cancer	  cells.	  
With	  bone	  metastasis	  formation	  being	  one	  of	  the	  most	  detrimental	  steps	  in	  cancer	  progression,	  a	  
better	  understanding	  of	  how	  bone	  metastases	  are	   initially	   formed	   is	  key	   to	  successfully	   targeting	  
bone	  metastasis	  and	  by	  that	  helping	  patients	  suffering	  from	  breast	  or	  prostate	  cancer.	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1.4. Aim	  of	  this	  thesis	  and	  experimental	  approach	  
In	  order	  to	  better	  understand	  the	  role	  of	  MSC	  in	  metastasis	  formation	  the	  present	  work	  was	  aimed	  
to	  model	  how	  MSC	  induce	  migration	  of	  cancer	  cells.	  A	  fundamental	  idea	  was	  to	  choose	  an	  unbiased	  
approach	  and	   to	   take	   the	  complete	   secretome	  of	  MSC	   into	  consideration.	  This	  approach	  allowed	  
omitting	  guesses	  on	  previously	  described	  potential	  chemotactic	  factors.	  To	  address	  this	  idea,	  I	  used	  
primary	  human	  bone	  marrow	  MSC	  isolated	  from	  healthy	  donors	  together	  with	  established	  prostate	  
and	  breast	  cancer	  cell	   lines	  able	  to	  metastasize	  to	  bone.	  The	  experimental	  approach	  was	  initiated	  
with	   the	   production	   of	  MSC	   cell	   culture	   supernatant	   under	   protein-­‐free	   and	   chemically	   defined	  
conditions.	   Cell	   culture	   supernatant	   then	   underwent	   multistep-­‐processing	   including	   filtration,	  
concentration,	  size	  exclusion	  and	  ion	  exchange	  chromatography	  in	  subsequent	  manner.	  After	  each	  
processing	   step,	   migration-­‐inducing	   activity	   towards	   cancer	   cells	   was	   determined.	   The	   use	   of	  
transwell	   migration	   chambers	   combined	   with	   impedance	   measurements	   allowed	   quantitative	  
analysis	  of	  cancer	  cell	  migration	  in	  a	  time-­‐resolved	  fashion	  and,	  most	  importantly,	  high-­‐throughput	  
format.	  Active	   chromatography	   fractions	  were	   analyzed	   for	  protein	   content	  by	   antibody	  array	  or	  
mass	   spectrometry	   and	   transferred	   to	   further	   processing.	   Finally,	   candidate	   proteins	   potentially	  
mediating	   the	   observed	  migration	   of	   cancer	   cells	   towards	  MSC	  were	   tested	   and	   validated	   using	  
recombinant	  proteins	  and	  RNAi	  approaches	  (Figure	  3).	  
	  
Figure	  3:	  Workflow	  to	  identify	  secreted	  proteins	  inducing	  migration	  of	  cancer	  cells	  towards	  mesenchymal	  
stem	  cells.	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2. Results	  
2.1. MSC	  induce	  rapid	  migration	  of	  cancer	  cells	  
In	   order	   to	   investigate	   the	   interactions	   between	   MSC	   and	   cancer	   cells,	   initial	   experiments	  
addressed	  the	  questions	  of	  whether	  MSC	  do	  induce	  cancer	  cell	  migration	  and	  which	  experimental	  
set	  up	  is	  best	  suited	  to	  monitor	  this	  migratory	  interaction.	  	  
Trial	  experiments	  showed	  that	  the	  migration-­‐inducing	  activity	  of	  MSC	  cell	  culture	  supernatant	  was	  
best	   analyzed	   in	   transwell	   migration	   chambers	   of	   the	   Acea	   xCELLigence	   system.	   In	   this	   system,	  
supporting	   up	   to	   48	  wells,	   cells	  migrating	   through	   the	   transwell	  membrane	   along	   a	   chemotactic	  
gradient	   from	   one	   cell	   culture	   chamber	   to	   the	   other	   induced	   an	   electronic	   signal	   which	  
accumulated	   over	   time.	   This	   device	   therefore	   allowed	   a	   non-­‐invasive,	   high-­‐throughput	   and	   real-­‐
time	  analysis	  of	  cancer	  cell	  lines	  migrating	  along	  a	  potential	  chemotactic	  gradient	  caused	  by	  the	  cell	  
culture	  supernatant	  of	  MSC	  (Figure	  15).	  
With	   this	   set-­‐up	   it	   could	  be	   shown	   that	  MSC	   induced	  a	   rapid	  migration	   response	  of	   the	  prostate	  
cancer	  cell	  line	  PC3	  and	  to	  a	  somewhat	  lesser	  extent	  the	  breast	  cancer	  cell	  line	  MDA-­‐MB-­‐231	  with	  a	  
full	  migration	  response	  in	  as	  little	  as	  two	  hours	  (Figure	  4	  A).	  Both	  of	  these	  cell	  lines	  have	  in	  common	  
that	  they	  have	  been	  reported	  as	  cancer	  cell	  lines	  to	  model	  bone	  metastasis	  formation	  in	  vivo97,98.	  	  
In	  order	  to	  address	  whether	  this	  observed	  migratory	  ability	  of	  cancer	  cells	  was	  specific	  for	  cells	  able	  
to	  form	  bone	  metastasis	  in	  vivo,	  additional	  prostate	  cancer	  cell	  lines	  were	  tested,	  known	  to	  have	  no	  
or	  only	  a	   reduced	  potential	   to	   induce	  bone	  metastasis	   in	  animal	  models.	   In	  contrast	   to	  PC3	  cells,	  
the	  prostate	  cancer	  cell	  line	  LNCaP99	  and	  VCaP100	  did	  not	  show	  migration	  towards	  MSC	  supernatant	  
(Figure	  4	  A).	  	  
The	  xCELLigence	  measurements	  are	  not	  only	  influenced	  by	  cell	  number,	  but	  also	  by	  cell	  adhesion,	  
cell	  size	  and	  cell	  spreading101-­‐103.	  These	  are	  characteristics	  differing	  between	  cell	  types.	  In	  order	  to	  
reliably	   compare	  migration	   of	   the	   different	   cell	   lines	   investigated,	  migration	   dynamics	  were	   also	  
analyzed	  as	  they	  are	  less	  influenced	  by	  cell	  adhesion	  and	  spreading.	  Analysis	  of	  dynamics	  in	  the	  first	  
hour	  of	  migration	  confirmed	   the	  previous	  observations	  with	  PC3	  and	  MDA-­‐MB-­‐231	  cells	   showing	  
high	  migration	  dynamics	  in	  contrast	  to	  LNCaP	  and	  VCaP	  cells	  (Figure	  4	  A’).	  	  
As	  the	  xCELLigence	  system	  does	  not	  allow	  visual	  inspection	  of	  the	  migrated	  cells,	  results	  obtained	  
with	   this	   system	  were	   confirmed	  with	   classic	   Boyden	   chamber	   transwell	   assays.	   A	   full	  migration	  
response	   of	   PC3	   cells	   after	   four	   hours	   was	   observed	   with	   cells	   showing	   full	   confluency	   on	   the	  
membrane.	  MDA-­‐MB-­‐231	  cells	  also	  showed	  a	  clear	  migration	  response	  after	  two	  hours	  compared	  
to	  the	  negative	  control.	  Even	  after	  48	  hours,	  LNCaP	  cells	  failed	  to	  show	  directed	  migration	  towards	  
the	  cell	  culture	  supernatant	  of	  MSC	  in	  comparison	  to	  a	  negative	  control	  (Figure	  4	  B).	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As	  MSC	   are	   of	   heterogeneous	   nature29,104	   and	   the	   cells	   used	   in	   this	   study	   are	   primary	   cells,	   the	  
observed	  potential	  of	  MSC	  to	  induce	  cancer	  cell	  migration	  required	  confirmation	  with	  several	  MSC	  
donors.	  In	  comparison	  to	  donor	  1,	  two	  further	  donors	  induced	  a	  migration	  response	  of	  approx.	  70%	  
and	  85%	  for	  the	  prostate	  cancer	  cell	  line	  PC3	  (Figure	  4	  C).	  These	  results	  could	  be	  confirmed	  when	  
looking	   at	   the	   PC3	  migration	   dynamics	   the	   respective	   cell	   culture	   supernatant	   samples	   induced.	  
Donor	  2	  induced	  over	  60%	  and	  donor	  3	  80%	  migration	  dynamics	  relative	  to	  donor	  1	  (Figure	  4	  C’).	  
Stromal	  cells	   in	  general	  are	  discussed	   for	   their	  contribution	   to	  cancer	  progression	  and	  metastasis	  
formation3,105.	   In	   order	   to	   understand	   whether	   the	   observed	   induction	   of	   migration	   was	   MSC	  
specific	   or	   held	   true	   for	   other	   stromal	   cells	   as	  well,	  migration	  of	   PC3	   cells	   towards	   two	  different	  
fibroblast	   cell	   lines	   was	   investigated.	   Neither	   the	   cell	   line	   HS68	   nor	   HFF1	   was	   able	   to	   induce	   a	  
migration	  response	  of	  PC3	  cells	  comparable	  to	  MSC.	  An	  early	  migration	  response	  towards	  both	  cell	  
lines	  was	  present	  but	  reached	  only	  10%	  compared	  to	  MSC	  donor	  1.	  These	  findings	  were	  confirmed	  
when	  analyzing	  the	  dynamics	  of	  the	  early	  migration	  response	  towards	  the	  fibroblast	  cell	  lines	  which	  
reached	   only	   7%	   respectively	   compared	   to	  MSC	   donor	   1.	   Interestingly,	   fibroblasts	   were	   able	   to	  
induce	  a	  second	  phase	  of	  migration	  after	  12	  hours.	  Nonetheless,	  the	  two	  migration	  phases	  did	  not	  
accumulate	  to	  more	  than	  30%	  migration	  response	  compared	  to	  MSC	  donor	  1	  (Figure	  4	  C,	  C’).	  	  
In	  conclusion,	   these	   initial	  experiments	  showed	  that	  cancer	  cell	   lines	  able	  to	  metastasize	  to	  bone	  
migrate	   towards	   MSC	   in	   a	   rapid	   fashion.	   This	   migration	   response	   was	   induced	   by	   MSC	   from	  
multiple	  donors,	  whereas	  fibroblasts	  were	  not	  able	  to	  induce	  comparable	  migration.	  
After	  establishing	  that	  the	  observed	  induction	  of	  cancer	  migration	  was	  reproducible	  and	  specific	  for	  
MSC,	  the	  mediators	  required	  for	  this	  cancer	  cell	  –	  MSC	  interaction	  were	  isolated	  through	  a	  series	  of	  
downstream	  processing	  steps	  of	  the	  MSC	  cell	  culture	  supernatant.	  
Results	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Figure	  4:	  MSC	  induce	  rapid	  migration	  of	  cancer	  cells	  able	  to	  form	  bone	  metastasis.	  	  
A:	   Migration	   response	   of	   cancer	   cell	   lines	   towards	  MSC	   supernatant	   in	   xCELLigence	   transwell	   system.	  A’:	  
Average	  dynamics	  of	  early	  migration	   response	  displayed	   in	   (A)	  between	  00:30	  h	  and	  01:15	  h.	  B:	   Images	  of	  
Boyden	   chamber	   transwell	  membranes	  with	   attached	   cells	   after	  migration	   towards	  MSC	   supernatant.	   Cell	  
lines,	  duration	  of	  migration	  and	  attractant	  are	  indicated	  for	  the	  respective	  images.	  C:	  Migration	  response	  of	  
PC3	   cells	   towards	   fibroblast	   and	  MSC	   supernatant	   of	  multiple	   donors	   in	   xCELLigence	   transwell	   system.	  C’:	  
Average	  dynamics	  of	  early	  migration	  response	  displayed	  in	  (C)	  between	  00:30	  h	  and	  01:15	  h.	  Average	  values	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2.2. Purification	  step	  1:	  Size	  exclusion	  chromatography	  of	  MSC	  cell	  culture	  
supernatant	  
In	   order	   to	   be	   able	   to	   isolate	   the	   migration-­‐inducing	   factors	   of	   interest	   from	   the	   cell	   culture	  
supernatant	  of	  MSC	   in	   a	  manageable	   time	  and	  work-­‐load	   frame,	   reproducibility	  of	   the	   individual	  
processing	   steps	   was	   crucial	   and	   the	   focus	   of	   process	   optimization.	   Reproducibility	   was	   also	  
considered	  a	  key	  process	  parameter,	  as	  the	  MSC	  are	  primary	  cells	  isolated	  from	  individual	  donors.	  
On	  account	  of	   this,	   variations	   in	   the	   secretome	  of	   the	  MSC	  populations	  were	   to	  be	  expected.	  To	  
minimize	  variations	  in	  protein	  concentrations,	  cells	  were	  grown	  to	  full	  confluency	  at	  passage	  5,	  cell	  
culture	   supernatant	   was	   produced	   for	   48	  hours	   in	   protein-­‐free	   as	   well	   as	   chemically	   defined	  
medium	   and	   stored	   at	   -­‐20°C.	   For	   downstream	   processing,	   supernatant	   was	   filtered	   and	  
concentrated	   via	   ultrafiltration	   to	   allow	   size	   exclusion	   chromatography	   (SEC)	   as	   the	   initial	  
downstream	  processing	  step.	  	  
2.2.1. Size	   exclusion	   chromatography	   yields	   highly	   reproducible	   fractionation	  
despite	  MSC	  donor	  heterogeneity	  
Reproducible	  SEC	   fractionation	  was	  mandatory,	  as	   the	  protocol	   required	  pooling	  of	   several	   same	  
molecular	  weight	  fractions	  of	  separate	  SEC	  runs	  for	  subsequent	  processing.	  	  
After	  testing	  various	  process	  parameters,	  the	  use	  of	  a	  Superdex	  200	  HR	  10/30	  column	  with	  50	  mM	  
tris-­‐buffer	  containing	  150	  mM	  NaCl	  as	   the	   fluid	  phase,	  combined	  with	  a	   loading	  of	  500	  μl	   sample	  
volume	   and	   a	   flow	   rate	   of	   250	  ml/min	   allowed	   for	   SEC	   fractionation	  with	   highest	   reproducibility	  
and	   reliability.	   Comparison	   of	   average	   FPLC	   chromatograms	   of	   three	   separate	   donors	   revealed	  
variations	   in	   peak	   height	   but	   very	   low	   differences	   in	   the	   retention	   volumes	   at	   which	   the	   peaks	  
eluted	  off	   the	  column	   (Figure	  5	  A).	   Low	  variations	   in	   retention	  volume	  were	  also	  observed	  when	  
comparing	  retention	  volumes	  of	  separate	  FPLC	  runs	  of	  one	  MSC	  donor	  (technical	  replicates)	  and	  by	  
comparing	  retention	  volumes	  of	  separate	  FPLC	  runs	  of	  two	  different	  MSC	  donors	  with	  each	  other	  
(biological	  replicates)	  (Figure	  5	  B,	  C).	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Figure	  5:	  Size	  exclusion	  chromatography	  yields	  highly	  reproducible	  fractionation	  despite	  heterogeneity	  of	  
primary	  MSC.	  	  
A:	   Size	   exclusion	   chromatograms	   of	   proteins	   detected	   at	   280	  nm	   during	   fractionation	   of	   cell	   culture	  
supernatant	   of	   MSC.	   For	   each	   technical	   replicate	   16	  ml	   MSC	   cell	   culture	   supernatant	   were	   filtered,	  
concentrated	  and	  fractionated	  by	  size	  exclusion	  chromatography.	  Results	  for	  each	  donor	  were	  confirmed	  by	  
five	   technical	   replicates	   and	   are	   presented	   as	   average	   values.	   Protein	   size	   estimations	   are	   based	   on	  
calibration	  experiments	   and	  extrapolation.	  B,C:	   Correlation	  plots	  of	  main	  peak	   retention	  volumes	  between	  
technical	   replicates	   of	   the	   same	   MSC	   donor	   (B)	   and	   between	   biological	   replicates	   of	   two	   different	   MSC	  
donors	  (C)	  (Pearson	  correlation	  is	  indicated).	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2.2.2. High-­‐molecular-­‐weight	   proteins	   induce	   breast	   and	   prostate	   cancer	   cell	  
migration	  
SEC	   fractions	   of	   three	  MSC	   donors	  were	   tested	   for	   their	  migration-­‐inducing	   activity	   towards	   the	  
prostate	  cancer	  cell	  line	  PC3.	  Fractions	  of	  up	  to	  31	  ml	  retention	  volume	  inducing	  a	  clear	  absorption	  
signal	  in	  the	  chromatogram	  (Figure	  5	  A)	  were	  analyzed	  for	  their	  migration-­‐inducing	  potential.	  These	  
fractions	  harbored	  proteins,	  protein	  fragments	  and	  single	  amino	  acids	  in	  an	  estimated	  size	  of	  down	  
to	   100	  Da	  determined	  by	   extrapolation	   calculations	  of	   column	   calibration	   experiments.	   Based	  on	  
the	   column	   bed	   volume	   of	   24	  ml,	   the	   final	   fractions	   exceeding	   24	  ml	   retention	   volume	   were	  
expected	  to	  be	  free	  of	  proteins	  or	  amino	  acids.	  The	  observed	  absorption	  signals	  must	  therefore	  be	  
based	  on	  variations	  in	  salt	  ion	  compositions	  of	  the	  buffer.	  As	  calcium	  ions	  are	  known	  to	  play	  a	  role	  
in	   homing	   of	   HSC	   to	   the	   bone106	   and	   can	   have	   a	   profound	   effect	   on	   cancer	   cell	   migration107,	  
proliferation108	   and	   metastasis	   to	   bone109,	   all	   fractions	   up	   to	   31	  ml	   retention	   volume	   were	  
investigated	  for	  their	  potential	  to	  induce	  cancer	  cell	  migration.	  
Migration	  response	  of	  PC3	  cells	  towards	  the	  SEC	  fractions	  was	  analyzed	  in	  relation	  to	  the	  maximum	  
response	  induced	  by	  the	  unprocessed	  cell	  culture	  supernatant	  of	  the	  respective	  donor.	  On	  average,	  
a	   strong	  migration	   response	   of	   over	   90%	  was	   seen	   towards	   SEC	   fractions	   harboring	   proteins	   or	  
protein	  complexes	  with	  molecular	  weights	   ranging	   from	  1500	  to	  800	  kDa.	  This	  was	   followed	  by	  a	  
steep	  decline	  in	  migration-­‐inducing	  activity	  with	  a	  slight	  elevation	  in	  migration	  response	  in	  fractions	  
of	  around	  100	  kDa	  reaching	  35%	  migration	  response.	  Afterwards	  the	  migration	  response	  reached	  a	  
plateau	   and	   fluctuated	   around	   10	   to	   20%	   with	   a	   gap	   of	   no	   migration	   towards	   SEC	   fractions	   of	  
around	  1	  to	  2	  kDa	  (Figure	  6	  A).	  
Single	  time	  point	  analysis	  of	  PC3	  migration	  response	  after	  three	  hours	  towards	  the	  SEC	  fractions	  of	  
three	   MSC	   donors	   individually	   confirmed	   strong	   migration-­‐inducing	   activity	   towards	   high-­‐
molecular-­‐weight	  fractions	  for	  all	   three	  donors	  (Figure	  6	  B).	   In	  the	  case	  of	  donor	  2,	  the	  migration	  
response	  even	  exceeded	  migration-­‐inducing	  activity	  of	  the	  untreated	  cell	  culture	  supernatant.	  The	  
slightly	   elevated	  migration-­‐inducing	   activity	   of	   the	  100	  kDa	   fractions	   could	  only	   be	   confirmed	   for	  
donor	  1	  and	  donor	  2.	  Donor	  3	   failed	  to	  show	  activity	   in	  100	  kDa	  fractions	  but	   instead	  triggered	  a	  
migration	  response	  at	  around	  1	  kDa,	  in	  contrast	  to	  donor	  1	  and	  donor	  2.	  In	  conclusion,	  the	  results	  
show	   that	   the	  migration-­‐inducing	   activity	   found	   in	   cell	   culture	   supernatant	   of	  MSC	   towards	   PC3	  
prostate	  cancer	  cells	  was	  primarily	  based	  on	  high-­‐molecular-­‐weight	  proteins	  or	  protein	  complexes	  
of	  around	  1000	  kDa	  in	  size.	  	  
In	   order	   to	   assess	   whether	   the	   migration	   of	   PC3	   prostate	   cancer	   cells	   towards	   high-­‐molecular-­‐
weight	  proteins	  was	  cell	   line	  or	  cancer	  specific,	   the	  breast	  cancer	  cell	   line	  MDA-­‐MB-­‐231	  was	  also	  
analyzed	   for	   its	  migratory	  behavior	   towards	  SEC	   fractions	  of	  MSC	  cell	   culture	   supernatant.	  MDA-­‐
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MB-­‐231	   cells,	   also	   known	   to	   form	   bone	   metastasis	   in	   vivo,	   showed	   overall	   a	   slower	   migration	  
response	  towards	  SEC	  fractions	  in	  contrast	  to	  PC3	  cells	  that	  required	  as	  little	  as	  two	  hours	  for	  a	  full	  
migration	   response.	   In	   addition,	   the	   migration-­‐inducing	   activity	   towards	   this	   cell	   line	   was	   more	  
broadly	  distributed	  compared	  to	  PC3	  cells	  that	  displayed	  migration	  towards	  a	  more	  defined	  set	  of	  
SEC	   fractions.	   Nonetheless,	   MDA-­‐MB-­‐231	   cells	   showed	   a	   similar	   migration	   pattern	   towards	   SEC	  
fractions	   of	   MSC	   supernatant.	   For	   all	   three	   donors,	   high-­‐molecular-­‐weight	   fractions	   of	   1500	  –
	  800	  kDa	   displayed	   the	   highest	   migration-­‐inducing	   activity	   followed	   by	   SEC	   fractions	   of	   around	  
100	  kDa	   (Figure	   7).	   After	   identifying	   high-­‐molecular-­‐weight	   fractions	   as	   the	   main	   source	   of	  
migration-­‐inducing	  activity	  in	  MSC	  supernatant,	  respective	  SEC	  fractions	  were	  analyzed	  for	  protein	  
content	  and	  applied	  to	  further	  downstream	  processing.	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   22	  
	  
Figure	  6:	  High-­‐molecular-­‐weight	  proteins	  induce	  prostate	  cancer	  cell	  migration.	  
A:	  Average	  migration	  response	  over	  time	  of	  prostate	  cancer	  cell	  line	  PC3	  towards	  SEC	  fractions	  of	  cell	  culture	  
supernatant	  of	  three	  individual	  MSC	  donors.	  B:	  Individual	  migration	  response	  of	  prostate	  cancer	  cell	  line	  PC3	  
towards	   SEC	   fractions	   of	   MSC	   culture	   supernatant	   after	   3	   h.	   Migration	   response,	   determined	   with	   the	  
xCELLigence	   system,	   is	   displayed	   as	   relative	   to	   the	  maximum	   response	  observed	   towards	   the	  unprocessed	  























A: Migration response of PC3 cells towards SEC fractions n=3
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Figure	  7:	  High-­‐molecular-­‐weight	  proteins	  induce	  breast	  cancer	  cell	  migration.	  
A:	  Average	  migration	  response	  over	  time	  of	  breast	  cancer	  cell	  line	  MDA-­‐MB-­‐231	  towards	  SEC	  fractions	  of	  cell	  
culture	  supernatant	  of	  three	  individual	  MSC	  donors.	  B:	  Individual	  migration	  response	  of	  breast	  cancer	  cell	  line	  
MDA-­‐MB-­‐231	  towards	  SEC	  fractions	  of	  MSC	  culture	  supernatant	  after	  3	  h.	  Migration	  response,	  determined	  
with	   the	   xCELLigence	   system,	   is	   displayed	   as	   relative	   to	   the	   maximum	   response	   observed	   towards	   the	  






















A: Migration response of MDA-MB-231 cells towards SEC fractions n=3
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2.2.3. Mass	   spectrometry	   identifies	   extracellular	   matrix	   proteins	   in	   high-­‐
molecular-­‐weight	  SEC	  fractions	  
After	  establishing	  that	  MSC	  induce	  migration	  of	  prostate	  and	  breast	  cancer	  cells	  via	  high-­‐molecular-­‐
weight	   proteins	   or	   protein	   complexes,	   the	   1000	  kDa	   SEC	   fractions	   of	   three	   MSC	   donors	   were	  
analyzed	   by	   electrospray	   mass	   spectrometry110.	   These	   fractions	   mainly	   contained	   structural	  
extracellular	  matrix	   proteins,	  matricellular	   proteins,	   glycoproteins,	   proteoglycans	   and	   other	   ECM	  
associated	  proteins	  (Table	  1).	  
	  
Table	   1:	   Proteins	   detected	   by	   mass	   spectrometry	   in	   high-­‐molecular-­‐weight	   SEC	   fractions	   of	   cell	   culture	  
supernatant	  of	  MSC.	  
Proteins	   listed	  were	   identified	   in	   samples	   of	   two	  or	   all	   three	   (*)	   donors.	   Proteins	   of	   bovine	   origin	   such	   as	  
remaining	   serum	  albumin	  or	  α-­‐2	  macroglobulin	  were	  discarded	   from	   the	   list	   as	  well	   as	   classic	   skin	  protein	  
contaminations	  including	  proteins	  such	  as	  keratins	  and	  dermicidin.	  	  
	  
Symbol Name	   Description	  
PGS1* Biglycan	   ECM	  Proteoglycan	  
CERU Ceruloplasmin	   Metalloprotein	  
COL1A1* Collagen	  α-­‐1(I)	  chain*	   Fibrillar	  collagen	  
COL3A1* Collagen	  α-­‐1(III)	  chain*	   Fibrillar	  collagen	  
COL6A1 Collagen	  α-­‐1(VI)	  chain	   Fibrillar	  collagen	  
COLCA1 Collagen	  α-­‐1(XII)	  chain	   Fibrillar	  collagen	  
COL1A2* Collagen	  α-­‐2(I)	  chain*	   Fibrillar	  collagen	  
COL6A2* Collagen	  α-­‐2(VI)	  chain*	   Fibrillar	  collagen	  
COL6A3* Collagen	  α-­‐3(VI)	  chain*	   Fibrillar	  collagen	  
PGS2 Decorin	   ECM	  proteoglycan	  	  
EMIL1 EMILIN-­‐1	   ECM	  glycoprotein	  
FBN1 Fibrillin-­‐1	   ECM	  glycoprotein	  
FINC* Fibronectin*	   ECM	  glycoprotein	  
LG3BP* Galectin-­‐3	  binding	  protein*	   ECM	  β-­‐galactoside-­‐binding	  protein	  
GPC1 Glypican-­‐1	   ECM	  proteoglycan	  
HEMO Hemopexin	   Acute	  phase	  plasma	  glycoprotein	  	  
LAMA4* Laminin	  subunit	  α-­‐4*	   ECM	  glycoprotein	  of	  basement	  membrane	  
LAMB1* Laminin	  subunit	  β-­‐1*	   ECM	  glycoprotein	  of	  basement	  membrane	  
LAMB2 Laminin	  subunit	  β-­‐2	   ECM	  glycoprotein	  of	  basement	  membrane	  
LAMC1 Laminin	  subunit	  γ-­‐1	   ECM	  glycoprotein	  of	  basement	  membrane	  
NID1 Nidogen-­‐1	   ECM	  matricellular	  protein	  
NID2 Nidogen-­‐2	   ECM	  matricellular	  protein	  
PTX3* Pentraxin-­‐related	  protein	  PTX3*	   Immune	  response	  protein	  
PXDN Peroxidasin	  homolog	  	   Heme-­‐containing	  peroxidase	  
HTRA1 Serine	  protease	  HTRA1	   Serine	  protease	  
TSP1* Thrombospondin-­‐1*	   ECM	  matricellular	  protein	  	  
TSP2 Thrombospondin-­‐2	   ECM	  matricellular	  protein	  
BGH3 Transforming	   growth	   factor-­‐β-­‐
induced	  protein	  ig-­‐h3	  
RGD	  containing	  ECM	  protein	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2.2.4. Antibody	  array	  reveals	  cytokine-­‐independent	  migration-­‐inducing	  activity	  of	  
high-­‐molecular-­‐weight	  SEC	  fractions	  
Chemokines,	  a	  family	  of	  cytokines	  of	  approx.	  10	  kDa	  in	  size,	  are	  extensively	  discussed	  in	  literature	  
in	   the	   context	   of	   cancer	   cell	  migration	   and	   as	  mediators	   of	  metastasis111-­‐113.	   Furthermore,	   it	   has	  
been	   reported	   that	   chemokines	   can	  bind	   to	  bone	  and	  a	  number	  of	   extracellular	  matrix	   proteins,	  
such	   as	   fibronectin,	   which	   were	   identified	   in	   the	   high-­‐molecular-­‐weight	   SEC	   fractions	   by	   mass	  
spectrometry	  (Table	  1)114,115.	  Additionally,	   it	   is	  known	  that	  MSC	  can	  secrete	  a	  number	  of	  different	  
cytokines29.	   For	   these	   reasons,	   1000	  kDa	   and	   100	  kDa	   molecular	   weight	   SEC	   fractions	   of	   two	  
donors,	  previously	  analyzed	  by	  mass	  spectrometry,	  were	  additionally	  investigated	  for	  the	  presence	  
of	  chemo-­‐	  and	  cytokines	  by	  antibody	  array.	  Of	  the	  72	  cytokines	  tested	  (Supplementary	  table	  1)	  ten	  
were	  identified	  in	  the	  unprocessed	  cell	  culture	  supernatant	  of	  both	  donors	  tested	  and	  an	  additional	  
three	  in	  only	  one	  of	  the	  two	  donors.	  In	  contrast	  to	  this	  finding,	  no	  classic	  chemokines	  were	  found	  in	  
the	  1000	  kDa	  or	  the	  100	  kD	  SEC	  fractions.	  Only	  a	  very	  faint	  presence	  of	  VEGFR3	  could	  be	  shown	  in	  
the	   1000	  kDa	   fraction	   of	   one	   of	   two	   donors.	   VEGFR3	   as	   well	   as	   uPAR,	   TIMP1	   and	   TIMP2	   were	  
detected	  in	  the	  100	  kDa	  SEC	  fraction	  of	  both	  donors	  (Table	  2).	  
	  
Table	  2:	  Angiogenic	  and	  chemoattractive	   factors	  detected	   in	  untreated	  MSC	  cell	   culture	  supernatant	  and	  
fractions	  of	  size	  exclusion	  chromatography.	  	  
Samples	   of	   two	  donors	  were	   analyzed	   for	   the	   presence	  of	   a	   total	   of	   72	   factors	   by	   antibody	   array.	   Factors	  
marked	  by	  *	  were	  detected	  in	  one	  of	  two	  analyzed	  donors.	  
	  
Cell	  culture	  supernatant	  (n=2)	  
CCL2	  	  (MCP1)	   CXCL5	  (ENA	  78)	   CXCL16*	  
TIMP1	   CXCL1,2,3	  (Gro)	   CXCL10	  (IP10)*	  
TIMP2	   Angiopoetin	  1	   uPAR	  
IL6*	   Angiopoetin	  2	   VEGFR3	  
CXCL8	  (IL8)	   	   	  
	  
	  
SEC	  fraction	  /	  1000	  kDa	  (n=2)	   SEC	  fraction	  /	  100	  kDa	  (n=1)	  
VEGFR3*	   VEGFR3	  
	   uPAR	  
	   TIMP1	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2.3. Purification	  step	  2:	   Ion	  exchange	  chromatography	  of	  high-­‐molecular-­‐
weight	  fractions	  of	  MSC	  cell	  culture	  supernatant	  
In	  order	  to	  reduce	  sample	  complexity	  and	  purify	  the	  migration-­‐inducing	  factor(s)	  mediating	  cancer	  
cell	   migration	   towards	   MSC,	   high-­‐molecular-­‐weight	   SEC	   fractions	   showing	   migration-­‐inducing	  
activity	   were	   pooled	   and	   further	   separated	   by	   ion	   exchange	   chromatography	   (IEX).	   A	   positively	  
charged	   stationary	  phase	  bound	  negatively	   charged	  proteins	   to	   the	   column	  and	   allowed	  a	  direct	  
elution	   of	   positively	   charged	   proteins.	   After	   loading	   the	   sample	   onto	   the	   column,	   the	   bound	  
proteins	  were	   eluted	   off	   the	   column	   by	   gradually	   increasing	   the	   NaCl	   concentration	   of	   the	   fluid	  
phase.	  Proteins	  eluted	  off	  the	  column	  depending	  on	  their	  ionic	  strength	  and	  on	  the	  amount	  of	  NaCl	  
required	  to	  disrupt	  the	  interaction	  between	  the	  proteins	  and	  the	  stationary	  phase	  (anion	  exchange	  
chromatography).	  
2.3.1. Ion	   exchange	   chromatography	   yields	   reproducible	   fractionation	   of	   high-­‐
molecular-­‐weight	  proteins	  
The	  use	  of	   a	  MonoQ	  HR	  5/5	   column	  with	   50	  mM	  Tris-­‐buffer	   containing	   50	  mM	  NaCl	   as	   the	   fluid	  
phase,	  combined	  with	  0.5	  ml/min	  flow	  rate	  and	  an	  automated	  continuous	  NaCl	  gradient	  resulted	  in	  
an	   anion	   exchange	   fractionation	   with	   high	   reproducibility	   and	   reliability.	   Prior	   to	   automated	  
elution,	   the	   samples	   were	   manually	   loaded	   via	   a	   superloop	   and	   the	   initial	   flow-­‐through	   was	  
discarded.	   The	   initial	   flow-­‐through	   did	   not	   require	   further	   analysis	   after	   establishing	   that	   it	  
contained	  no	  observable	  migration-­‐inducing	  activity	  towards	  PC3	  cells.	  
Comparison	  of	  chromatograms	  of	  three	  separate	  donors	  revealed	  variations	  in	  peak	  height	  but	  very	  
low	  differences	   in	   the	   retention	   volumes	   at	  which	   the	  main	   peaks	   eluted	  off	   the	   column	   (Figure	  
8	  A).	   Low	   variations	   in	   retention	   volume	  were	   observed	   by	   comparing	   the	   retention	   volumes	   of	  
chromatogram	  peaks	  of	  separate	  FPLC	  runs	  of	  two	  MSC	  donors	  (biological	  replicates)	  (Figure	  8	  B).	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Figure	   8:	   Ion	   exchange	   chromatography	   yields	   reproducible	   fractionation	   of	   high-­‐molecular-­‐weight	  
proteins	  isolated	  from	  MSC	  cell	  culture	  supernatant.	  	  
A:	   Ion	   exchange	   chromatogram	   of	   proteins	   detected	   at	   280	  nm	   during	   elution.	   For	   each	   donor	   a	   total	   of	  
130	  ml	   of	   MSC	   cell	   culture	   supernatant	   were	   filtered,	   concentrated	   and	   fractionated	   by	   multiple	   size	  
exclusion	   chromatography	   runs.	   Resulting	   high-­‐molecular-­‐weight	   fractions,	   approx.	   1500	   –	   800	  kDa	   in	   size,	  
with	  high	  migration-­‐inducing	  activity	  were	  pooled,	  loaded	  onto	  an	  anion	  exchange	  column	  and	  eluted	  off	  the	  
column	   by	   a	   NaCl	   gradient.	  B:	   Correlation	   plot	   of	   main	   peak	   retention	   volumes	   between	   samples	   of	   two	  



































































	   28	  
2.3.2. High-­‐molecular-­‐weight	   proteins	   of	   distinct	   ionic	   strength	   show	   elevated	  
migration-­‐inducing	  activity	  towards	  prostate	  cancer	  cells	  
IEX	  fractions	  of	  three	  MSC	  donors	  eluted	  off	  the	  anion	  exchange	  column	  with	  NaCl	  concentrations	  
ranging	   from	   50	  mM	   to	   870	  mM	   were	   tested	   for	   their	   migration-­‐inducing	   activity	   towards	   the	  
prostate	   cancer	   cell	   line	   PC3.	   Migration	   response	   of	   PC3	   cells	   towards	   the	   IEX	   fractions	   was	  
analyzed	  relative	  to	  the	  maximum	  response	  induced	  by	  the	  unprocessed	  cell	  culture	  supernatant	  of	  
the	   respective	   donor.	   Fractions	   eluting	   off	   the	   column	   at	   around	   250	  mM	   showed	   migration-­‐
inducing	  activity	  of	  up	  to	  35%	  compared	  to	  the	  unprocessed	  cell	  culture	  supernatant.	  On	  average	  
though,	  the	  strongest	  migration	  response	  of	  up	  to	  70%	  was	  seen	  for	  proteins	  eluted	  off	  the	  column	  
at	  a	  NaCl	  concentration	  of	  approx.	  340	  mM	  (Figure	  9	  A).	  In	  contrast	  to	  SEC	  fractions	  (Figure	  6	  A),	  IEX	  
fractions	  showed	  a	  more	  focused	  distribution	  of	  migration-­‐inducing	  activity	  in	  fewer	  fractions.	  
Individual	  analysis	  of	  PC3	  migration	  response	  after	  three	  hours	  towards	  the	   IEX	  fractions	  of	  three	  
MSC	   donors	   confirmed	   strong	   migration-­‐inducing	   activity	   towards	   340	  mM	   IEX	   fractions	   for	   all	  
three	  donors	  ranging	   from	  50%	  to	  80%	  (peak	  2).	  Donor	  1	  and	  donor	  2	  showed	  additional	  activity	  
peaks	   (peak	   3)	   in	   fractions	   eluted	   at	   approx.	   380	  mM	   NaCl	   with	   comparable	   migration-­‐inducing	  
activity.	  This	  peak	  was	  not	  observed	  for	  donor	  3.	  Migration-­‐inducing	  activity	  of	  fractions	  eluted	  at	  
250	  mM	  NaCl	   (peak	   1)	   could	   also	   only	   be	   confirmed	   for	   donor	   1	   and	   donor	   2	   of	  which	   donor	   1	  
induced	   a	   migration	   response	   of	   approx.	   60%	   whereas	   donor	   2	   only	   showed	   minor	   activity	   of	  
approx.	   20%.	   IEX	   fractions	   of	   Donor	   3	   showed	   an	   overall	   reduced	   migration-­‐inducing	   activity	  
towards	  the	  prostate	  cancer	  cell	  line	  PC3	  (Figure	  9	  B).	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Figure	   9:	   Proteins	   of	   distinct	   ionic	   strength	   show	   elevated	  migration-­‐inducing	   activity	   towards	   prostate	  
cancer	  cells.	  	  
A:	  Average	  migration	  response	  over	  time	  of	  prostate	  cancer	  cell	  line	  PC3	  towards	  IEX	  fractions	  of	  cell	  culture	  
supernatant	  of	  three	  individual	  MSC	  donors.	  B:	  Individual	  migration	  response	  of	  prostate	  cancer	  cell	  line	  PC3	  
towards	   IEX	   fractions	   of	   MSC	   culture	   supernatant	   after	   3	   h.	   Migration	   response,	   determined	   with	   the	  
xCELLigence	   system,	   is	   displayed	   as	   relative	   to	   the	  maximum	   response	  observed	   towards	   the	  unprocessed	  




























A: Migration response of PC3 cells towards fractions of ion exchange chromatography n=3
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2.3.3. Mass	   spectrometry	   confirms	   the	  presence	  of	   extracellular	  matrix	  proteins	  
in	  IEX	  fractions	  with	  elevated	  migration-­‐inducing	  activity	  
Due	  to	  fluctuations	  in	  migration-­‐inducing	  activity	  of	  IEX	  fractions	  of	  individual	  MSC	  donors	  (Figure	  9	  
B),	   varying	   fractions	   were	   chosen	   for	   mass	   spectrometry	   analysis	   depending	   on	   the	   donor.	   All	  
analyzed	  IEX	  fractions	  showed	  elevated	  migration-­‐inducing	  activity	  and	  could	  be	  assigned	  to	  activity	  
peak	  1	  (donor	  1,	  donor	  2),	  peak	  2	  (donor	  1,	  donor	  2,	  donor	  3)	  as	  well	  as	  peak	  3	  (donor	  1,	  donor	  2)	  
(Figure	  9	  B).	  A	  full	  list	  of	  proteins	  identified	  in	  IEX	  fractions	  with	  elevated	  migration-­‐inducing	  activity	  
towards	  the	  prostate	  cancer	  cell	  line	  PC3	  can	  be	  found	  for	  peak	  1	  (Table	  3),	  for	  peak	  2	  (Table	  4)	  and	  
for	  peak	  3	  (Table	  5).	  
A	  number	  of	  proteins	   that	  were	  previously	  detected	   in	  migration-­‐inducing	  SEC	   fractions	   (Table	  1)	  
were	  also	  identified	  in	  at	  least	  one	  of	  the	  IEX	  fractions	  showing	  peaks	  in	  migration-­‐inducing	  activity	  
(Table	  3,	  Table	  4,	  Table	  5).	  These	  proteins	  included	  type	  I,	   III	  and	  VI	  collagen,	  fibrillin,	  fibronectin,	  
galectin-­‐3	   binding	   protein,	   hemopexin,	   laminins	   with	   subunits	   β-­‐2	   and	   γ-­‐1	   such	   as	   laminin	   421,	  
serine	  protease	  and	  TGF-­‐β	  induced	  protein.	  
	  
Table	  3:	  Proteins	  detected	  by	  mass	  spectrometry	  in	   IEX	  fractions	  of	  MSC	  cell	  culture	  supernatant;	  activity	  
peak	  1	  found	  in	  MSC	  donors	  1	  and	  2.	  
Migration-­‐inducing	  proteins	  were	  eluted	  off	  the	  column	  at	  varying	  salt	  concentrations	  ranging	  from	  200	  mM	  
to	  250	  mM	  NaCl	  depending	  on	  the	  MSC	  donor.	  Nonetheless,	  these	  fractions	  shared	  the	  first	  eluted	  migration-­‐
inducing	  activity	  towards	  PC3	  cells.	  Proteins	  listed	  were	  identified	  in	  samples	  of	  both	  donor	  1	  and	  donor	  2.	  
	  
Symbol Name	   Description	  
CO1A1 Collagen	  α-­‐1(I)	  chain	  OS	   Fibrillar	  collagen	  
CO1A2 Collagen	  α-­‐2(I)	  chain	  OS	   Fibrillar	  collagen	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Table	  4:	  Proteins	  detected	  by	  mass	  spectrometry	  in	   IEX	  fractions	  of	  MSC	  cell	  culture	  supernatant;	  activity	  
peak	  2	  found	  in	  MSC	  donors	  1,	  2	  and	  3.	  
Migration-­‐inducing	  proteins	  were	  eluted	  off	  the	  column	  at	  salt	  concentrations	  of	  approx.	  325	  mM	  NaCl	  for	  all	  
three	  MSC	  donors.	  Proteins	  listed	  were	  identified	  in	  samples	  of	  two	  or	  all	  three	  (*)	  donors.	  
	  
Symbol Name	   Description	  
CD63* CD63	  antigen*	   Transmembrane	  protein	  
COL1A1* Collagen	  α-­‐1(I)	  chain*	   Fibrillar	  collagen	  
COL3A1* Collagen	  α-­‐1(III)	  chain*	   Fibrillar	  collagen	  
COL6A1* Collagen	  α-­‐1(VI)	  chain*	   Fibrillar	  collagen	  
COL1A2* Collagen	  α-­‐2(I)	  chain*	   Fibrillar	  collagen	  
COL6A2* Collagen	  α-­‐2(VI)	  chain*	   Fibrillar	  collagen	  
COL6A3* Collagen	  α-­‐3(VI)	  chain*	   Fibrillar	  collagen	  
DSG1 Desmoglein-­‐1	   Cell	  adhesion	  protein	  of	  the	  desmosome	  
complex	  
DESP* Desmoplakin*	   Intra	  cellular	  protein	  of	  desmosome	  complex	  
G3P Glyceraldehyde-­‐3-­‐phosphate	  
dehydrogenase	  
Energy	  metabolism	  enzyme	  
HEMO* Hemopexin*	   Acute	  phase	  plasma	  glycoprotein	  
PLAK Junction	  plakoglobin	   Cytoplasmic	  protein	  of	  desmosome	  complex	  
LAMC1 Laminin	  subunit	  γ-­‐1	   ECM	  glycoprotein	  of	  basement	  membrane	  
LAMP2 Lysosome-­‐associated	  membrane	  
glycoprotein	  2	  
Cell	  membrane	  glycoprotein	  
PZP Pregnancy	  zone	  protein	   Proteinase	  binding	  macroglobulin	  
PIP Prolactin-­‐inducible	  protein	   Secreted	  protein	  with	  aspartyl	  protease	  
activity	  
RAB7A Ras-­‐related	  protein	  Rab-­‐7a	   Endosomal	  protein	  
TRFE* Serotransferrin*	   Iron	  binding	  protein	  
SDCB1 Syntenin-­‐1	   Intra	  cellular	  syndecan	  binding	  protein	  
BGH3* Transforming	  growth	  factor-­‐β-­‐
induced	  protein	  ig-­‐h3*	  
RGD	  containing	  ECM	  protein	  
RS27A Ubiquitin-­‐40S	  ribosomal	  protein	  
S27a	  
Ribosomal	  protein	  
ZA2G Zinc-­‐α-­‐2-­‐glycoprotein	   Secreted	  stimulant	  of	  lipolysis	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Table	  5:	  Proteins	  detected	  by	  mass	  spectrometry	  in	  IEX	  fractions	  of	  MSC	  cell	  culture	  supernatant;	  activity	  
peak	  3	  found	  in	  MSC	  donors	  1	  and	  2.	  
Migration-­‐inducing	   proteins	   were	   eluted	   off	   the	   column	   at	   salt	   concentrations	   off	   approx.	   380	   mM	   NaCl	  
depending	  on	  the	  MSC	  donor.	  Proteins	  listed	  were	  identified	  in	  samples	  of	  both	  donor	  1	  and	  donor	  2.	  
	  
Symbol Name	   Description	  
CO1A1 Collagen	  α-­‐1(I)	  chain	   Fibrillar	  collagen	  
CO3A1 Collagen	  α-­‐1(III)	  chain	   Fibrillar	  collagen	  
CO6A1 Collagen	  α-­‐1(VI)	  chain	   Fibrillar	  collagen	  
CO1A2 Collagen	  α-­‐2(I)	  chain	   Fibrillar	  collagen	  
CO6A2 Collagen	  α-­‐2(VI)	  chain	   Fibrillar	  collagen	  
CO6A3 Collagen	  α-­‐3(VI)	  chain	   Fibrillar	  collagen	  
DESP Desmoplakin	   Intra	  cellular	  protein	  of	  desmosome	  
complex	  
FBN1 Fibrillin-­‐1	   ECM	  glycoprotein	  
FINC Fibronectin	   ECM	  glycoprotein	  
LG3BP Galectin-­‐3-­‐binding	  protein	   ECM	  β-­‐galactoside-­‐binding	  protein	  
HEMO Hemopexin	   Acute	  phase	  plasma	  glycoprotein	  
LAMB2 Laminin	  subunit	  β-­‐2	   ECM	  glycoprotein	  of	  basement	  membrane	  
LAMC1 Laminin	  subunit	  γ-­‐1	   ECM	  glycoprotein	  of	  basement	  membrane	  
MYH9 Myosin-­‐9	   Intra	  cellular	  non-­‐muscle	  myosin	  
LRP1 Prolow-­‐density	  lipoprotein	  
receptor-­‐related	  protein	  1	  
Plasma	  membrane	  receptor	  
TRFE Serotransferrin	   Iron	  binding	  protein	  
TARSH Target	  of	  Nesh-­‐SH3	   SH3	  domain-­‐binding	  protein	  of	  NESH-­‐
SH3/Abi3	  
TENA Tenascin	   ECM	  glycoprotein	  
BGH3 Transforming	  growth	  factor-­‐β-­‐
induced	  protein	  ig-­‐h3	  
RGD	  containing	  ECM	  protein	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2.4. Functional	  analysis	  of	  extracellular	  matrix	  proteins	  secreted	  by	  MSC	  
Size	  exclusion	  chromatography	  of	  MSC	  cell	  culture	  supernatant	  revealed	  migration-­‐inducing	  activity	  
towards	  the	  prostate	  cancer	  cell	  line	  PC3	  and	  the	  breast	  cancer	  cell	  line	  MDA-­‐MB-­‐231	  to	  be	  mainly	  
caused	  by	  high-­‐molecular-­‐weight	  proteins	  or	  protein	  complexes	  of	  approximately	  1000	  kDa	  in	  size.	  
Mass	   spectrometry	   and	   antibody	   array	   analysis	   of	   these	   fractions	   revealed	   the	   presence	   of	   ECM	  
proteins	   and	   the	   absence	   of	   classic	   chemokines.	   Ion	   exchange	   chromatography	   of	   SEC	   fractions	  
with	  migration-­‐inducing	  activity	  further	  enriched	  the	  migration-­‐inducing	  factors	  and	  confirmed	  the	  
presence	  of	  extracellular	  matrix	  proteins.	   In	  order	  to	  understand	  the	  effect	  of	  extracellular	  matrix	  
proteins	   on	   the	   migration	   of	   cancer	   cells	   towards	   MSC,	   recombinant	   and	   isolated	   extracellular	  
matrix	   proteins	   as	   well	   as	   chemokines	   were	   purchased	   and	   tested	   for	   their	   potential	   to	   trigger	  
prostate	  cancer	  cell	  migration.	  	  
2.4.1. Prostate	  cancer	  cells	  do	  not	  migrate	  towards	  recombinant	  chemokines	  
Mass	   spectrometry	   and	   antibody	   array	   analysis	   failed	   to	   show	   the	   presence	   of	   chemokines	   in	  
chromatographic	   fractions	   with	   migration-­‐inducing	   activity.	   Nonetheless,	   three	   recombinant	  
chemokines	  were	  tested	  for	  their	  effect	  on	  the	  migratory	  behavior	  of	  PC3	  cells,	  since	  chemokines	  
are	   intensely	   discussed	   in	   the	   process	   of	   metastasis	   formation111,112.	   Furthermore,	   CCL2	   was	  
detected	   in	   the	   unprocessed	   cell	   culture	   supernatant	   of	   MSC	   prior	   to	   chromatographic	  
fractionation	  and	  CCL2116,	  CCL5117	  as	  well	  as	  CXCL12118	  are	  reported	  to	  play	  a	  role	  in	  prostate	  cancer	  
progression	  or	   cell	  migration.	   Therefore,	   these	   chemokines,	   in	   recombinant	   form,	  were	   analyzed	  
for	  their	  ability	  to	   induce	  PC3	  prostate	  cancer	  cell	   line	  migration	  in	  comparison	  to	  the	  cell	  culture	  
supernatant	  of	  MSC.	  	  
CCL2,	  CCL5	  and	  CXCL12	  were	  tested	  in	  concentrations	  ranging	  from	  10	  ng/ml	  to	  500	  ng/ml	  and	  the	  
most	  potent	  concentration	  was	  used	  to	  describe	  the	  chemotactic	  potential	  the	  respective	  protein	  
had	   to	   induce	   prostate	   cancer	   cell	   migration.	   All	   three	   chemokines	   failed	   to	   induce	   a	  migration	  
response	   comparable	   to	   the	   cell	   culture	   supernatant	   of	   MSC.	   After	   24	   hours	   CCL2	   was	   able	   to	  
induce	  a	  slight	  migration	  response	  of	  10%	  but	  results	  varied	  strongly	  between	  experiments	  (Figure	  
10	  A	  –	  C).	  
Some	  reports	  have	  suggested	  that	  bone-­‐metastasizing	  cancers	  may	  mimic	  the	  process	  of	  homing	  of	  
hematopoietic	   stem	   cells	   to	   their	   bone	   niche,	   in	   which	  MSC	   play	   a	   crucial	   role21,22.	   It	   has	   been	  
demonstrated	   that	   CXCL12	   secreted	   by	  MSC	   is	   a	   key	   driver	   of	   HSC	  migration	   and	   homing119.	   By	  
comparing	  the	  migration	  response	  of	  freshly	  isolated	  primary	  HSC	  and	  PC3	  cells	  towards	  a	  gradient	  
of	   CXCL12	   to	   their	   respective	   negative	   control,	   it	   was	   observed	   that	   CXCL12	   induced	   a	   fourfold	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average	   increase	   in	   HSC	   migration,	   whereas	   CXCL12	   failed	   to	   induce	   an	   increase	   of	   PC3	   cell	  
migration	  (Figure	  10	  D).	  	  
	  
	  
Figure	  10:	  Prostate	  cancer	  cells	  do	  not	  migrate	  towards	  recombinant	  chemokines.	  
A	   –	   C:	   Migration	   response	   of	   PC3	   prostate	   cancer	   cells	   towards	   chemokines	   is	   displayed	   relative	   to	   the	  
migration	  towards	  MSC	  cell	  culture	  supernatant	  at	  the	  respective	  time	  points.	  CXCL12	  (A),	  CCL2	  (B)	  and	  CCL5	  
(C)	  were	   used	   at	   a	   concentration	  of	   100	  ng/ml.	   Error	   bars	   of	   boxplots	   are	   based	  on	   Tukey-­‐whiskers	  which	  
extend	  to	  data	  points	   that	  are	   less	   than	  1.5	  x	   inter	  quartile	   range	  away	  from	  1st	  or	  3rd	  quartile.	  D:	  Average	  
migration	   response	   of	   primary	   hematopoietic	   stem	   cells	   (HSC)	   and	   PC3	   cells	   towards	   CXCL12	   (100	  ng/ml)	  
relative	  to	  the	  corresponding	  negative	  controls.	  Error	  bars	  indicate	  standard	  deviation.	  Migration	  response	  of	  
PC3	  cells	  was	  determined	  with	  the	  xCELLigence	  system,	  whereas	  non-­‐adherent	  HSC	  migration	  was	  monitored	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2.4.2. Prostate	  cancer	  cells	  migrate	  towards	  recombinant	  and	  isolated	  proteins	  of	  
the	  extracellular	  matrix	  
Extracellular	  matrix	  proteins	  identified	  by	  mass	  spectrometry	  in	  SEC	  or	  IEX	  fractions	  with	  migration-­‐
inducing	   activity,	   and	   which	   were	   previously	   discussed	   in	   the	   literature	   in	   the	   context	   of	  
metastasis120	  or	  cancer	  progression78,	  were	  investigated	  for	  their	  ability	  to	  trigger	  migration	  of	  the	  
prostate	  cancer	  cell	  line	  PC3.	  	  
Commercially	   available	   recombinant	   and	   isolated	   ECM	   proteins	   were	   tested	   in	   concentrations	  
ranging	   from	   0.1	  μg/ml	   to	   10	  μg/ml.	   The	   most	   potent	   concentration	   was	   used	   to	   analyze	   the	  
migration-­‐inducing	  potential	   the	   respective	  proteins	  had	   to	   induce	  prostate	  cancer	   cell	  migration	  
(Figure	  11).	  Fibrillar	   type	   I	  and	   III	  collagen	   induced	  a	  rapid	  PC3	  migration	  response	  after	  only	  two	  
hours.	   Type	   I	   collagen	   even	   exceeded	   the	   migration-­‐inducing	   potential	   of	   the	   cell	   culture	  
supernatant	  of	  MSC,	   triggering	  a	  140%	  migration	  response	  after	   two	  hours	   (Figure	  11	  A).	  Type	   III	  
collagen	   induced	   an	   early	   migration	   response	   of	   over	   45%	   compared	   to	   MSC	   cell	   culture	  
supernatant.	   Interestingly,	   type	   III	   collagen	   was	   not	   able	   to	   induce	   a	   sustainable	   migration	  
response,	  with	  values	  declining	  down	  to	  12%	  over	  time	  (Figure	  11	  B).	  Plasma	  fibronectin	  induced	  a	  
linearly	   increasing	  migration	   response	  over	   time	  starting	  at	  20%	  after	   two	  hours	  and	   reaching	   its	  
maximum	  response	  after	  24	  hours	  of	  approx.	  80%	  compared	  to	  the	  MSC	  cell	  culture	  supernatant	  
(Figure	  11	  C).	  Laminin	  421	  showed	  similar	  dynamics	  in	  PC3	  migration	  induction	  but	  reached	  up	  to	  
90%	  of	  migration	  response	  induced	  by	  the	  MSC	  cell	  culture	  supernatant	  after	  24	  hours	  (Figure	  11	  
D).	   In	   contrast	   to	   laminin	  421,	   Laminin	  411,	  also	   found	   in	  mesenchymal	   tissues,	  did	  not	   induce	  a	  
migration	   response	  with	   only	   a	  median	   response	   of	   20%	   after	   12	   hours,	  which	   again	   diminished	  
after	  24	  h	  (Figure	  11	  E).	  Matricellular	  proteins	  nidogen1	  (Figure	  11	  F)	  as	  well	  as	  thrombospondin	  1	  
&	  2	  (Figure	  11	  G,	  H)	  also	  failed	  to	  induce	  clear	  PC3	  migration	  with	  only	  a	  slight	  migration	  response	  
after	  24h.	  Nonetheless,	  this	   late	  response	  towards	  thrombospondin	  1	  &	  2	  did	  not	  exceed	  6%	  and	  
20%	   respectively	   and	   showed	   a	   high	   degree	   of	   variability	   between	   experiments.	   Both	   galectin-­‐3	  
binding	   protein	   (Figure	   11	  I)	   and	   TGF-­‐β	   induced	   protein	   (Figure	   11	   J)	   showed	   no	   induction	   of	  
migration.	  	  
In	  summary,	  the	  tested	  proteins	  could	  be	  classified	  into	  three	  groups:	  	  
 Proteins	  inducing	  rapid	  migration,	  including	  type	  I	  and	  III	  collagen.	  
 Proteins	   inducing	   migration	   with	   slower	   or	   delayed	   dynamics,	   including	   fibronectin	   and	  
laminin	  421.	  
 Proteins,	   which	   do	   not	   induce	  migration,	   including	   laminin	   411,	   thrombospondin	   1	   &	   2,	  
galectin-­‐3	  binding	  protein	  as	  well	  as	  TGF-­‐β	  induced	  protein.	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Figure	   11:	   Prostate	   cancer	   cells	  migrate	   towards	   recombinant	   and	   isolated	   proteins	   of	   the	   extracellular	  
matrix.	  
Migration	  response	  of	  PC3	  prostate	  cancer	  cells	  towards	  ECM	  proteins	  is	  displayed	  relative	  to	  the	  migration	  
towards	   MSC	   cell	   culture	   supernatant	   at	   the	   respective	   time	   points.	   All	   proteins	   were	   tested	   with	  
concentrations	   ranging	   from	   0.1	  μg/ml	   to	   10	  μg/ml	   and	   the	   most	   potent	   concentration	   was	   chosen	   for	  
analysis.	  A:	   Type	   I	   collagen	   isolated	   from	   human	   skin,	   5	  μg/ml.	   B:	   Type	   III	   collagen	   isolated	   from	   human	  
placenta,	   10	  μg/ml.	  C:	   Fibronectin	   isolated	   from	  human	  plasma,	   10	  μg/ml.	  D:	   Recombinant	   human	   laminin	  
421,	  10	  μg/ml.	  E:	  Recombinant	  human	  laminin	  411,	  10	  μg/ml.	  F:	  Recombinant	  human	  nidogen	  1,	  1	  μg/ml.	  G:	  
Recombinant	   human	   thrombospondin	   1,	   1	  μg/ml.	  H:	   Recombinant	   human	   thrombospondin	   2,	   0.1	  μg/ml.	   I:	  
Recombinant	   human	   galectin-­‐3	   binding	   protein,	   1	  μg/ml.	   J:	   Recombinant	   human	   TGF-­‐β	   induced	   protein,	  
1	  μg/ml.	  Error	  bars	  of	  boxplots	  are	  based	  on	  Tukey-­‐whiskers	  which	  extend	  to	  data	  points	   that	  are	  less	  than	  
1.5	  x	  inter-­‐quartile	  range	  away	  from	  1st	  or	  3rd	  quartile.	  Migration	  response	  of	  PC3	  cells	  was	  determined	  with	  
the	  xCELLigence	  system	  (A	  –	  J).	  
2.5. Knockdown	   of	   β1	   integrin	   in	   prostate	   cancer	   cells	   by	   RNAi	   impairs	  
migration	  towards	  MSC	  
After	  establishing	  that	  ECM	  proteins	  triggered	  the	  observed	  prostate	  cancer	  cell	  migration	  towards	  
MSC,	   integrin	   receptors	   potentially	   mediating	   the	   response	   of	   the	   migrating	   cancer	   cells	   were	  
investigated.	  Integrins	  are	  essential	  cellular	  receptors	  of	  extracellular	  matrix	  proteins.	  They	  consist	  
of	  an	  α-­‐	  and	  β-­‐	  subunit	  forming	  a	  functional	  dimer121.	  In	  order	  to	  better	  understand	  how	  prostate	  
cancer	   cells	  migrate	   along	   a	   diffusible	   gradient	   of	   ECM	  proteins	   towards	  MSC,	   β-­‐integrins	   (ITGB)	  
expressed	   in	  PC3	   cells	  were	   chosen	   for	   siRNA-­‐mediated	   knockdown122.	   Integrins	  of	   interest	  were	  
identified	  by	  in	  house	  RNAseq	  experiments	  on	  PC3	  cells	  and	  current	  knowledge	  in	  the	  literature123.	  
Here	  β1,	  β3,	  β6,	  β7	  and	  β8	  integrins	  were	  chosen	  for	  knockdown	  in	  PC3	  cells	  migrating	  towards	  the	  
cell	  culture	  supernatant	  of	  MSC.	  	  
Targeting	   gene	   expression	   by	   siRNA	   mediated	   knockdown	   required	   a	   number	   of	   control	  
experiments.	  As	  the	  general	  fitness	  of	  a	  cell	  has	  an	  impact	  on	  its	  motility	  and	  migration	  capacity,	  a	  
control	  siRNA	  was	   included	  in	  the	  experiments	  to	  consider	  cell	  viability	  and	  fitness	  effects	  caused	  
by	  the	  toxicity	  of	  the	  siRNA	  reagents	  and	  transfection	  procedure.	  As	  control	  siRNA	  siRLUC	  targeting	  
Renilla-­‐luciferase,	   which	   is	   not	   expressed	   in	   PC3	   cells,	   was	   chosen.	   Furthermore,	   successful	  
reduction	  of	  mRNA	  levels	  by	  siRNA	  knockdown	  of	  the	  respective	  genes	  was	  confirmed	  by	  qPCR	  for	  
each	   experiment	   (Figure	   12	   F).	   As	   cellular	   migration	   depends	   on	   the	   cells	   ability	   to	   attach	   and	  
spread,	  PC3	  cells	  were	  also	  analyzed	  by	  phase	  contrast	  microscopy	  after	  siRNA	  treatment	  to	  assess	  
the	  capability	  of	  the	  cells	  to	  attach	  and	  spread.	  
Among	  targeted	  β-­‐integrins,	  only	  β1	   integrin	  knockdown	  showed	  a	  strong	  reduction	   in	  cancer	  cell	  
migration.	  In	  comparison	  to	  siRLUC	  treated	  cells,	  siITGB1	  treated	  cells	  showed	  a	  reduced	  migration	  
response	  towards	  the	  cell	  culture	  supernatant	  of	  MSC	  over	  the	  complete	  time	  course	  of	  24	  hours.	  
After	   two	   hours	   in	   which	   PC3	   cells	   normally	   showed	   a	   full	   migration	   response,	   β1	   integrin	  
knockdown	   fully	   inhibited	   PC3	   migration.	   A	   gradual	   migration	   response	   of	   siITGB1	   treated	   cells	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could	  be	  observed	  in	  the	  following	  hours,	  reaching	  only	  30%	  of	  siRLUC	  treated	  cells	  after	  24	  hours	  
(Figure	   12	   A).	   Phase	   contrast	   imaging	   of	   PC3	   cells	   after	   siITGB1	   knockdown	   (Figure	   13	   B,	  
Supplementary	  figure	  4)	  showed	  a	  slight	  viability	  effect	  and	  cellular	  attachment	  deficits	  compared	  
to	  siRLUC	  treated	  cells	  (Figure	  12	  A,	  Supplementary	  figure	  3).	  Nonetheless,	  the	  strong	  reduction	  of	  
cell	   migration	   after	   siITGB1	   treatment	   was	   not	   accompanied	   by	   such	   strong	   morphological	  
differences	  that	  could	  explain	  the	  decreased	  migration	  phenotype.	  
In	  contrast	  to	  siITGB1	  treatment,	  siITGB3	  treated	  PC3	  cells	  showed	  the	  opposite	  effect.	  After	  only	  a	  
slight	  reduction	  in	  migration	  of	  approx.	  10%	  after	  two	  hours,	  a	  clear	  increase	  in	  migration	  response	  
after	   four	  hours	  of	  over	   twofold	  was	  observed	  when	  comparing	   siITGB3	  and	   siRLUC	   treated	  cells	  
(Figure	   12	   B).	   Furthermore,	   a	   strong	   change	   in	   cellular	   morphology	   was	   observed	   with	   cells	  
presenting	  reduced	  phase	  contrast,	  indicating	  increased	  cellular	  attachment	  and	  spreading	  (Figure	  
13	  C,	  Supplementary	  figure	  5).	  	  
A	  similar	  effect	  could	  be	  observed	  with	  PC3	  cells	  undergoing	  siITGB8	  treatment,	  albeit	  not	  quite	  as	  
pronounced.	   Cells	   showed	   an	   increased	   migration	   response	   of	   up	   to	   twofold	   after	   eight	   hours	  
(Figure	   12	   E).	   siITGB8	   cells	   also	   showed	   morphological	   changes	   and	   reduced	   intensity	   in	   phase	  
contrast	  microscopy	  compared	  to	  siRLUC	  treated	  cells.	  This	  difference	  was	  not	  as	  strong	  as	   in	  the	  
case	   of	   siITGB3	   treated	   cells,	   suggesting	   that	   the	   attachment	   and	   spreading	   did	   not	   increase	   as	  
strongly	  as	  in	  the	  case	  of	  siITGB3	  treated	  cells.	  	  
siITGB6	  treated	  cells	  showed	  a	  slight	  delay	  in	  migration	  response	  with	  cells	  reaching	  full	  migration	  
after	   four	   hours.	   These	   cells	   were	   therefore	   still	   able	   to	   migrate	   towards	   the	   cell	   culture	  
supernatant	  of	  MSC,	  but	  were	  not	  able	  to	  show	  the	  high	  migration	  dynamics	  seen	  in	  siRLUC	  treated	  
cells	   (Figure	   12	   C).	   No	   visible	  morphological	   changes	   could	   be	   observed	   after	   siITGB6	   treatment	  
(Figure	  13	  D,	  Supplementary	  figure	  6).	  
siITGB7	  treated	  cells	  showed	  a	  similar	  migration	  phenotype	  to	  siITGB6	  treated	  cells	  with	  a	  stronger	  
delay	  in	  early	  migration	  response	  reaching	  approx.	  40%	  of	  siRLUC	  treated	  cells	  after	  two	  hours.	  Full	  
migration	   response	   towards	   the	   cell	   culture	   supernatant	   of	  MSC	  was	   regained	   after	   eight	   hours	  
(Figure	  12	  D).	  No	  morphological	  changes	  were	  observed	  compared	  to	  siRLUC	  treated	  cells	   (Figure	  
13	  E,	  Supplementary	  figure	  7).	  	  
In	  summary,	  the	  expression	  of	  β1	   integrin	  was	  essential	   for	   the	  observed	  migratory	   interaction	  of	  
PC3	   cells	   and	   MSC.	   PC3	   cells	   lacking	   β-­‐1	   integrin	   not	   only	   failed	   to	   show	   the	   observed	   rapid	  
migration	  response	  after	  two	  hours	  but	  also	  showed	  a	  strong	  decrease	  in	  migration	  after	  24	  hours.	  
Cells	  lacking	  β6	  integrin,	  and	  even	  more,	  cells	  lacking	  β7	  integrin	  showed	  a	  reduction	  in	  early	  rapid	  
migration	   response	   towards	   the	   cell	   culture	   supernatant	   of	   MSC.	   Nonetheless,	   a	   full	   migration	  
response	  was	  observed	  after	  four	  and	  eight	  hours	  respectively.	  Loss	  of	  β3	   integrin	  and	  β8	   integrin	  
did	  not	  alter	  the	  early	  migration	  response	  but	  led	  to	  an	  increase	  of	  migration	  response	  at	  later	  time	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points.	   This	   observation	  was	   in	   line	  with	  morphological	   changes	   of	   cells	   undergoing	   siITGB3	   and	  
siITGB8	   knockdown.	   In	   contrast	   to	   siITGB1,	   siITGB6	   and	   siITGB7	   treated	   cells,	   they	   showed	  
morphological	  changes,	  including	  enhanced	  adhesion	  and	  cell	  spreading.	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Figure	  12:	  Migration	  of	  prostate	   cancer	   cell	   line	  PC3	   towards	   cell	   culture	   supernatant	  of	  MSC	  after	  RNAi	  
treatment.	  	  
PC3	  prostate	   cancer	   cell	  migration	   response	   towards	  MSC	  cell	   culture	   supernatant	   after	  RNAi	   treatment	   is	  
displayed	  relative	  to	  the	  migration	  response	  of	  PC3	  cells	  undergoing	  treatment	  with	  a	  siRNA	  control	  (siRLUC)	  
for	   each	   time	   point	   respectively.	   Migration	   experiments	   were	   conducted	   72	  h	   after	   reverse	   siRNA	  
transfection.	  A:	  Migration	  of	  PC3	  cells	  after	  β1	  integrin	  knockdown.	  B:	  Migration	  of	  PC3	  cells	  after	  β3	  integrin	  
knockdown.	  C:	  Migration	  of	  PC3	  cells	  after	  β6	  integrin	  knockdown.	  D:	  Migration	  of	  PC3	  cells	  after	  β7	  integrin	  
knockdown.	  E:	  Migration	  of	  PC3	  cells	  after	  β8	  integrin	  knockdown.	  F:	  Confirmation	  of	  successful	  knockdown	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gene	   expression	   found	   in	   cells	   treated	   with	   siRLUC	   control.	   Missing	   values	   are	   based	   on	   siRNA	  mediated	  
reduction	  of	  gene	  expression	  levels	  below	  the	  detection	  limit.	  
Error	  bars	  of	  boxplots	  are	  based	  on	  Tukey-­‐whiskers	  which	  extend	  to	  data	  points	  that	  are	  less	  than	  1.5	  x	  inter	  
quartile	  range	  away	  from	  1st	  or	  3rd	  quartile.	  Migration	  response	  of	  PC3	  cells	  undergoing	  siRNA	  treatment	  was	  




Figure	  13:	  Imaging	  of	  RNAi	  treated	  PC3	  cells.	  	  
PC3	  prostate	  cancer	  cells	  were	  seeded	  72	  h	  post	   reverse	  siRNA	  transfection	   in	  96-­‐well	   tissue	  culture	  plates	  
and	   imaged	   at	   10	  x	  magnification	   12	  h	   after	   seeding.	  A:	   siRLUC	   control.	  B:	   siITGB1.	  C:	   siITGB3	  D:	   siITGB6.	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3. Discussion	  
Previous	  work	  has	  linked	  mesenchymal	  stem	  cells	  and	  their	  progeny	  to	  the	  progression	  of	  cancer.	  
As	  a	  cell	  type	  capable	  of	  migrating	  to	  sites	  of	  tissue	  damage	  and	  inflammation,	  MSC	  are	  shown	  to	  
migrate	  towards	  the	  primary	  tumor	  and	  participate	  in	  tumor	  stroma	  formation,	  enabling	  a	  number	  
of	  cancer	  hallmarks	   including	   tumor	  growth	  and	  angiogenesis124,125.	  The	   importance	  of	   the	   tumor	  
microenvironment	   and	   its	   mesenchymal	   constituents	   has	   been	   appreciated,	   their	   role	   in	   cancer	  
progression	   is	  being	   intensely	   studied	  and	   therapeutic	   strategies	  are	  being	  developed	   specifically	  
designed	  to	  target	  the	  tumor	  stroma	  of	  the	  primary	  tumor126.	  	  
When	   it	   comes	   to	   the	   role	   of	   MSC	   in	   bone	   metastasis,	   less	   is	   known.	   A	   limitation	   towards	  
understanding	   the	   role	   of	  MSC	   in	   this	   step	   of	   tumor	   progression	   is	   that	   the	   in	   vivo	   identity	   and	  
localization	   of	   bona	   fide	   MSC	   in	   the	   bone	   marrow	   niche	   remains	   a	   matter	   of	   speculation27,29.	  
Nonetheless,	   three	  findings	  have	  suggested	  a	  potential	   role	  of	  MSC	   in	  bone	  metastasis	   formation	  
and	   have	   sparked	   the	   interest	   in	   understanding	   how	  MSC	   –	   cancer	   crosstalk	  might	  mediate	   the	  
formation	  of	  bone	  metastasis.	  	  
First,	  the	  chemokine	  CXCL12	  is	  secreted	  by	  MSC	  and	  acts	  as	  a	  key	  regulator	  of	  HSC	  homing	  into	  the	  
bone	  marrow	  niche127-­‐129.	  It	  is	  also	  an	  important	  signaling	  molecule	  in	  cancer	  related	  processes130,131	  
since	  it	  can	  induce	  cancer	  cell	  migration	   in	  vitro132.	   In	  vivo	  experiments	  confirmed	  the	  importance	  
of	  this	  chemokine	  by	  showing	  that	  blocking	  the	  CXCL12	  receptors	  CXCR4	  and	  CXCR7	  in	  cancer	  cells	  
can	  reduce	  the	  incidences	  and	  severity	  of	  bone	  lesions87,88.	  Second,	  cancer	  cells	  and	  HSC	  have	  been	  
shown	  to	  co-­‐localize	  in	  the	  bone21.	  Lastly,	  the	  formation	  of	  bone	  lesions	  not	  only	  leads	  to	  skeletal	  
complications	  regarding	  the	  structural	  integrity	  but	  also	  seems	  to	  affect	  the	  functional	  integrity	  of	  
the	  bone	  marrow	  niche	  as	  HSC	  and	  cancer	  cells	  compete	  for	  this	  niche133,134.	  This	  can	  result	   in	  an	  
increased	  amount	  of	  blood	  progenitor	  cells	  in	  the	  circulation,	  reduced	  immune	  cell	  count	  and	  even	  
anemia	   in	   later	   stages	   of	   bone	   metastasis	   growth135,136.	   These	   findings	   have	   fueled	   a	   debate	  
whether	   cancer	   cells	   might	   mimic	   the	   homing	   process	   of	   HSC	   into	   their	   bone	   marrow	   niche	   in	  
which	  MSC	  play	  a	  critical	  role.	  
Since	  MSC	  are	  a	  known	  source	  of	  growth	  factors	  and	  cytokines,	  which	  are	  well	  described	  drivers	  of	  
cancer	  progression112,130,137,	  research	  has	  focused	  on	  how	  MSC	  influence	  cancer	  cells	  via	  these	  small	  
molecular	  weight	  molecules53,138.	  However,	   systematic	   approaches	   taking	   all	   secreted	  proteins	  of	  
MSC	  into	  consideration	  are	  lacking.	  I	  therefore	  decided	  to	  study	  the	  MSC	  –	  cancer	  cell	  cross	  talk	  by	  
investigating	  the	  complete	  secretome	  of	  MSC	  in	  order	  to	  identify	  potential	  factors	  enabling	  cancer	  
cells	   to	  metastasize	   to	   bone.	   This	   unbiased	   approach	   allowed	  me	   to	   identify	   extracellular	  matrix	  
proteins	  as	  drivers	  of	  cancer	  cell	  migration	  and	  as	  acting	  independently	  of	  classic	  chemokines.	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3.1. Strategy	  of	  experiments	  
To	   contribute	   to	   the	   understanding	   how	  MSC	   induce	  metastasis	   to	   bone,	   I	   investigated	  whether	  
MSC	  mediate	  cancer	  cell	  migration	   in	  an	   in	  vitro	   setting.	  By	  combining	  high	  performance	  FPLC	  of	  
MSC	  cell	  culture	  supernatant	  with	  the	  xCELLigence	  	  transwell	  migration	  system	  I	  was	  able	  to	  analyze	  
and	  decipher	  the	  complete	  secretome	  of	  MSC	  for	  its	  ability	  to	  induce	  cancer	  cell	  migration.	  	  
Investigating	  biological	  processes	  in	  an	  in	  vitro	  setting	  allows	  for	  experiments	  to	  be	  conducted	  with	  
a	  clear	  definition	  of	  experimental	  parameters,	  in	  a	  shorter	  time	  frame	  and	  with	  reduced	  complexity	  
allowing	   for	   easier	   interpretation	   of	   the	   data.	   Furthermore,	   high-­‐throughput	   experiments	   enable	  
the	  analysis	  of	  large	  numbers	  of	  factors	  and	  parameters,	  which	  is	  not	  possible	  in	  an	  in	  vivo	  setting.	  
On	   the	   other	   hand,	   one	   must	   consider	   that	   all	   cells	   are	   influenced	   and	   regulated	   by	   their	  
surrounding	  (outside-­‐in	  signaling)	  affecting	  a	  multitude	  of	  cellular	  processes.	  This	  is	  especially	  true	  
for	   stem	   cells	   like	   MSC	   with	   physical	   and	   chemical	   cues	   affecting	   identity,	   stemness	   and	  
differentiation79,80,121.	  One	  must	  therefore	  expect	  effects	  of	  the	   in	  vitro	  conditions	  on	  the	  cultured	  
MSC	  and	  consider	  that	  they	  can	  only	  model	  the	  cells	  found	  in	  vivo	  to	  a	  certain	  extent139,140.	  For	  this	  
reason,	  the	  interpretation	  of	  in	  vitro	  results	  requires	  caution	  and,	  ideally,	  subsequent	  confirmation	  
in	   an	   in	   vivo	   setting,	   as	   this	   issue	   has	   potentially	   contributed	   to	   contradicting	   results	   and	   the	  
uncertainty	   regarding	   the	   role	  MSC	  play	   in	  cancer	  progression50.	  To	  model	   the	   in	  vivo	   situation,	   I	  
based	  the	   in	  vitro	  experiments	  on	  primary	  MSC	  freshly	   isolated	  from	  the	  bone	  marrow	  of	  healthy	  
donors	   and	   characterized	   according	   to	   current	   standards	   of	   the	   International	   Society	   of	   Cellular	  
Therapy	  by	  multi-­‐lineage	  differentiation	  with	   the	   Stemflow	  hMSC	  Analysis	   Kit	   (BD)26.	   In	   addition,	  
established	   cancer	   cell	   lines	   commonly	   used	   in	   bone	  metastasis	   mouse	   models	   were	   chosen	   to	  
investigate	   the	  MSC	   –	   cancer	   cell	   cross	   talk.	  My	   results	   were	   in	   line	   with	   observations	  made	   in	  
previous	   in	   vivo	   studies	   with	   prostate	   cancer	   cells	   lines.	   LNCaP	   cells,	   which	   do	   not	   form	   bone	  
metastasis141,	  and	  VCaP	  cells,	  which	  require	  direct	   injection	   into	   the	  bone	  marrow	  to	  successfully	  
form	  an	  osseous	  tumor142,143,	  failed	  to	  respond	  to	  signals	  from	  the	  MSC.	  In	  contrast,	  PC3	  cells97	  and	  
MDA-­‐MB-­‐231	  breast	  cancer	  cells98	  readily	  migrated	  towards	  MSC	  (Figure	  4	  A,	  A’).	  	  
3.1.1. Strategy	  of	  cell	  culture	  and	  migration	  assay	  
Cellular	  movement	  in	  a	  tissue	  always	  includes	  movement	  past	  other	  cells	  and	  through	  a	  framework	  
of	   extracellular	   constituents.	   This	   can	   be	   partly	   mimicked	   in	   vitro	   with	   transwell	   migration	  
chambers144	  equipped	  with	  a	  permeable	  membrane	  coated	  with	  cells	   such	  as	  endothelial	   cells145,	  
matrigel	   or	   specific	   ECM	   proteins	   146-­‐148.	   During	   assay	   development	   I	   compared	   the	   migration	  
through	  coated	  and	  uncoated	  membranes.	  I	  observed	  that	  coating	  the	  membranes	  of	  the	  transwell	  
chambers	  with	  matrigel	  did	  not	  change	  the	  investigated	  migration	  response	  apart	  from	  the	  several	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additional	   hours	   the	   cancer	   cells	   needed	   to	   surpass	   the	   added	   matrigel	   towards	   the	   MSC	   cell	  
culture	   supernatant	   (data	   not	   shown).	   For	   this	   reason,	   I	   chose	   to	   conduct	   the	   high	   throughput	  
migration	  assay	  without	  coating	  the	  transwell	  membranes	  to	  reduce	  experimental	  complexity	  and	  
enhance	  reproducibility	  (Figure	  15).	  
The	   presence	   of	   additives	   in	   the	   culture	  medium	   used	   can	   pose	   an	   experimental	   obstacle	  when	  
analyzing	   the	   cell	   culture	   supernatant	   of	   cells.	   First,	   FCS	   or	   albumin,	   often	   used	   in	   high	  
concentrations,	   can	   interfere	  with	   the	  purification	  process149.	   In	  addition,	   they	  can	  also	  mask	   the	  
presence	  of	  proteins	  present	   in	   low	  concentrations	  or	   can	   lead	   to	   false	  positive	   results	  based	  on	  
FCS-­‐derived	   proteins	   in	   a	   mass	   spectrometry	   analysis.	   I	   therefore	   decided	   to	   conduct	   a	   whole	  
secretome	   analysis	   on	  MSC	   that	  were	   cultured	   in	   a	   protein-­‐free	   and	   chemically	   defined	  medium	  
during	   the	   process	   of	   supernatant	   production.	   This	   allowed	   a	   reduced	   total	   protein	   load	   and	  
ensured	  that	  all	  proteins	  present	  in	  the	  cell	  culture	  supernatant	  were	  of	  mesenchymal	  origin.	  Prior	  
to	  supernatant	  production,	  MSC	  were	  expanded	  in	  low	  FCS	  medium	  according	  to	  Verfaillie150	  which	  
aimed	  to	  reduce	  the	  potential	  impact	  that	  changes	  of	  FCS	  concentrations	  can	  have	  on	  the	  behavior	  
of	   cultivated	   cells151.	   To	   ensure	   that	   the	   observed	  migration	   of	   cancer	   cells	   was	   not	   due	   to	   the	  
culture	  conditions	  during	  supernatant	  production,	  MSC	  were	  cultured	   in	  multiple	   types	  of	  media,	  
with	   and	   without	   additives	   (data	   not	   shown).	   In	   all	   cases,	   MSC	   induced	   a	   comparable	   rapid	  
migration	   response	  of	   the	  prostate	   cancer	   cell	   line	   PC3	  as	   seen	   for	  MSC	   cultured	   in	   protein	   free	  
conditions	  (Figure	  4	  A).	  This	  confirmed	  that	  the	  observed	  cross	  talk	  between	  cancer	  cells	  and	  MSC	  
was	  independent	  of	  in	  vitro	  culture	  conditions.	  
In	   addition	   to	   culture	   conditions,	   the	   general	   heterogeneity	   observed	   between	   primary	   cells	   of	  
different	   donors	   did	   not	   pose	   an	   experimental	   obstacle	  with	  MSC	   of	  multiple	   donors	   inducing	   a	  
strong	   migration	   response	   of	   PC3	   cells.	   By	   contrast,	   fibroblast	   cell	   lines	   failed	   to	   induce	   a	  
comparable	   migration	   of	   PC3	   cells	   (Figure	   4	   C),	   further	   indicating	   that	   MSC,	   based	   on	   their	  
secretion	   profile,	   are	   distinct	   of	   other	   stromal	   cells.	   Not	   only	   did	   all	   three	  MSC	   donors	   similarly	  
induce	   cancer	   cell	   migration,	   but	   they	   also	   showed	   a	   highly	   comparable	   molecular	   weight	  
distribution	   of	   secreted	   proteins	   (Figure	   5	   A),	   of	   which	   only	   the	   high-­‐molecular-­‐weight	   proteins	  
induced	  a	  strong	  migration	  response	  (Figure	  6,	  Figure	  7).	  	  
3.1.2. Strategy	  of	  protein	  purification	  under	  native	  conditions	  
In	   order	   to	   identify	   the	   secreted	   proteins	   triggering	   the	   observed	   cancer	   cell	   migration	   towards	  
MSC,	  they	  had	  to	  be	  purified	  from	  the	  complex	  MSC	  cell	  culture	  supernatant.	  
One	  important	  characteristic	  of	  the	  executed	  experimental	  approach	  to	  identify	  these	  mediators	  of	  
cancer	   cell	   migration	   (Figure	   3)	   was	   the	   fact	   that	   an	   unknown	   protein	   with	   a	   known	   functional	  
property	  required	  purification.	  Therefore,	  the	  purification	  process	  needed	  functional	  testing	  of	  all	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samples	  after	  each	  purification	  step	  to	  confirm	  the	  presence	  of	  the	  proteins	  of	  interest	  in	  a	  certain	  
sample.	   This	   approach	   differs	   from	   classic	   downstream	   protein	   purification	   approaches	   in	  which	  
the	  protein	  of	   interest	   is	   known	  and	   can	  be	  easily	  detected	  by	   classic	  methods	   such	  as	   antibody	  
detection.	  
This	  situation	  resulted	  in	  two	  requirements	  which	  the	  experimental	  workflow	  needed	  to	  fulfill.	  For	  
one,	  the	  functional	  migration	  assay	  had	  to	  be	  high-­‐throughput	  compatible	  in	  order	  to	  allow	  analysis	  
of	   a	   large	   number	   of	   samples	   in	   a	   reproducible	   fashion	   and	   in	   a	   manageable	   time	   frame.	   The	  
xCELLigence	  transwell	  system	  enabled	  the	  analysis	  of	  48	  samples	  in	  parallel	  and	  due	  to	  the	  electrical	  
impedance	  readout	  offered	  online	  and	  fast	  analysis	  of	  cancer	  cell	  migration.	  	  
The	  second	  requirement	  was	  to	  purify	  the	  protein	  of	  interest	  under	  native	  conditions,	  which	  caused	  
a	   significant	   limitation	   in	   the	   purification	   techniques	   applicable.	   In	   initial	   experiments	   the	   cell	  
culture	   supernatant	   was	   precipitated	   by	   salting	   out	   with	   ammonium	   sulfate.	   This	   approach	  
separates	  proteins	  that	  easily	  aggregate	  from	  those	  that	  are	  more	  soluble.	  This	  technique	  can	  be	  a	  
good	  initial	  purification	  step	  as	  it	  is	  cheap	  and	  does	  not	  require	  advanced	  technology.	  Nonetheless,	  
this	   approach	  was	   not	   feasible	   as	   a	   clear	   separation	   of	   fractions	  with	   and	  without	   the	   ability	   to	  
induce	  cancer	  cell	  migration	  was	  not	  possible.	  This	  was	   in	  part	  due	   to	   the	   fact	   that	   salting	  out	   is	  
especially	   suitable	   for	   small	   soluble	   proteins	   and	   for	   bulk	   samples	   with	   very	   high	   protein	  
concentration152-­‐154.	  
For	   increased	   reproducibility	   I	  based	   the	   final	  downstream	  processing	  design	  on	   semi-­‐automated	  
size	   exclusion	   and	   ion	   exchange	   FPLC	   using	   an	   Äkta	   Explorer	   system.	   In	   contrast	   to	   classic	   FPLC	  
purification	   strategies155,156,	   I	   chose	   size	   exclusion	   chromatography	   as	   the	   initial	   separation	   step.	  
This	  was	  based	  on	   the	   fact	   that	   ion	  exchange	   chromatography	   failed	   to	   separate	   the	  proteins	  of	  
interest	   from	   the	   crude	   cell	   culture	   supernatant,	  with	   a	   large	  number	  of	   resulting	   FPLC	   fractions	  
harboring	  the	  potential	   to	   induce	  cancer	  cell	  migration	  after	  the	   initial	  purification	  step	  (data	  not	  
shown).	   In	   contrast	   to	   ion	   exchange	   chromatography,	   size	   exclusion	   chromatography	   produced	  
distinct	  FPLC	   fractions	  with	   the	  potential	   to	   induce	  cancer	  cell	  migration	   (Figure	  6,	  Figure	  7).	  Size	  
exclusion	  chromatography,	  routinely	  applied	  as	  a	   final	  polishing	  step	  of	  a	  downstream	  processing	  
strategy,	  requires	  samples	  of	  reduced	  volume	  and	  high	  protein	  load157.	  By	  initiating	  the	  purification	  
process	   with	   a	   concentration	   step	   via	   ultrafiltration,	   the	   sample	   volume	   was	   reduced	   while	   the	  
protein	  concentration	  increased,	  enabling	  the	  unconventional	  but	  successful	  establishment	  of	  size	  
exclusion	   chromatography	   as	   the	   initial	   purification	   step.	   As	   the	   subsequent	   ion	   exchange	  
chromatography	  allowed	  for	  the	  loading	  of	  large	  volumes	  onto	  the	  column,	  multiple	  size	  exclusion	  
fractions	  harboring	  migration-­‐inducing	  activity	  were	  pooled,	  addressing	  the	  issue	  that	  size	  exclusion	  
chromatography	  causes	  dilution	  of	  the	  sample.	  Furthermore,	  by	  running	  both	  FPLC	  techniques	  with	  
a	   tris	   buffer	   as	   the	   mobile	   phase,	   samples	   could	   be	   directly	   transferred	   from	   size	   exclusion	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chromatography	   to	   the	   final	   downstream	  processing	   step	   of	   ion	   exchange	   chromatography	   after	  
adjusting	   the	   salt	   concentration.	   Due	   to	   the	   fact	   that	   ion	   exchange	   chromatography	   leads	   to	   a	  
concentration	  of	  the	  separated	  proteins158,	  fractions	  could	  be	  diluted	  for	  the	  subsequent	  migration	  
assay,	  circumventing	  the	  effect	  high	  salt	  concentrations	  can	  have	  on	  cells.	  
3.2. MSC	  induce	  cancer	  cell	  migration	  independent	  of	  cytokines	  
MSC	  are	  known	  to	  exert	  a	  number	  of	  physiological	  functions	  through	  their	  ability	  to	  secrete	  growth	  
factors	  and	  cytokines.	  These	   include	   factors	  aiding	  hematopoiesis59,63,159,	  modulating	   immune	  cell	  
functionality35-­‐40	  and	  facilitating	  tissue	  regeneration30,160.	  Furthermore,	  MSC	  are	  a	  known	  source	  of	  
migration-­‐inducing	  chemokines161	  enabling	  immune162	  and	  hematopoietic	  stem	  cell163	  migration.	  In	  
regard	  to	  cancer,	  this	  characteristic	  of	  being	  a	  potent	  source	  of	  growth	  factors	  and	  cytokines	  makes	  
MSC	  a	  prime	  suspect	  in	  the	  facilitation	  of	  cancer	  progression3,49,105.	  On	  that	  account	  I	  anticipated	  a	  
role	  of	  these	  small	  signaling	  molecules	  in	  the	  observed	  ability	  of	  MSC	  to	  induce	  transwell	  migration	  
of	  cancer	  cells	  (Figure	  4).	  
Unexpectedly,	  size	  exclusion	  chromatography	  of	  MSC	  cell	  culture	  supernatant	  revealed	  that	   high-­‐
molecular-­‐weight	  proteins	  exceeding	  300	  kDa	   in	  size	  were	   the	  main	  drivers	  of	  prostate	   (Figure	  6)	  
and	  breast	  cancer	  cell	  migration	  (Figure	  7).	  In	  contrast,	  small	  molecular	  weight	  fractions	  potentially	  
harboring	   chemokines	   (5	   –	   20	  kDa)	   failed	   to	   induce	   a	   comparable	   migration	   response.	   Mass	  
spectrometry	   analysis	   of	   the	   active	   size	   exclusion	   fractions	   revealed	   multiple	   ECM	   and	   ECM-­‐
associated	  proteins	  but	  no	  cytokines	  (Table	  1).	  As	  cytokines	  and	  growth	  factors	  are	  known	  to	  bind	  
to	  ECM	  proteins114,115	  I	  speculated	  that	  chemokines	  might	  be	  bound	  to	  ECM	  proteins	  causing	  their	  
elution	  in	  fractions	  of	  high	  molecular	  weight.	  In	  addition,	  the	  failed	  detection	  by	  mass	  spectrometry	  
might	  have	  been	  based	  on	  a	  masking	  effect	  of	  the	  abundant	  high-­‐molecular-­‐weight	  ECM	  proteins.	  
To	   address	   these	   questions,	   the	   cell	   culture	   supernatant	   and	   the	   active	   size	   exclusion	   fractions	  
were	   further	   analyzed	   by	   cytokine	   and	   chemokine	   antibody	   array.	   While	   the	   unprocessed	   cell	  
culture	  supernatant	  of	  MSC	  contained	  several	  cytokines,	  the	  antibody	  array	  failed	  to	  detect	  any	  in	  
the	  high-­‐molecular-­‐weight	  fractions,	  with	  the	  exception	  of	  uPAR	  (Table	  2).	  This	  suggested	  that	  the	  
small	   molecular	   weight	   proteins	   had	   been	   indeed	   removed	   by	   the	   chromatographic	   separation	  
process	   and	   that	   the	   chemokines	   secreted	   by	  MSC	  were	   not	   responsible	   for	   the	   observed	   rapid	  
migration	  of	  prostate	  and	  breast	  cancer	  cells	  towards	  MSC.	  	  
As	   failure	   of	   detection	   is	   only	   insufficient	   proof	   for	   absence,	   I	   decided	   to	   further	   investigate	   the	  
potential	  role	  of	  the	  chemokines	  CCL2,	  CCL5	  and	  CXCL12	  on	  the	  migratory	  behavior	  of	  PC3	  prostate	  
cancer	  cells.	  These	  chemokines	  were	  chosen	  for	  further	  investigation,	  as	  CCL2	  was	  detected	  in	  the	  
unprocessed	  MSC	   supernatant	   and	   it	   could	   have	   been	   potentially	  missed	   in	   the	   high-­‐molecular-­‐
weight	   fractions.	   In	   addition,	   CCL5	   detection	   in	   the	   antibody	   array	   failed	   due	   to	   a	   strong	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background	   signal	   (Supplementary	   figure	   1).	   Lastly,	   CCL2164-­‐166,	   CCL5117,167	   and	   CXCL12131	   are	   all	  
being	   studied	   as	   mediators	   of	   bone	   metastasis	   and	   have	   been	   reported	   to	   induce	   cancer	   cell	  
migration.	  	  
For	   further	  analysis,	   the	   recombinant	   chemokines	  were	   investigated	   for	   their	  potential	   to	   induce	  
PC3	  prostate	  cancer	  cell	  migration.	  To	  assure	  functionality,	  only	  chemokines	  were	  chosen	  that	  had	  
been	   successfully	   applied	   in	   published	   and	   peer	   reviewed	   studies168,169.	   To	   prove	   functionality	   of	  
the	   protein,	   CXCL12,	   a	   known	   chemoattractant	   for	   HSC127,	   	   was	   successfully	   tested	   to	   induce	  
primary	  HSC	  migration	  (Figure	  10	  D)	  comparable	  to	  previous	  reports170.	  Although	  chemokines	  are	  
classic	   mediators	   of	   cell	   migration,	   none	   of	   the	   investigated	   chemokines	   were	   able	   to	   induce	   a	  
migration	  response	  comparable	  to	  the	  cell	  culture	  supernatant	  of	  MSC	  (Figure	  10).	  However,	  due	  to	  
the	   limitation	  of	  this	   in	  vitro	  study	  the	   isolation	  and	  culture	  conditions	  of	  MSC	  could	  have	  had	  an	  
effect	   on	   the	   secretion	   of	   specific	   chemokines171,172.	   The	   portfolio	   of	   secreted	   chemokines	   will	  
therefore	  differ	  from	  the	  secretome	  of	  MSC	  found	  in	  vivo.	  Nonetheless,	  my	  results	  emphasize	  that	  
MSC	   can	   induce	   a	   very	   strong	   and	   rapid	  migration	   responses	  of	   prostate	   and	  breast	   cancer	   cells	  
independent	  of	  chemokines.	  This	  contradicts	  the	  notion	  that	  chemokines	  are	  essential	  mediators	  of	  
cancer	   metastasis	   causing	   them	   to	   be	   the	   focus	   of	   a	   number	   of	   clinical	   trials173.	   Moreover,	   my	  
findings	   are	   supported	   by	   studies	   showing	   that	   blocking	   chemokine	   function	   reduces	   but	   not	  
necessarily	  fully	  inhibits	  metastasis	  formation174.	  This	  suggests	  that	  other	  factors	  have	  the	  potential	  
to	  mediate	  the	  formation	  of	  new	  lesions	  at	  the	  metastatic	  site	  synergistically	  with	  or	  independent	  
of	  classic	  chemokines.	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3.3. MSC	  induce	  cancer	  cell	  migration	  by	  extracellular	  matrix	  proteins	  
The	   ECM	   is	   a	   non-­‐cellular	   constituent	   found	   in	   all	   tissues	   and	   organs.	   It	   comprises	   roughly	   300	  
different	   ECM	   and	   ECM-­‐associated	   proteins,	   the	   majority	   being	   fibrous	   proteins	   and	  
proteoglycans175.	  These	  proteins	  are	  secreted	  by	  cells	   into	  the	  space	  surrounding	  them.	  Assembly	  
and	  further	  modifications	  result	  in	  the	  formation	  of	  a	  mechanical	  framework	  providing	  a	  structural	  
entity	  to	  which	  cells	  can	  adhere176.	  In	  addition	  to	  providing	  anchorage,	  ECM	  proteins	  affect	  cellular	  
function	   and	   differentiation177,178.	  What	   is	  more,	   ECM	  proteins	   act	   as	   signaling	  molecules.	   In	   this	  
context	  they	  can	  act	  alone	  by	  binding	  to	  integrin	  receptors,	  inducing	  subsequent	  signaling	  cascades	  
via	   integrin	   linked	   kinases179	   or	   Src	   kinases180.	   A	   further	  mode	   of	   signaling	   is	   through	   synergistic	  
crosstalk	  between	  integrin	  activation	  and	  growth	  factor	  signaling	  including	  examples	  such	  as	  PDGF,	  
c-­‐Met	  and	  EGF	  signaling181.	  Lastly,	  ECM	  molecules	  can	  act	  as	  signaling	  factor	  precursors	  which	  are	  
activated	   upon	   enzymatic	   degradation	   of	   the	   ECM	   molecule.	   Examples	   include	   the	   plasma	  
membrane	  protein	  laminin	  322	  and	  tenascin	  containing	  an	  EGF-­‐like	  domain	  which	  upon	  enzymatic	  
degradation	  is	  released	  and	  able	  to	  activate	  the	  EGF	  receptor182,183.	  
As	  an	  interaction	  partner	  with	  cells,	  ECM	  proteins	  influence	  virtually	  all	  cellular	  processes	  including	  
cell	   adhesion,	   shape,	   movement,	   proliferation	   and	   viability176.	   Due	   to	   their	   ubiquitous	   role,	   the	  
homeostasis	   of	   ECM	   proteins	   is	   tightly	   regulated	   under	   physiological	   conditions	   and	   often	  
unbalanced	   in	   pathological	   situations.	   This	   is	   also	   the	   case	   for	   cancer	   in	   which	   increased	   ECM	  
synthesis	   or	   excessive	   enzymatic	   breakdown	   can	   be	   observed	   in	   multiple	   steps	   of	   cancer	  
progression184,185.	  	  
For	   example,	   correct	   cellular	   polarity	   and	   architecture	   in	   epithelial	   tissues	   is	   vital	   to	   organ	  
formation	   as	   well	   as	   function	   and	   depends	   on	   ECM	   proteins.	   Correct	   polarity	   is	   lost	   upon	   ECM	  
deregulation	   which	   can	   lead	   to	   epithelial-­‐mesenchymal	   transition	   of	   cells	   and	   loss	   of	   basement	  
membrane	  barrier	  function	  enabling	  tumor	  invasion	  into	  the	  surrounding	  tissue186-­‐188.	  Upon	  tumor	  
growth,	  the	  demand	  for	  oxygen	  and	  nutrients	  cannot	  be	  met	  by	  diffusion	  through	  the	  tissue	  alone,	  
but	   instead	   requires	  angiogenesis.	  This	   can	  be	   facilitated	  by	  ECM	  proteins	  and	  protein	   fragments	  
acting	   as	   pro-­‐angiogenic	   factors189,	   enabling	   endothelial	   cell	   proliferation	   or	   by	   establishing	   the	  
biomechanical	   structures	   required	   for	   vessel	   formation190.	   In	   the	   end,	   ECM	   proteins	   also	   play	  
functional	  roles	  at	  the	  sites	  of	  cancer	  metastasis.	  In	  the	  final	  steps	  of	  cancer	  progression,	  enhanced	  
fibronectin	  deposition	  and	  increased	  activity	  of	  ECM	  modifying	  matrix	  metalloproteases	  have	  been	  
reported	  to	  aid	  in	  the	  formation	  of	  a	  pre-­‐metastatic	  niche90.	  	  
All	   in	  all,	  my	   investigation	   regarding	   the	   role	  of	  MSC	   in	  cancer	  cell	  migration	  supports	   the	  notion	  
that	  ECM	  proteins	  can	  be	  powerful	  drivers	  of	  cancer	  progression.	  My	  results	  show	  that	  MSC	  from	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the	  bone	  marrow	  can	  mediate	  a	  strong	  and	  rapid	  migration	  response	  of	  cancer	  cells	  by	  diffusible	  
gradients	  of	  ECM	  proteins.	  
During	   the	   multi-­‐step	   purification	   of	   MSC	   cell	   culture	   supernatant,	   proteins	   inducing	   migration	  
were	   eluted	   off	   the	   size	   exclusion	   column	   at	   high-­‐molecular-­‐weight	   ranges	   exceeding	   300	  kDa	  
(Figure	   6,	   Figure	   7).	   Subsequent	   fractionation	   of	   these	   active	   fractions	   by	   ion	   exchange	  
chromatography	  showed	  the	  elution	  of	  migration	   inducing	  proteins	  at	  250	  mM	  and	  340	  mM	  NaCl	  
(Figure	   9).	  Mass	   spectrometry	   analysis	   identified	   a	   number	  of	   ECM	  and	  ECM	  associated	  proteins	  
that	   were	   present	   in	   FPLC	   fractions	   harboring	   the	   activity	   to	   induce	   PC3	   prostate	   cancer	   cell	  
migration	  (Table	  1,	  Table	  3,	  Table	  4,	  Table	  5).	  ECM	  proteins	  that	  were	  present	  in	  these	  fractions	  and	  
that	   have	   been	   previously	   discussed	   in	   the	   context	   of	   cancer	   progression	   were	   tested	   for	   their	  
ability	   to	   induce	   prostate	   cancer	   cell	  migration.	   These	   included	   structural	   proteins	   type	   I	   and	   III	  
collagen	   as	   well	   as	   fibronectin,	   mesenchymal	   α-­‐4	   laminins	   laminin	   421	   and	   411191,	   matricellular	  
proteins	   nidogen,	   thrombospondin	   1	   and	   2192,193,	   TGF-­‐β	   induced	   protein194	   as	   well	   as	   galectin-­‐3	  
binding	  protein195,196.	  Of	  these,	  type	   I	  and	  III	  collagen,	   fibronectin	  and	   laminin	  421	   induced	  strong	  
migration	  of	  prostate	  cancer	  cells.	  
3.3.1. Type	  I	  &	  III	  collagen	  
In	  the	  transwell	  migration	  experiments,	  isolated	  fibrillar	  type	  I	  and	  III	  collagen	  induced	  a	  rapid	  PC3	  
prostate	  cancer	  cell	  migration	  response	  in	  as	  little	  as	  two	  hours.	  Type	  I	  collagen	  even	  exceeded	  the	  
migration-­‐inducing	   potential	   of	   the	   cell	   culture	   supernatant	   of	  MSC,	   triggering	   a	   140%	  migration	  
response	   after	   two	   hours	   compared	   to	   the	  MSC	   cell	   culture	   supernatant	   (Figure	   11	   A,).	   Type	   III	  
collagen	   induced	   an	   early	   migration	   response	   of	   over	   45%	   compared	   to	   MSC	   cell	   culture	  
supernatant.	   In	   contrast	   to	   type	   I	   collagen,	   type	   III	   collagen	  was	  not	  able	   to	   induce	  a	   sustainable	  
migration	  response	  with	  values	  declining	  down	  to	  12%	  over	  time	  (Figure	  11	  B).	  
Although	  collagens	  have	  been	   traditionally	   seen	  as	  physical	  barriers	  against	  cancer	  growth	  at	   the	  
primary	  tumor	  requiring	  their	  enzymatic	  degradation	  for	  cancer	  cell	  invasion	  and	  migration197,198,	  it	  
has	  become	  clear	   that	   fibrillar	  collagens	  can	  play	  an	   important	   tumorigenic	   role	   in	  driving	  cancer	  
progression199.	  
Fibrillar	   collagens	   are	   an	   important	   part	   in	   the	   tumor	   microenvironment	   in	   general,	   showing	  
increased	  deposition	  during	  tumor	  growth200-­‐202.	  In	  breast	  cancer,	  collagen	  mediated	  tissue	  stiffness	  
is	  an	   indicator	  of	  cancer	  risk203	  as	  collagen	  can	  enable	   invasion	   into	  the	  surrounding	  epithelium204	  
and	   cancer	   cell	   migration	   along	   collagen	   bundles205.	   As	   collagen	   fragments	   are	   potent	  
chemoattractants	  for	  stromal	  cells206-­‐208,	  monocytes209-­‐211	  and	  neutrophils212	  fibrillar	  collagens	  may	  
not	   only	   exert	   tumorigenic	   functions	   through	   physical	   cues	   but	   may	   also	   act	   as	   diffusible	  
chemoattractants	   upon	   enzymatic	   degradation213.	   These	   fragments	   may	   then	   mediate	   the	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infiltration	  of	   stroma	   and	   immune	   cells	   into	   the	   tumor	  microenvironment,	   thus	   helping	   facilitate	  
the	  hallmark	  of	  tumor	  inflammation.	  
As	   a	  major	   constituent	   of	   the	   bone,	   type	   I	   collagen	   has	   been	   repeatedly	   discussed	   in	   context	   of	  
bone	  metastasis.	  During	  bone	  metastasis	  formation,	  remodeling	  of	  the	  bone	  tissue	  by	  osteoclasts	  
and	  osteoblasts	  is	  a	  key	  hallmark	  in	  which	  the	  calcified	  bone	  matrix	  is	  degraded	  leading	  to	  a	  release	  
of	   collagen	   fragments	   into	   the	   bloodstream.	   As	   collagen	   fragment	   concentration	   in	   the	   blood	  
correlates	  with	  osseous	  spread,	  these	  fragments	  are	  used	  as	  a	  biomarker	  with	  prognostic	  value	  for	  
patients	  suffering	  from	  breast	  and	  prostate	  cancer214,215.	  	  
Although	   type	   I	   collagen	   fragments	  have	  been	   reported	   to	   induce	  migration	  of	   several	   cell	   types	  
including	  breast216	  and	  prostate210	  cancer	  cells,	  fibrillar	  collagen	  fragments	  are	  predominantly	  seen	  
as	  a	  bio	  marker	  and	  not	  as	  drivers	  of	  bone	  metastasis	  formation.	  Concerning	  the	  mechanisms	  which	  
drive	  bone	  metastasis,	  attention	   is	  strongly	  focused	  on	  chemokines,	  cytokines	  and	  growth	  factors	  
as	  the	  key	  mediators	  of	  cancer	  metastasis111,132,217,218.	  
Although	   chemokines	   are	   clearly	   important	  mediators	   of	   cancer	   cell	  metastasis	   to	   the	   bone,	  my	  
results	   show	   that	   breast	   and	   prostate	   cancer	   cells	   migrate	   rapidly	   towards	   type	   I	   and	   type	   III	  
collagen,	   suggesting	   that	   these	   collagens	  which	   are	   released	   from	   the	   bone	   can	   aid	   in	   attracting	  
metastasizing	  cancer	  cells	  to	  the	  bone	  independent	  of	  chemokines.	  	  
Our	  observations	  are	  further	  supported	  by	  studies	  suggesting	  that	  the	  ability	  to	  bind	  type	  I	  collagen	  
may	  be	  a	  prerequisite	  for	  prostate	  cancer	  cells	  metastasizing	  to	  bone.	  This	  ability	  was	  shown	  to	  be	  
limited	  to	  prostate	  cancer	  cell	   lines	  harboring	  the	  potential	   to	  metastasize	  to	  bone	  with	  PC3	  cells	  
readily	  adhering	  to	  type	  I	  collagen	  whereas	  LNCaP	  cells,	  derived	  from	  lymph	  node	  metastasis99,219,	  
failed	  to	  do	  so220-­‐222.	  This	  is	  in	  agreement	  with	  my	  observations	  in	  which	  PC3	  cells	  migrated	  strongly	  
towards	  MSC	  whereas	  LNCaP	  cells	  failed	  to	  show	  a	  migration	  response	  (Figure	  4	  A).	  
Research	  on	  fibrillar	  collagens	  is	  mainly	  focused	  on	  the	  adhesive	  and	  proliferative	  effects	  collagens	  
can	  exert	  on	   cancer	   cells	   forming	  a	   suitable	   ‘soil’	   for	   cancer	   cell	   growth223.	  My	   results	   show	   that	  
fibrillar	   collagens	   can	   act	   as	   strikingly	   potent	   attractants	   of	   cancer	   cells	   suggesting	   that	   further	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3.3.2. Fibronectin	  
In	  comparison	  to	  type	  I	  and	  III	  collagen,	  fibronectin	  did	  not	   induce	  such	  a	  rapid	  cell	  migration	  but	  
induced	  more	   of	   a	   gradual	   response.	   Over	   a	   period	   of	   24	   hours	   the	  migration	   response	   linearly	  
increased	  up	  to	  80%	  compared	  to	  the	  unprocessed	  cell	  culture	  supernatant	  of	  MSC	  (Figure	  11	  C).	  
Fibronectin	   is	   a	   glycoprotein	   expressed	   as	   soluble	   plasma	   fibronectin	   or	   as	   less	   soluble	   cellular	  
fibronectin	   acting	   as	   a	   structural	   protein224.	   As	   an	   ECM	   protein	   important	   in	   wound	   healing225,	  
fibronectin	  was	   reported	   to	   be	   up	   regulated	   in	   the	   stroma	   of	   breast	   cancer	   tissue	   and	   to	   aid	   in	  
multiple	   steps	  of	   tumor	  progression226.	  Additionally,	   studies	   suggest	   that	   fibronectin	  might	   cause	  
resistance	   to	   chemo-­‐	   and	   radiation-­‐	   as	   well	   as	   ionization	   therapy	   in	   lung	   and	   breast	   cancer,	  
indicating	  that	  expression	  of	  fibronectin	  is	  a	  bad	  prognosis	  marker227-­‐230.	  	  
Fibronectin	   is	   involved	   in	   ovarian	   cancer	  metastasis231,232.	   A	   potential	   role	   of	   fibronectin	   in	   bone	  
metastasis	   is	   supported	  by	   the	   fact	   that	   its	   receptor	  α4β1	   integrin	   is	   involved	   in	  homing	  of	  blood	  
progenitor	  cells	  to	  the	  bone	  marrow233-­‐235,	  a	  process	  potentially	  mimicked	  by	  metastasizing	  cancer	  
cells236.	   Taken	   together,	   including	   its	   potential	   to	   induce	  migration	   of	   several	   cell	   types	   such	   as	  
stromal	  cells237	  and	  monocytes238	  as	  well	  as	  enhanced	  attachment	  of	  prostate	  cancer	  cell	   lines239,	  
my	  results	  suggest	  that	  prostate	  cancer	  cells	  metastasizing	  to	  bone	  might	  interact	  with	  fibronectin	  
to	   establish	   a	   foothold	   in	   the	   bone	  marrow.	   A	   role	   of	   fibronectin	   in	   cancer	  metastasis	   is	   further	  
supported	  by	  the	  fact	  that	  fibronectin	  expression	  is	  increased	  in	  pre-­‐metastatic	  niches	  observed	  in	  
the	  lungs	  and	  other	  organs17,90.	  	  
3.3.3. Laminin	  421	  
In	   contrast	   to	   MSC	   supernatant,	   recombinant	   laminin	   421	   did	   not	   induce	   a	   rapid	   migration	  
response	  of	  PC3	  prostate	  cancer	  cells	  requiring	  only	  several	  hours	  but	  induced	  a	  gradual	  and	  linear	  
migration	  response.	  Nonetheless,	  the	  response	  exceeded	  the	  migration	  induced	  by	  fibronectin	  and	  
reached	  a	   similar	   response	   compared	   to	   the	  MSC	   cell	   culture	   supernatant	   after	   24	  hours	   (Figure	  
11	  D).	  
Laminin	   421	   (α4-­‐β2-­‐γ1)	   belongs	   to	   the	   protein	   family	   of	   laminins	   comprising	   16	   different	  
glycoproteins	  each	  composed	  of	  an	  α,	  β	  and	  γ	  chain.	  Laminins	  are	  involved	  in	  the	  assembly	  and	  the	  
structural	  integrity	  of	  basement	  membranes	  interacting	  with	  type	  IV	  collagen,	  nidogen,	  fibulin	  and	  
other	   laminins.	   Failure	  of	   correct	  assembly	  may	   result	   in	  a	  number	  of	  diseases	   ranging	   from	  skin	  
blistering	   diseases240	   to	   muscular	   dystrophy241.	   In	   addition	   to	   its	   important	   structural	   function,	  
laminins	   interact	  with	  cells	  via	   integrins242	  and	  a	  number	  of	  different	  non-­‐integrin	  receptors243.	   In	  
the	  context	  of	  cancer,	  a	  number	  of	  laminins	  are	  known	  to	  potentially	  contribute	  to	  several	  cancer	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hallmarks	   including	   proliferation244	   and	   angiogenesis243.	   These	   include	   the	  well	   studied	   examples	  
laminin	  111,	  laminin332245,246	  and	  laminin	  511247.	  	  
However,	  less	  is	  known	  about	  laminin	  421,	  a	  laminin	  protein	  belonging	  to	  the	  α4	  laminins	  including	  
laminin	  411	  and	  421,	  which	  are	  both	  found	  in	  the	  bone	  marrow86.	  At	  the	  primary	  tumor	  α4	  laminin	  
chains	  were	  overexpressed	   in	  the	  stroma	  of	  squamous	  cell	  carcinoma248	  and	  were	  upregulated	   in	  
renal	  carcinomas249.	   In	  glioma,	  the	  switch	  from	  laminin	  421	  expression	  to	  411	  is	  reported	  to	  drive	  
the	  progression	  of	  the	  disease	  and	  is	  predictive	  for	  patient	  survival250.	  A	  similar	  switch	  can	  be	  seen	  
in	   breast	   cancer	  with	   a	   suspected	   role	   in	   tumor	   angiogenesis251,252.	   This	   ratio	   of	   pro-­‐tumorigenic	  
potential	   is	  not	  mirrored	   in	  my	  experiments	  which	  describe	   laminin	  421	  to	  be	  the	  more	  powerful	  
inducer	   of	   cancer	   cell	  migration	   compared	   to	   laminin	   411	   (Figure	   11	   D,	   E).	   In	   contrast,	   previous	  
reports	   describe	   the	   ability	   of	   laminin	   411	   to	   facilitate	   chemotaxis	   of	   endothelial	   cells253,	   blood	  
cells254	  and	  inflammatory	  cells255	  as	  well	  as	  hapotaxis	  of	  several	  cancer	  cell	  lines191.	  
In	   contrast	   to	   laminin	   332256	   and	   511247,	   laminin	   421	   has	   not	   been	   linked	   to	   cancer	  metastasis.	  
Moreover,	   little	   is	   known	   about	   the	   potential	   of	   laminin	   421	   to	   induce	  migration	  with	   only	   few	  
studies	  describing	  induction	  of	  melanoma	  cell	  migration257	  and	  hapotaxis	  of	  a	  number	  of	  cancer	  cell	  
lines191.	  My	   in	  vitro	  experiments	  confirm	  these	  results	  showing	  that	   laminin	  421	   induced	  a	  strong	  
migration	  response	  of	  prostate	  cancer	  cells.	  Furthermore,	  laminins	  in	  general	  are	  reported	  to	  play	  a	  
role	   in	   the	   bone	   marrow	   niche	   including	   adhesive258,	   mitogenic86	   and	   mobilizing259	   function	   for	  
blood	   progenitor	   cells.	   I	   therefore	   propose	   that	   laminin	   421	  might	   act	   as	   an	   important	   driver	   of	  
prostate	  or	  breast	  cancer	  metastasis	  to	  bone	  and	  is	  in	  need	  of	  further	  investigation.	  
3.4. Cancer	  cell	  migration	  towards	  MSC	  requires	  β1	  integrin	  receptor	  
After	  establishing	  that	  the	  observed	  cancer	  cell	  migration	  was	  primarily	  mediated	  by	  ECM	  proteins,	  
I	   investigated	   the	   role	  of	  ECM-­‐binding	   integrin	   receptors	   in	   the	  observed	  crosstalk	  between	  MSC	  
and	  PC3	  prostate	  cancer	  cells.	  	  
The	  binding	  of	  ECM	  proteins	  through	  transmembrane	  glycoprotein	  integrin	  receptors	  is	  enabled	  by	  
integrins	  forming	  heterodimers	  consisting	  of	  one	  of	  18	  α	  and	  one	  of	  eight	  β	  subunits.	  Ligand	  affinity	  
is	   determined	   by	   up	   to	   25	   combinations	   of	   the	   α	   and	   β	   subunits.	   Therefore,	   the	   expression	   of	  
integrins	  determines	  how	  well	  a	  cell	  can	  adhere,	  migrate	  or	   invade	  a	  certain	  surface.	  The	  cellular	  
response	  of	  a	  cell	  to	  an	  ECM	  ligand	  is	  initated	  by	  the	  receptors	  undergoing	  conformational	  changes	  
and	   inducing	   cellular	   signaling	   pathways	   (outside-­‐in	   signaling).	   This	   signaling	   also	   affects	  
proliferation,	   survival,	   and	   cellular	   architecture260-­‐262.	   Further	   complexity	   arises	   through	   the	   fact	  
that	  integrins	  can	  interact	  with	  chemokine	  receptors,	  immunoglobulin	  membrane	  receptors	  such	  as	  
CD47,	  growth	  factor	  receptors	  and	  tetraspanins263-­‐265.	  This	  enables	  integrins	  to	  initiate	  a	  multitude	  
of	  signaling	  pathways	  and	  cellular	  responses121	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Our	  investigations	  showed	  that,	  in	  contrast	  to	  β3,	  β6,	  β7	  and	  β8	  integrin,	  only	  the	  knockdown	  of	  β1	  
integrin	  strongly	  reduced	  the	  responsiveness	  of	  PC3	  prostate	  cancer	  cells	  to	  migrate	  towards	  MSC.	  
This	  correlates	  with	  the	  fact	  that	  β1	  integrin	  can	  be	  involved	  in	  the	  binding	  of	  all	  four	  ECM	  proteins	  
identified	   as	   potential	  mediators	   of	   PC3	   prostate	   cancer	  migration	   towards	  MSC.	   β1	   integrin	   can	  
form	  heterodimers	  with	  a	  multitude	  of	  α	  subunits	  mediating	  binding	  of	  type	  I	  collagen	  through	  α2β1	  
and	  α11β1	  integrin,	   binding	   of	   laminins	   through	  α1β1,	   α2β1	  and	  α6β1	   integrin	   as	  well	   as	   binding	   of	  
fibronectin	  through	  α4β1,	  α5β1,	  α9β1	  and	  αvβ1	  integrin
266,267.	  	  
The	  fact	  that	  β1	   integrin	  knockdown	  abolished	  migration	  towards	  MSC	  is	  most	  probably	  based	  on	  
two	   facts.	   First,	   PC3	   cells	   were	   hindered	   to	   sense	   the	   migration-­‐inducing	   stimulus	   due	   to	   the	  
missing	  receptor.	  Second,	  PC3	  cells	  required	  β1	   integrin	  mediated	  signaling	  to	   initiate	  a	  migratory	  
response	   towards	   the	   stimulus	   secreted	   by	   the	   MSC.	   I	   can	   exclude	   an	   unspecific	   side	   effect	   of	  
impaired	  cell	  adhesion	  of	  PC3	  prostate	  cancer	  cells	  since	  these	  cells	  readily	  adhered	  to	  a	  cell	  culture	  
dish	   after	   β1	   integrin	   knockdown	   (Figure	   13	   B).	   In	   agreement	   with	  my	   results,	   a	   different	   study	  
showed	  that	  PC3	  cells	  have	  higher	  β1	  integrin	  activity	  than	  LNCaP	  cells,	  potentially	  contributing	  to	  
the	  differences	  these	  two	  cell	  lines	  displayed	  in	  my	  experiments	  and	  in	  their	  metastatic	  potential	  in	  
general268.	  
The	  importance	  of	  the	  observed	  β1	  integrin	  dependent	  cancer	  cell	  migration	  is	  reflected	  by	  various	  
studies	   describing	   a	   role	   of	   β1	   integrin	   in	   cancer.	   In	   these	   studies	   α2β1	   integrin	   was	   reported	   to	  
promote	  bone	  metastasis269.	  This	  is	  potentially	  mediated	  by	  talin	  1	  which	  in	  turn	  enables	  essential	  
β1	   integrin	   activity	   to	   form	   bone	  metastases	   in	   prostate	   cancer
270.	   These	   studies	   suggest	   that	   β1	  
integrin	  is	  required	  to	  mediate	  attachment	  to	  collagen	  in	  the	  bone.	  Accordingly,	  my	  studies	  suggest	  
that	  β1	  integrin	  can	  also	  mediate	  the	  interaction	  with	  bone-­‐derived	  MSC.	  Furthermore,	  induction	  of	  
α4β1	  integrin	  in	  Chinese	  hamster	  ovary	  cells	  facilitated	  bone	  metastases	  of	  cells	  otherwise	  unable	  to	  
form	   bone	   lesions271.	   Moreover,	   fibronectin	   binding	   α5β1	   integrin	   plays	   a	   role	   in	   invasion	   and	  
migration	   of	   ovarian	   cancer	   cells231,272	   and	   melanoma	   cells273	   as	   well	   as	   metastasis	   enabling	  
adhesion	  to	  the	  bone	  marrow	  stroma	  in	  general274.	  
In	  contrast	  to	  these	  reports,	  β1	  integrins	  including	  α2β1	  and	  α3β1	  integrin	  have	  also	  been	  suggested	  
to	   act	   as	   tumor	   suppressors	   and	   are	   down	   regulated	   in	   some	   primary	   tumors.	   This	   tumor	  
suppressing	   activity	   is	   derived	   from	   the	   fact	   that	   these	   integrins	   can	   facilitate	   adhesion	   to	   the	  
basement	   membrane,	   quiescence,	   growth	   inhibition	   and	   differentiation	   of	   cells229,275-­‐278.	   These	  
contradictions	   might	   be	   explained	   by	   the	   fact	   that	   the	   role	   of	   integrins	   is	   probably	   tissue	   and	  
context	   dependent,	   allowing	   for	   both	   an	   anti-­‐tumorigenic	   role	   in	   the	   primary	   tumor	   and	   a	   pro-­‐
metastatic	   role	   in	   metastasis	   formation.	   All	   in	   all,	   these	   contradicting	   results	   emphasize	   the	  
importance	  of	  better	  understanding	  the	  role	  of	  integrins	  in	  cancer	  progression.	  In	  regard	  to	  MSC	  –	  
cancer	  cell	  crosstalk,	  RNAi	  mediated	  knockdown	  of	  α	  integrins	  could	  help	  identify	  which	  α-­‐β	  integrin	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heterodimers	  are	  required	  for	  the	  PC3	  prostate	  cancer	  cells	  to	  migrate	  towards	  MSC.	  Validation	  of	  
these	  results	  by	  antibody	  inhibition	  would	  further	  substantiate	  these	  results.	  
In	   line	   with	   contradicting	   reports	   regarding	   the	   role	   of	   β1	   integrin	   in	   cancer,	   my	   observations	  
indicate	   that	  β3	  integrin	   is	  not	   required	   to	  migrate	   towards	  MSC,	  although	  αVβ3	  integrin	  has	  been	  
reported	  to	  play	  a	  role	  in	  bone	  metastasis	  formation279,280.	  The	  discrepancy	  between	  these	  reports	  
and	   my	   results	   requires	   further	   investigation	   and	   might	   be	   based	   on	   limitations	   my	   in	   vitro	  
approach	   causes.	   Nonetheless,	   it	   is	   important	   to	   note	   that	   hampering	   β3	   integrin	   receptors	  may	  
cause	  unexpected	  effects	  such	  as	  increased	  cell	  adhesion	  (Figure	  13	  C,	  Supplementary	  figure	  5)	  and	  
potentially	   stronger	   interaction	  with	  stromal	  cells	   (Figure	  12	  B)	  upon	  β3	  integrin	   inhibition.	  This	   is	  
possibly	   mediated	   by	   compensatory	   mechanisms	   upon	   integrin	   inhibition281	   and	   should	   be	  
considered	  as	  αVβ3	  integrin	  inhibitors	  are	  already	  in	  clinical	  trial.	  
	  
	  
Figure	  14:	  Possible	  roles	  of	  ECM	  proteins	  in	  bone	  metastasis	  formation.	  
Studies	  suggest	  numerous	   roles	  of	  ECM	  proteins	   in	  bone	  metastasis	   formation.	  A:	  Remodeling	  of	   the	  bone	  
matrix	  by	  osteoblasts	  and	  osteoclasts	  causes	  the	  release	  of	  ECM	  fragments	  from	  the	  bone	  tissue.	  These	  ECM	  
fragments	   can	   act	   as	   signaling	   mimetics	   inducing	   cancer	   growth	   and	   angiogenesis.	   They	   can	   also	   act	   as	  
chemoatractants	  possibly	  enabling	  cancer	  cells	  to	  extravasate	   into	  the	  bone	  marrow.	  B:	  ECM	  proteins	  have	  
been	   shown	   to	   induce	   either	   enhanced	   tumor	   cell	   proliferation	   or	   tumor	   cell	   dormancy	   and	   may	   cause	  
resistance	  to	  cancer	  therapy.	  C:	  ECM	  proteins,	  such	  as	  fibronectin	  may	  be	  involved	  in	  the	  formation	  of	  a	  pre-­‐
metastatic	   niche.	   D:	   The	   analysis	   of	   the	   complete	   secretome	   of	   MSC	   confirmed	   the	   importance	   of	   ECM	  
proteins	  in	  cancer	  progression	  as	  laminin	  421,	  fibronectin	  and	  type	  I	  and	  type	  III	  collagen	  were	  identified	  to	  
be	  powerful	   inducers	  of	  prostate	   cancer	   cell	  migration.	  These	   results	   suggest	  a	  possible	   role	  of	   these	  ECM	  
proteins	  in	  cancer	  cell	  migration,	  extravasation	  and	  bone	  metastasis	  formation.	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3.5. Conclusion	  	  
The	  English	  surgeon	  Lou	  Paget	  was	  one	  of	  the	  first	  to	  propose	  in	  1895	  that	  cancer	  metastasis	   is	  a	  
non-­‐random	   event6.	   Since	   then	   the	   understanding	   of	  what	   triggers	   and	   drives	   cancer	  metastasis	  
has	   increased	  dramatically2,7.	  Nonetheless	  and	  despite	  all	   the	  achievements	  and	  efforts	   in	  cancer	  
research,	  metastasis	  formation	  still	  causes	  severe	  morbidity	  and	  mortality	  of	  cancer	  patients.	  With	  
worldwide	  14	  million	  new	  cancer	  cases,	  8	  million	  cancer	  deaths	  and	  32	  million	  people	   living	  with	  
cancer	  (within	  5	  years	  of	  diagnosis)	   in	  20129,	  further	  progress	  in	  understanding	  the	  principles	  and	  
processes	  of	  metastasis	  formation	  is	  of	  great	  importance.	  
Chemokines	  are	  known	  mediators	  of	  cancer	  metastasis	  and	  the	  focus	  of	  attention	  in	  a	  number	  of	  
clinical	   trials	   (www.clicialtrials.gov)217.	   Nonetheless,	   studies	   in	   breast	   cancer	   have	   shown	   that	  
blocking	  chemokine	  function	  does	  reduce	  but	  not	  necessarily	  fully	  inhibits	  metastasis	  formation174.	  
This	  suggests	  that	  other	  factors	  have	  the	  potential	  to	  mediate	  the	  formation	  of	  new	  lesions	  at	  the	  
metastatic	   site	   synergistically	   with	   or	   independently	   of	   chemokines.	   In	   the	   context	   of	   MSC	   as	  
mediators	  of	  cancer	  metastasis	  to	  the	  bone,	  my	  results	  showed	  that	  MSC	  were	  able	  trigger	  cancer	  
cell	   migration	   via	   secreted	   ECM	   proteins	   independent	   of	   small	   molecular	   weight	   signaling	  
molecules	  including	  cytokines	  and	  chemokines.	  	  
The	   aggressiveness	   which	   PC3	   prostate	   cancer	   and	   MDA-­‐MB-­‐231	   breast	   cancer	   cells	   display	   in	  
animal	  models	  might	  therefore	  be	  based	  on	  their	  ability	  to	  respond	  to	  multiple	  ECM	  proteins.	  This	  
could	  make	  them	  especially	  adaptive	  to	  different	  sites	  in	  the	  body	  allowing	  them	  to	  efficiently	  form	  
metastasis.	  My	   results	   support	   the	   idea	   that	   the	  metastatic	   potential	   of	   a	   cancer	   cell	   is	   derived	  
from	  its	  ability	  to	  interact	  with	  the	  cells	  and	  the	  matrix	  found	  at	  the	  site	  of	  metastasis.	  In	  the	  case	  
of	  prostate	  cancer	  cells	  metastasizing	  to	  bone,	  I	  have	  shown	  that	  PC3	  prostate	  cancer	  cells	  readily	  
interact	  with	  bone	  marrow	  MSC	  and	  migrate	  to	  a	  variety	  of	  ECM	  proteins,	  found	  to	  be	  secreted	  by	  
these	  MSC.	  	  
A	   further	  study	  using	  a	  high-­‐throughput	  screening	  platform	  and	  hierarchical	  clustering	  analysis	  to	  
measure	   the	   response	  of	   cancer	   cells	   to	  a	  multitude	  of	  ECM	  proteins	  showed	   that	  depending	  on	  
their	  metastatic	  potential,	  lung	  adenocarcinoma	  cell	  lines	  clustered	  according	  to	  their	  tendency	  to	  
interact	  with	  and	  adhere	  to	  certain	  ECM	  proteins	  and	  ECM	  protein	  combinations282.	  These	  results	  
clearly	   show	   that	   the	  metastatic	   trait	   of	   a	   cancer	   cell	   is,	   at	   least	   in	   part,	   defined	  by	   its	   ability	   to	  
interact	  with	  certain	  ECM	  molecules.	  Additionally,	  this	  study	  revealed	  that	  the	  combination	  of	  ECM	  
proteins	   is	   relevant,	  with	   lung	   adenocarcinoma	   cells	   adhering	   best	   to	   fibronectin	   in	   combination	  
with	   galectin-­‐3	   or	   galectin-­‐8.	   This,	   in	   turn,	   could	  mean	   that	  MSC	   are	   such	   powerful	   inducers	   of	  
breast	  and	  prostate	   cancer	   cell	  migration	  due	   to	   the	   composition	  of	   secreted	  ECM	  proteins.	   This	  
could	  be	  the	  reason	  why	  PC3	  and	  MDA-­‐MB-­‐231	  cells	  shared	  the	  tendency	  to	  migrate	  towards	  the	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same	   size	   exclusion	   chromatography	   fractions	   (Figure	   6,	   Figure	   7)	   and	   why,	   even	   at	   higher	  
concentrations,	   single	   recombinant	   proteins	   were	   not	   able	   to	   completely	   mimic	   the	   migration	  
inducing	  potential	  of	  the	  MSC	  supernatant.	  Only	  type	  I	  collagen	  isolated	  from	  human	  tissue	  induced	  
a	   similar	  migration	   response	   compared	   to	  MSC,	  which	  might	   have	   been	   due	   to	   the	   presence	   of	  
remaining	  ECM	  impurities	  or	  artificially	  high	  concentrations	  (Figure	  11	  A).	   Importantly,	  one	  has	  to	  
consider	  that	  ECM	  proteins	  are	  modified	  enzymatically	  making	  a	  multitude	  of	  conformational	  and	  
fragmentation	  states	  possible175.	  The	  ECM	  proteins,	  produced	  recombinantly	  or	  secreted	  by	  in	  vitro	  
cultured	  MSC,	  will	   therefore	  not	  necessarily	   reflect	   the	  exact	  proteins	   found	   in	  vivo	   in	   regards	   to	  
conformation	   and	   concentration.	   Despite	   these	   limitations,	   my	   results	   do	   show	   that	   ECM	  
molecules,	   including	   type	   I	   and	   type	   III	   collagen,	   fibronectin	   and	   laminin	   421,	   not	   only	   act	   as	   an	  
important	  ‘soil’	  once	  the	  breast	  or	  prostate	  cancer	  cells	  have	  metastasized	  to	  bone	  but	  also	  harbor	  
the	  potential	  to	  act	  as	  diffusible	  chemoattractants	  in	  their	  own	  right.	  Moreover,	  my	  results	  suggest	  
that	   MSC	   secrete	   migration-­‐inducing	   ECM	   proteins	   that	   are	   soluble	   and	   not	   necessarily	   require	  
enzymatic	   degradation	   to	   matrikines213,283,	   since	   high-­‐molecular-­‐weight	   fractions	   after	   size	  
exclusion	  chromatography	  were	  most	  potent	  to	  induce	  cancer	  cell	  migration	  (Figure	  6,	  Figure	  7).	  	  
In	   patients	   suffering	   from	   bone	  metastasis,	   targeting	   bone	   turnover	   is	   standard	   care	   in	   order	   to	  
reduce	   the	   release	   of	   growth	   factors	   entrapped	   in	   the	   bone	   tissue.	   My	   results	   suggest	   that	  
targeting	   bone	   turnover	   and	   ECM	   degradations	   could	   also	   prove	   to	   be	   important	   in	   order	   to	  
prevent	  the	  release	  of	  ECM	  fragments	  that	  could	  have	  the	  potential	  to	  drive	  cancer	  cell	  migration	  
and	  initiate	  metastasis	  formation	  in	  the	  first	  place.	  This	  hypothesis	  is	  supported	  by	  studies	  showing	  
that	   prophylactic	   treatment	   with	   bisphosphonates,	   inhibitors	   of	   bone	   turn-­‐over284,	   were	   able	   to	  
reduce	  the	  formation	  of	  bone	  metastases	  in	  vivo285,286.	  
I	   therefore	  postulate	   that	  solely	   targeting	  chemokine	  and	  growth	   factor	   receptors	  will	  not	  suffice	  
and	  future	  treatments	  will	  have	  to	  consider	  multiple	  drugable	  targets	  including	  the	  interactions	  of	  
cancer	  cells	  with	  ECM	  proteins	  and	  MSC	  in	  the	  bone.	  
This	   approach	   has	   been	   proven	   valid	   in	   studies	   considering	   that	   cancer	   cells	   might	   mimic	   the	  
homing	  process	  of	  HSC	  to	  the	  bone.	  The	  combination	  of	  AMD3100	  or	  GCSF,	  classic	  HSC	  mobilization	  
agents,	   and	   α4β1	   integrin	   inhibition	   increased	   HSC	   mobilization	   out	   of	   their	   niche	   into	   the	  
circulation287.	  This	   study	  has	  shown	  that	   targeting	   the	  chemokine	   receptor	  CXCR4	   in	  combination	  
with	   integrin	   receptors	   strongly	   inhibits	   interactions	  between	  homing	  cells	  and	   the	  bone	  marrow	  
stem	   cell	   niche.	   Consistent	   with	   these	   results,	   further	   studies	   have	   demonstrated	   efficacy	   of	  
combined	  AMD3100	  and	  α4β1	  integrin	  antibody	  treatment	  in	  acute	  myeloid	  leukemia
288-­‐290.	  
In	  conclusion,	  my	  results	  have	  contributed	  to	  a	  better	  understanding	  of	  how	  cancer	  cells	   interact	  
with	   mesenchymal	   stem	   cells	   and	   extracellular	   matrix	   proteins	   of	   the	   bone	   marrow	   niche.	   In	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addition,	  my	  work	  highlights	  that	  a	  better	  understanding	  of	  this	  crosstalk	  will	  ultimately	  contribute	  
to	  the	  development	  of	  more	  advanced	  strategies	  that	  aim	  to	  prevent	  and	  treat	  bone	  metastasis.	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4. Materials	  
4.1. Reagents	  &	  buffers	  
FPLC	  buffer	  A	   	   	   	   50	  mM	  Tris	  buffer	  (Sigma)	  
FPLC	  buffer	  B	   	   	   	   50	  mM	  Tris	  buffer	  (Sigma),	  1M	  NaCl	  (Sigma)	  
Adjust	   pH	   of	   FPLC	   buffers	   to	   pH	   7.5	   by	   adding	   10M	   NaOH.	   Buffers	   were	   sterile	   filtered	   before	  
storage	  and	  degased	  with	  helium	  prior	  to	  use.	  
	  
Fixation	  solution	   4%	  paraformaldehyde	  in	  PBS	  (Sigma)	  
Heat	  to	  70°C	  until	  dissolved;	  adjust	  pH	  after	  cooling	  to	  pH	  7.4.	  
	  
Low-­‐FCS	  stem	  cell	  medium150	   60%	  DMEM	  low	  glucose	  (PAA)	  
38%	  MCSB	  201	  basemedium	  (Sigma)	  
2%	  FCS	  (HyClone)	  
100	  M	  l-­‐ascorbic	  acid-­‐2-­‐PO4	  in	  PBS	  (Sigma)	  
1x	  insulin	  transferrin	  selenium	  (Invitrogen)	  
2	  mM	  l-­‐glutamine	  (Life	  Technologies)	  
1x	  linoleic	  acid	  (Sigma)	  
20	  nM	  dexamethasone	  in	  PBS	  (Sigma)	  
10	  ng/ml	  PDGF-­‐BB	  (Peprotech)	  
10	  ng/ml	  EGF	  (Peprotech)	  
4.2. Primers	  
Table	  6:	  List	  of	  primers.	  
Primers	  were	  designed	  with	  the	  Roche	  ProbeFinder	  V2.45	  and	  synthesized	  by	  Eurofins.	  
	  
Gene	  	   Forward	  Primer	   Reverse	  Primer	   Probe	  #	  
ITGB1	   cagttactgaagaatttcagcctgt	   gcagataatttcctactgctgac	   17	  
ITGB3	   tgcaggctacagtctgtgatg	   tggcatcagtggtaaacacc	   19	  
ITGB6	   ctgcctgcttattggacctc	   gccaactccagatggatgag	   2	  
ITGB7	   gcttcgatgccattctgc	   gaatgtgtcgtctgaagtgaaca	   19	  
ITGB8	   gcattatgtcgaccaaacttca	   gcaacccaatcaagaatgtaact	   19	  
GAPDH	   agccacatcgctcagacac	   gcccaatacgaccaaatcc	   60	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4.3. siRNA	  reagents	  
Table	  7:	  List	  of	  siRNAs.	  
siRNAs	  were	  purchased	  from	  Dharmacon/GE	  Healthcare.	  
	  
Target	  gene	  symbol	   siRNA	  ID	   Sequence	  -­‐	  Sense	  
siRLUC	   P-­‐002070-­‐1-­‐20	   aaacaugcagaaaaugcug	  
ITGB1	  #1	   D-­‐004506-­‐01	   gaacagaucugaugaauga	  
ITGB1	  #2	   D-­‐004506-­‐02	   caagagagcugaagacuau	  
ITGB1	  #3	   D-­‐004506-­‐03	   gaagggaguuugcuaaauu	  
ITGB1	  #4	   D-­‐004506-­‐04	   ccacagacauuuacauuaa	  
ITGB3	  #2	   D-­‐004124-­‐02	   gaaaguccauccuguaugu	  
ITGB3	  #5	   D-­‐004124-­‐05	   gaaaauccguucuaaagua	  
ITGB3	  #6	   D-­‐004124-­‐06	   uuacugccgugacgagauu	  
ITGB3	  #7	   D-­‐004124-­‐07	   cgucuaccuucaccaauau	  
ITGB6	  #1	   D-­‐008012-­‐01	   gcuaaaggaugucaauuaa	  
ITGB6	  #2	   D-­‐008012-­‐02	   gaacggcucuuuccagugu	  
ITGB6	  #3	   D-­‐008012-­‐03	   caucucagcuuaugaagaa	  
ITGB6	  #5	   D-­‐008012-­‐05	   gccaacccuugcaguagua	  
ITGB7	  #2	   D-­‐008013-­‐02	   gaccugagcuacuccauga	  
ITGB7	  #3	   D-­‐008013-­‐03	   gaugauggcuggugcaaag	  
ITGB7	  #4	   D-­‐008013-­‐04	   ggacaguaauccucucuac	  
ITGB7	  #5	   D-­‐008013-­‐05	   acaguaauccucucuacaa	  
ITGB8	  #2	   D-­‐008014-­‐02	   cugcaaaccucaauaauuu	  
ITGB8	  #4	   D-­‐008014-­‐04	   gcagaaacgugacgagcaa	  
ITGB8	  #5	   D-­‐008014-­‐05	   uggaaacgauuuaucuaga	  
ITGB8	  #6	   D-­‐008014-­‐06	   gaucagacgucucaucucg	  
4.4. Patient	  material	  
Table	  8:	  List	  of	  primary	  mesenchymal	  stem	  cell	  donors.	  
MSC	   were	   collected	   by	   the	   Heidelberg	   University	   Clinic	   after	   written	   consent	   according	   to	   the	   guidelines	  
approved	  by	  the	  Ethics	  Committee	  of	  Heidelberg	  University	  (348/2004).	  
	  
Donor	  ID	   Gender	   Source	   age	  
275	  /	  Donor	  1	   male	   Bone	  marrow	  of	  the	  Iliac	  crest	   50	  
304	  /	  Donor	  2	   male	   Bone	  marrow	  of	  the	  Iliac	  crest	   26	  
345	  /	  Donor	  3	   male	   Bone	  marrow	  of	  the	  Iliac	  crest	   25	  
	  
	  
Table	  9:	  List	  of	  primary	  hematopoietic	  stem	  cell	  donors.	  
HSC	   were	   collected	   by	   the	   Heidelberg	   University	   Clinic	   after	   written	   consent	   according	   to	   the	   guidelines	  
approved	   by	   the	   Ethics	   Committee	   of	   Heidelberg	   University	   (cord	   blood:	   257/2002,	   peripheral	   blood:	  
348/2204).	  
	  
Donor	  ID	   description	  
CB4090-­‐CB4092	   Pooled	  HSC	  from	  cord	  blood	  of	  two	  donors	  
mPB170	   Mobilized	  HSC	  from	  peripheral	  blood	  of	  one	  donor	  
CB4496-­‐CB4502	   Pooled	  HSC	  from	  cord	  blood	  of	  four	  donors	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4.5. Proteins	  
Table	  10:	  List	  of	  recombinant	  and	  isolated	  proteins.	  
	  
Protein	   Source	   Type	   Cat	  #	   Manufacturer	  










CXCL12	   E.	  Coli	  	   Recombinant,	  
human	  
350-­‐NS-­‐010	   R&D	  Systems	  
Type	  I	  collagen	   Placenta	  tissue	   Isolated,	  	  
human	  
C5483-­‐1MG	   Sigma	  
Type	  III	  collagen	   Skin	  tissue	   Isolated,	  	  
human	  
C4407-­‐1MG	   Sigma	  
Fibronectin	   Human	  plasma	   Isolated,	  	  
human	  
F0895-­‐1MG	   Sigma	  
Galectin-­‐3	  binding	  
protein	  
Mouse	  NSO	  cell	  line	   Recombinant,	  
human	  
2226-­‐GA-­‐050	   R&D	  Systems	  




LN411-­‐02	   BioLamina	  




LN421-­‐02	   BioLamina	  
Nidogen	  1	   Mouse	  NSO	  cell	  line	   Recombinant,	  
human	  
2570-­‐ND-­‐050	   R&D	  Systems	  
TGF-­‐β	  induced	  
protein	  
Mouse	  NSO	  cell	  line	   Recombinant,	  
human	  
3409-­‐BG-­‐050	   R&D	  Systems	  
Thrombospondin	  1	   Mouse	  NSO	  cell	  line	   Recombinant,	  
human	  
3074-­‐TH-­‐050	   R&D	  Systems	  
Thrombospondin	  2	   Mouse	  NSO	  cell	  line	   Recombinant,	  
human	  
1635-­‐T2-­‐050	   R&D	  Systems	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5. Methods	  
5.1. Cell	  culture	  and	  cell-­‐based	  assays	  
5.1.1. Isolation	  and	  characterization	  of	  MSC	  
Human	  bone	  marrow	  samples	  from	  the	  iliac	  crest	  were	  collected	  by	  bone	  marrow	  aspiration	  after	  
written	   consent	   using	   the	   guidelines	   approved	  by	   the	   Ethics	   Committee	  of	  Heidelberg	  University	  
(348/2004).	   The	   mononucleated	   cell	   fraction	   was	   isolated	   after	   density	   gradient	   centrifugation	  
using	   lymphocyte	   separation	  medium	  LSM	  1077	   (PAA).	  After	  washing,	  mononucleated	   cells	  were	  
re-­‐suspended	   according	   to	   Verfaillie150	   in	   low	   FCS	   culture	   medium	   consisting	   of	   low	   glucose	  
Dulbecco's	   modified	   Eagle's	   medium	   (DMEM)	   (PAA)	   supplemented	   with	   40%	   (v/v)	   MCDB201	  
(Sigma),	   2%	   (v/v)	   fetal	   calf	   serum	   (FCS)	   (HyClone),	   2	  mM	   L-­‐glutamine	   (Sigma),	   100	  U/ml	  
penicillin/streptomycin	  (Pen/Strep)	  (Lonza),	  1%	  (v/v)	   insulin	  transferrin	  selenium	  (Sigma),	  1%	  (v/v)	  
linoleic	  acid-­‐albumin	  from	  bovine	  serum	  albumin	  (Sigma),	  10	  nM	  dexamethasone	  (Sigma),	  0.1	  mM	  
l-­‐ascorbic	  acid	  2-­‐phosphate	  (Sigma),	  10	  ng/ml	  of	  each	  PDGF-­‐BB	  and	  EGF	  (PreproTech)	  and	  seeded	  
in	   T75	   vented	   filter	   cap	   tissue	   culture	   flasks	   (Greiner	   bio-­‐one)	   at	   a	   concentration	   of	   about	  
1x106	  cells/cm2.	  Medium	  was	  changed	  after	  2-­‐3	  days	  to	  remove	  non-­‐adherent	  cells.	  Initial	  colonies	  
were	  separated	  and	  further	  cultured.	  After	  reaching	  80%	  confluence	  the	  cells	  were	  detached	  with	  
0.25%	  Trypsin	  EDTA	  (PAA),	  washed	  and	  seeded	  at	  a	  density	  of	  10,000	  cell/cm2	  for	  expansion.	  MSC	  
were	   further	   characterized	   for	   their	   ability	   to	   differentiate	   towards	   osteogenic	   and	   adipogenic	  
lineages	  and	  their	  immunophenotype	  with	  the	  Stemflow	  hMSC	  Analysis	  Kit	  (BD).	  After	  passage	  two,	  
cell	  banks	  of	  each	  donor	  were	  generated	  and	  stored	  in	  liquid	  nitrogen.	  
5.1.2. Expansion	  of	  MSC	  and	  production	  of	  MSC	  cell	  culture	  supernatant	  
MSC	  were	   thawed	   and	   further	   expanded	  under	   previously	   described	   conditions	   in	   T75	   and	   T175	  
vented	   filter	   cap	   tissue	   culture	   flasks	   (Greiner	   bio-­‐one).	   After	   expansion	   up	   to	   passage	   six,	   cells	  
were	  grown	  to	  full	  confluence	  and	  washed	  with	  PBS	  followed	  by	  48	  h	  of	  cultivation	  in	  DMEM	  F12	  
medium	  (Invitrogen)	  without	  any	  further	  additives.	  Cell	  culture	  supernatant	  of	  MSC	  was	  harvested	  
under	  sterile	  conditions	  and	  stored	  at	  -­‐20C°.	  	  
5.1.3. Isolation,	  characterization	  and	  culture	  of	  HSC	  
Human	   HSC	   were	   either	   collected	   from	   fresh	   umbilical	   cord	   blood,	   or	   from	   granulocyte	   colony-­‐
stimulating	  factor	  mobilized	  peripheral	  blood.	  All	  samples	  were	  taken	  after	  informed	  consent	  using	  
guidelines	  approved	  by	  the	  Ethics	  Committee	  on	  the	  “Use	  of	  Human	  Subjects”	  at	  the	  University	  of	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Heidelberg.	   Mononuclear	   cells	   were	   isolated	   after	   density	   gradient	   centrifugation	   on	   Ficoll-­‐
Hypaque	  (Biochrom	  KG,	  Berlin,	  Germany).	  CD34+	  cells	  were	  enriched	  by	  labeling	  with	  a	  monoclonal	  
anti-­‐CD34	   antibody	   conjugated	   with	   magnetic	   MicroBeads	   and	   passing	   them	   over	   an	   affinity	  
column	  in	  an	  AutoMACS	  system	  (Miltenyi	  Biotec,	  Bergisch-­‐Gladbach,	  Germany).	  
After	  isolation,	  HSC	  were	  stored	  up	  to	  several	  hours	  at	  4°	  in	  MACS	  buffer	  containing	  0.1%	  FCS.	  Cells	  
were	  then	  directly	  transferred	  to	  the	  respective	  experiments	  in	  DMEM	  F12	  medium	  containing	  10%	  
FCS.	  	  
5.1.4. Culture	  of	  cancer	  cell	  lines	  
PC3,	  VCaP	  and	  LNCaP	  prostate	  cancer	  cell	  lines	  as	  well	  as	  the	  MDA-­‐MB-­‐231	  breast	  cancer	  cell	  line	  
were	   obtained	   from	   ATCC.	   All	   cancer	   cell	   lines	   were	   cultivated	   in	   DMEM	   high	   glucose	  
supplemented	  with	  10%	  (v/v)	  FCS	  and	  100	  U/ml	  penicillin/streptomycin	  under	  standard	  conditions.	  
Media	  was	  changed	  every	  other	  day	  and	  cells	  were	  passaged	  at	  80-­‐90%	  confluence.	  
5.1.5. Mycoplasma	  testing	  of	  cultured	  cells	  
All	   cells	   and	   cell	   lines	   cultured	   und	   utilized	   in	   preparation	   of	   this	   work	   were	   checked	   for	  
mycoplasma	   contaminations	   on	   a	   regular	   basis	   and	   were	   shown	   to	   be	   free	   of	   mycoplasma.	  
Mycoplasma	  tests	  were	  conducted	  according	  to	  Uphoff	  and	  Drexler291.	  
5.1.6. Cell	  line	  authentication	  
The	  identity	  of	  all	  cell	  lines	  cultured	  und	  utilized	  in	  preparation	  of	  this	  work	  was	  confirmed	  by	  the	  
Genomics	   and	   Proteomics	   Core	   Facility	   of	   the	   German	   Cancer	   Research	   Center	   Heidelberg	  
according	  to	  Castro	  et	  al.292.	  
5.1.7. siRNA	  transfections	  
siRNAs	  against	  genes	  of	   interest	  (Table	  7)	  were	  obtained	  from	  Dharmacon.	  Cells	  were	  transfected	  
in	  6	  well	  plates	  with	  20	  nm	  siRNA	  using	  0.15%	  Viromer	  Blue	   transfection	   reagent	   (Lypocalix)	   in	  a	  
reverse	   transfection	   protocol.	   1.5µl	  siRNA	   stock	   (5	  µM)	   was	   prepared	   in	   98.5	  µl	   siRNA	   buffer	  
(Lypocalix)	  and	  applied	  to	  single	  6-­‐wells.	  2	  µl	  Viromer	  Blue	  transfection	  reagent	  was	  diluted	  in	  98	  µl	  
siRNA	  buffer,	  briefly	  mixed,	   incubated	   for	  10	  min	  at	   room	  temperature,	   finally	  added	   to	  single	  6-­‐
wells	  containing	  siRNAs	  and	  incubated	  for	  20-­‐30	  min.	  Cancer	  cells	  were	  added	  to	  the	  transfections	  
mix	   in	   1.3	  ml	   DMEM	   high	   glucose	   supplemented	   with	   10%	   (v/v)	   FCS	   for	   a	   total	   of	   1.5	  ml	   and	  
cultured	  for	  72	  h.	  After	  48	  h,	  1	  ml	  of	  fresh	  medium	  was	  added.	  To	  identify	  adverse	  effects	  caused	  
by	  the	  transfection	  protocol,	  siRLUC	  was	  used	  as	  control.	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5.1.8. Quantitative	  real-­‐time	  PCR	  
Total	   RNA	   was	   extracted	   according	   to	   the	   RNeasy	   Mini	   Kit	   protocol	   (Quiagen)	   and	   RNA	  
concentration	  determined	  prior	  to	  cDNA	  synthesis.	  The	  cDNA	  was	  prepared	  from	  1	  µg	  of	  total	  RNA,	  
using	  the	  RevertAid	  H	  Minus	  First	  Strand	  cDNA	  Synthesis	  Kit	  (Thermo	  Fischer	  Scientific)	  and	  oligodT	  
primer	  according	  to	  manufacturer	  protocol.	  	  
Subsequent	   quantitative	   real-­‐time	   PCR	   (qPCR)	   was	   performed	   using	   the	   Lightcycler	   480	   system	  
(Roche)	   in	  a	  384-­‐well	   format.	  5	  µl	  of	  cDNA	  (5	  µg/µl)	  per	  well	  was	  transferred	  to	  384-­‐qPCR	  plates.	  
6ul	   of	   reaction	   mix	   was	   then	   added	   to	   each	   well.	   Reaction	   mix	   consisted	   of	   5.5	  ml	   master	   mix	  
(Roche),	  0.22	  µl	  forward	  and	  reverse	  primer	  mix	  (20	  µM),	  0.11	  µl	  UPL-­‐hydrolysis	  probe	  (Roche)	  and	  
0.17	  µl	  ddH2O.	  The	  combinations	  of	   intron	  spanning	  primer	  and	  probe	   for	  each	  query	  gene	  were	  
designed	   using	   the	   Roche	   ProbeFinder	   V2.45.	   All	   samples	   were	   amplified	   as	   triplicates	   and	  
differential	   gene	  expression	  was	   calculated	  using	   the	  delta	  delta	  Ct	  method.	  GAPDH	  was	  used	  as	  
reference	  gene	  for	  relative	  quantification.	  
5.1.9. Transwell	  migration	  (xCELLigence)	  of	  cancer	  cell	  lines	  
Cancer	  cell	  migration	  was	  analyzed	  using	  transwell	  migration	  CIM-­‐plates	  with	  the	  xCELLigence	  RTCA	  
DP	  system	  (Acea	  Bioscience)	  in	  a	  quantitative	  and	  time	  resolved	  fashion.	  CIM	  plates	  are	  based	  on	  
classic	  transwell	  migration	  chambers.	  The	  upper	  chamber	  has	  16	  single	  wells	  that	  are	  sealed	  at	  the	  
bottom	   with	   a	   microporous	   polyethylene	   terephthalate	   membrane	   containing	   micro-­‐fabricated	  
gold	  electrode	  arrays	  conducting	  an	  electrical	  current	  on	  the	  bottom	  side	  of	   the	  membrane.	  	  The	  
median	  pore	   size	  of	   this	  membrane	   is	  8	  μm.	  Cells	   surpassing	   the	  membrane	  along	  a	   chemotactic	  
gradient	  will	  attach	  to	  the	  gold	  electrodes	  causing	  electrical	  impedance.	  The	  xCELLigence	  readout	  is	  
defined	   by	   the	  manufacturer	   as	   ‘cell	   index	   (CI)’.	   The	   cell	   index	   is	   dependent	   on	   the	   background	  
resistance	  measured	  at	  time	  point	  zero	  (Rt0),	  resistance	  measured	  at	  time	  point	   ‘n’	   (Rtn)	  and	  the	  
frequency	  dependent	  constant	  of	  the	  instrument	  (Figure	  15).	  
Prior	  to	  migration,	  175	  µl	  of	  chemoattractant	  was	  placed	  in	  the	  lower	  and	  50	  µl	  of	  fresh	  DMEM	  F12	  
medium	   pipetted	   into	   the	   top	   chamber.	   After	   assembly,	   a	   background	   measurement	   was	  
conducted	   to	   determine	   the	   resistance	   at	   time	  point	   zero.	   Cells	  were	   then	  detached	  with	   0.25%	  
trypsin,	   resuspended	   in	   fresh	   DMEM	   F12	  medium	  without	   additives	   and	   50,000	   cells	   introduced	  
into	  the	  upper	  chamber.	  The	  measurement	  interval	  was	  set	  to	  5	  min.	  
Cells	  migrating	   towards	  a	  known	  or	  suspected	  chemoattractant	  were	  also	  analyzed	   in	  parallel	   for	  
their	   migration	   towards	   clean	   buffer	   or	   clean	   medium	   without	   chemoattractant.	   This	   biological	  
background	  measurement	  allowed	   for	   the	  differentiation	  between	  baseline	  motility	   and	  directed	  
migration	   of	   the	   cells	   towards	   the	   respective	   chemoattractants.	   By	   subtracting	   the	   biological	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background	   for	  each	   time	  point,	   variability	   caused	  by	  passage	  number,	   cellular	   fitness	  or	   toxicity	  
effects	   caused	  by	   treatments	  was	   reduced	  and	  allowed	  better	   comparison	  between	   independent	  
experiments.	  Migration	  dynamics	  were	  determined	  with	  the	  RTCA	  xCELLigence	  software	  version	  	  
1.2.	  
Figure	   15:	   Graphical	   representation	   of	  
single	  xCELLigence	  transwell.	  
Cancer	   cells	   seeded	   into	   the	   top	   chamber	  
migrate	   along	   a	   chemotactic	   gradient	  
towards	   the	   bottom	   chamber,	   surpassing	  
the	   microporous	   membrane	   and	   attaching	  
to	   the	   electrodes	   conducting	   an	   electrical	  
current.	   This	   attachment	   influences	   the	  
electrical	   current	   by	   causing	   impedance,	  
which	   is	  directly	  dependent	  on	   the	  amount	  
of	  migrated	  cells	   that	  have	  attached	   to	   the	  
electrodes.	  
	  
5.1.10. Transwell	  migration	  (classic	  Boyden	  chambers)	  of	  cancer	  cell	  lines	  
As	  the	  xCELLigence	  system	  does	  not	  allow	  visual	  inspection	  of	  the	  migrated	  cells,	  results	  obtained	  
with	   the	   xCELLigence	   system	   were	   confirmed	   and	   complemented	   with	   classic	   Boyden	   chamber	  
transwell	  assays	  (8 μm	  pore	  size;	  Corning	  Costar)	  using	  uncoated	  filters.	  Cells	  were	  detached	  with	  
0.25%	   trypsin,	   resuspended	   in	   fresh	   DMEM	   F12	   medium	   without	   additives	   and	   50,000	   cells	   in	  
200	  μl	  cell	  suspension	  were	  introduced	  into	  the	  upper	  chamber.	  600	  µl	  chemoattractant	  was	  placed	  
in	   the	   lower	   chamber.	  Cells	  migrating	   towards	   a	   known	  or	   suspected	   chemoattractant	  were	  also	  
analyzed	   in	   parallel	   for	   their	   migration	   towards	   clean	   buffer	   or	   clean	   medium	   without	  
chemoattractant	  for	  comparison.	  After	  migration,	  transwells	  were	  washed	  in	  PBS,	  placed	  in	  4%	  PFA	  
fixation	   solution	   for	   10	  min,	   washed	   twice	   with	   PBS	   and	   placed	   in	   haematoxylin	   cell	   staining	  
solution	   (Carl	   Roth	  GmbH)	   for	   30	  min.	   Transwells	  were	   then	   thoroughly	   rinsed	   in	   tap	  water	   and	  
non-­‐migrated	  cells	  remaining	  on	  the	  top	  side	  of	  the	  membrane	  were	  removed	  with	  a	  cotton	  swab.	  
Afterwards	  the	  membranes	  were	   left	  to	  dry.	  Dry	  membranes	  were	  cut	  out	  and	  mounted	  on	  glass	  
slides	  for	  microscopy	  analysis.	  	  
5.1.11. Transwell	  migration	  of	  HSC	  
In	   order	   to	   investigate	   the	  migration	   of	   HSC	   towards	   the	   recombinant	   chemokine	   CXCL12,	   cells	  
were	  analyzed	  in	  classic	  24-­‐well	  Boyden	  chamber	  transwell	  assays	  (3 μm	  pore	  size;	  Corning	  Costar)	  
using	  uncoated	   filters.	  Non-­‐adherent	  HSC	  accumulated	  at	   the	  bottom	  of	   the	  well	   after	  migration	  
through	   the	   filter	   inserts.	   This	   allowed	   them	   to	   be	   monitored	   using	   an	   IncuCyte	   Zoom	   live-­‐cell	  
imaging	  microscope	  (Essen	  Bioscience).	  Phase	  contrast	  and	  red	  fluorescence	  images	  were	  acquired	  
every	  hour	  and	   the	  number	  of	  migrated	   cells	  per	  well	  were	  determined	  with	   the	   IncuCyte	  Zoom	  
Impedance [Cell Index] + -
chemotactic gradient formed by
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software.	  Fluorescence	   imaging	  of	   the	  HSC	   required	   treatment	  with	   the	   life	   cell	  dye	  PKH26.	  Cells	  
were	   stained	   with	   the	   PKH26	   red	   fluorescent	   cell	   linker	   kit	   according	   to	   manufacturer	   protocol	  
(Sigma).	  HSC	  were	  washed	  once	  in	  DMEM	  F12	  medium	  without	  FCS,	  pelleted	  and	  resuspended	  in	  
500	  μl	  diluent	  C.	  500	  μl	  staining	  solution	  (6	  μM	  PKH26	  in	  diluent	  C)	  was	  added	  and	  cells	  incubated	  
for	  2	  to	  5	  min	  under	  constant	  rotation.	  The	  staining	  was	  stopped	  by	  the	  addition	  of	  1	  ml	  FCS.	  Cells	  
were	   then	   washed	   three	   times	   with	   DMEM	   F12	   medium	   containing	   10%	   FCS	   resulting	   in	   a	   cell	  
suspension	   of	   107	  cells/ml.	   Finally,	   the	   transwell	   migration	   experiments	   were	   set	   up	   by	   placing	  
600	  μl	  DMEM	  F12	   (10%	  FCS,	   100	  ng/ml	  CXCL12)	   and	  DMEM	  F12	   (10%	  FCS)	   as	   a	   negative	   control	  
into	   the	   bottom	   chambers.	   200	   µl	   HSC	   cell	   suspension	   were	   then	   introduced	   into	   the	   upper	  
chamber	  and	  the	  24-­‐well	  plate	  set	  into	  the	  IncuCyte	  microscope	  for	  real	  time	  imaging.	  During	  the	  
imaging	  process	   the	   IncuCyte	   system	  had	  problems	   choosing	   the	   correct	   focus	  plane	   resulting	   in	  
occasional	  images	  of	  the	  filter	  insert	  instead	  of	  the	  cells	  on	  the	  well	  bottom.	  The	  addition	  of	  small	  
amounts	   of	   inert	   agar	   beads	   into	   the	   bottom	  of	   the	  wells	   helped	   the	   imaging	   system	   to	   set	   the	  
focus	  plane	  correctly	  onto	  the	  well	  bottom.	  	  
5.1.12. Processing	  of	  cell	  culture	  supernatant	  by	  FPLC	  
Complexity	  of	  SN	  MSC	  samples	  was	  reduced	  by	  fast	  protein	  liquid	  chromatography	  (FPLC)	  using	  an	  
Äkta	  Explorer	  100	  system	  coupled	  with	  a	  Frac	  950	  fraction	  collector	  (GE	  Healthcare).	  System	  control	  
and	  data	  analysis	  was	  conducted	  with	  Unicorn	  Software	  Version	  4.0	  (GE	  Healthcare).	  FPLC	  was	  run	  
at	  RT	  with	  50	  mM	  Trizma®Base	  buffer	   (Sigma-­‐Aldrich),	  pH	  7.5	   (Buffer	  A)	   and	  50	  mM	  Trizma®	  Base	  
buffer,	  pH	  7.5	  containing	  1M	  NaCL	  (Sigma-­‐Aldrich)	  (Buffer	  B).	  Prior	  to	  use,	  buffers	  were	  filtered	  and	  
degased.	  
5.1.13. Sample	  preparation	  
Prior	   to	   FPLC,	   remaining	   cells	   as	  well	   as	   cellular	  debris	   and	  precipitated	  protein	  was	   removed	  by	  
passing	   the	   cell	   culture	   supernatant	   through	   a	   0.22	  µm	   sterile	   filter	   (Millipore).	   For	   each	   size	  
exclusion	  chromatography	  run,	  16	  ml	  of	  filtered	  SN	  MSC	  was	  concentrated	  to	  approximately	  700	  µl	  
by	  ultrafiltration	  using	  Amicon	  ultra-­‐filter	  units	  with	  a	  molecular	  weight	  cut-­‐off	  of	  3	  kDa	  (Millipore).	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5.1.14. Size	  exclusion	  chromatography	  
700	  µl	  of	  SN	  MSC	  concentrate	  was	   injected	   into	  a	  500	  µl	  sample	   loop	  ensuring	  an	  air	  bubble-­‐free	  
loading	   of	   the	   sample.	   After	   manually	   equilibrating	   the	   Superdex	   200	   HR	   10/30	   column	   (GE	  
Healthcare),	  proteins	  present	  in	  SN	  MSC	  were	  separated	  based	  on	  their	  size	  and	  fractionated	  in	  an	  
automated	  fashion	  (Table	  11)	  into	  a	  low-­‐protein-­‐bind	  96	  well	  plate	  (Eppendorf).	  
In	  order	  to	  estimate	  the	  size	  of	  eluted	  proteins,	  the	  Superdex	  200	  column	  was	  calibrated	  with	  a	  size	  
exclusion	   chromatography	   calibration	   kit	   containing	   a	   set	   of	   proteins	   of	   defined	   size	   (Bio-­‐Rad).	  
500	  µl	  of	  calibration	  standard	  was	   injected	  and	  fractionated	  under	  standard	  conditions	  (Table	  11)	  
and	  according	  to	  manufacturer	  instructions.	  Elution	  volume	  and	  protein	  size	  were	  then	  correlated	  
by	   determining	   the	   void	   volume	   of	   the	   column	   V0	   and	   the	   retention	   volume	   VR	   of	   each	   protein	  
present	  in	  the	  protein	  standard	  solution.	  By	  plotting	  the	  known	  molecular	  size	  of	  each	  protein	  over	  
its	  corresponding	  ratio	  of	  VR/V0,	  a	  logarithmic	  standard	  curve	  was	  determined.	  	  
	  
Table	  11:	  Äkta-­‐Unicorn	  process	  parameters	  for	  automated	  SEC	  FPLC.	  
	  
Process	  Block	   Variable	   Value	  
Main	   Column	   Superdex	  200	  10/30	  
Flow	  rate	   Flow	  rate	   0.25	  ml/min	  
Column	  pressure	  limit	   Column	  pressure	  limit	   1.5	  MPa	  
Start	  instructions	   Wavelength	  1	   290	  nm	  
	   Wavelength	  2	  &	  3	   off	  
	   Averaging	  time	  UV	   2.56	  s	  
Start	  with	  pump	  wash	  explorer	   Wash	  inlet	  A1,	  A2,	  B1,	  B2	   Off	  
Start	  conc.	  B	   Start	  conc.	  B	   15%	  
Column	  equilibration	   Equilibrate	  with	   0.2	  cv	  
Sample	  injection	   Empty	  loop	  with	   1.5	  ml	  
Isocratic	  elution	  before	  fractionation	   Length	  before	  fractionation	   0.2	  cv	  
Volume	  fractionation	   Eluate	  fraction	  size	   0.6	  ml	  
Isocratic	  elution	  with	  fractionation	   Length	  with	  fractionation	   1.2	  cv	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5.1.15. Ion	  exchange	  chromatography	  
After	   SEC,	   fractions	   of	   interest	   were	   pooled	   and	   further	   fractionated	   by	   ion	   exchange	  
chromatography	  (IEX)	  with	  a	  Mono	  QTM	  5/50	  GL	  ion	  exchange	  column	  (GE	  Healthcare).	  The	  column	  
was	   manually	   equilibrated	   and	   the	   sample	   manually	   loaded	   with	   the	   help	   of	   a	   superloop	   (GE	  
Healthcare).	  	  Flow-­‐through	  while	  loading	  the	  column	  was	  discarded	  and	  bound	  protein	  was	  eluted	  
off	  the	  column	  by	  a	  NaCl	  gradient	  in	  an	  automated	  fashion	  (Table	  12)	  and	  fractionated	  into	  a	  low-­‐
protein-­‐bind	  96-­‐well	  plate.	  
	  
Table	  12:	  Äkta-­‐Unicorn	  process	  parameters	  for	  automated	  IEX	  FPLC.	  
	  
Block	   Variable	   Value	  
Main	   Column	   Mono_Q_HR_5/5	  
Flow	  rate	   Flow	  rate	   0.5	  ml/min	  
Column	  pressure	  limit	   Column	  pressure	  limit	   4	  MPa	  
Start	  instructions	   Wavelength	  1	   290	  nm	  
	   Wavelength	  2	  &	  3	   off	  
	   Averaging	  time	  UV	   2.56	  s	  
Start	  conc.	  B	   Start	  conc.	  B	   5%	  
Column	  equilibration	   Equilibrate	  with	   5	  cv	  
Sample	  injection	   Empty	  loop	  with	   24	  cv	  
Wash	  out	  unbound	  sample	   Wash	  column	  with	   2	  cv	  
Volume	  fractionation	   Start	  fractionation	  at	   5%	  
	   End	  fractionation	  at	   100%	  
	   Eluate	  fractions	  size	   0.5	  ml	  
Linear	  gradient	   Target	  concentration	   100%	  
	   Length	  of	  gradient	   20	  cv	  
Gradient	  delay	   Gradient	  delay	   2	  cv	  
Clean	  after	  elution	   Clean	  with	   5	  cv	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5.2. Protein	  analysis	  
5.2.1. Electrospray	  ionization	  mass	  spectrometry	  
Electrospray	   ionization	   mass	   spectrometry	   (ESI-­‐MS)110	   experiments	   were	   conducted	   by	   the	  
proteomics	   core	   facility	  of	   the	  German	  Cancer	  Research	  Center	   in	   collaboration	  with	  Dr.	  Martina	  
Schnölzer	  and	  Ramona	  Mayer.	  Mass	  spectrometry	  analysis	  of	  FPLC	  fractions	  required	  the	  following	  
preparation	  of	  the	  samples.	  In	  order	  to	  remove	  non-­‐protein	  contaminants	  and	  prepare	  the	  sample	  
for	   in-­‐solution	   digestion	   a	   quantitative	   precipitation	   was	   performed.	   Protein	   precipitation	   was	  
induced	   using	   a	   methanol-­‐chloroform-­‐water	   mixture	   according	   to	  Wessel	   and	   Flügge293.	   Protein	  
precipitation	  was	  achieved	  by	  mixing	  100	  μl	  sample	  with	  400	  μl	  methanol	  followed	  by	  the	  addition	  
of	   100	  μl	   chloroform	   and	   300	  μl	   ddH2O.	   After	   each	   mixing	   step,	   the	   sample	   was	   vortexed	  
thoroughly.	  Phase	  separation	  was	  then	  induced	  by	  centrifugation	  of	  the	  sample	  at	  15,000	  rpm	  for	  
2	  min.	   The	   upper	   phase	   containing	   the	   chloroform	   was	   then	   removed	   without	   touching	   the	  
interphase	   containing	   the	   precipitated	   protein.	   After	   the	   further	   addition	   of	   300	  μl	   methanol,	  
vortexing	   and	   subsequent	   centrifugation	   at	   15,000	  rpm	   for	   2	  min	   the	   complete	   supernatant	  was	  
removed	   and	   the	   precipitated	   protein	   pellet	   was	   dried	   for	   10	  min.	   After	   drying,	   the	   pellet	   was	  
redissolved	   in	   10	  μl	   buffer	   containing	   40	  mM	   ammonium	   bicarbonate	   and	   2	  μl	   10	  mM	  
dithiothreitol.	   Finally,	   proteins	  were	   alkylated	   by	   the	   addition	   of	   1	  μl	   55	  mM	   iodoacetamide	   and	  
lastly	   the	   reaction	   quenched	   by	   the	   addition	   of	   further	   2.5	  μl	   dithiothreitol.	   Proteins	   were	   then	  
enzymatically	  digested	  by	  the	  addition	  of	  0.05	  to	  0.1	  μg	  trypsin.	  
For	   ESI-­‐MS,	   tryptic	   peptides	   were	   separated	   using	   a	   nanoAcquity	   UPLC	   system	   (Waters	   GmbH).	  
Peptides	  were	  loaded	  on	  a	  C18	  trap	  column	  (180	  µm	  x	  20	  mm)	  with	  a	  particle	  size	  of	  5	  µm	  (Waters	  
GmbH).	  Liquid	  chromatography	  separation	  was	  performed	  on	  a	  BEH130	  C18	  main-­‐column	  (100	  µm	  
x	   100	  mm)	   with	   a	   particle	   size	   of	   1.7	  µm	   (Waters	   GmbH)	   at	   a	   flow	   rate	   of	   0.4	  µl/min.	   The	  
chromatography	  was	   carried	  out	  using	  a	  1	  h	   gradient	  of	   solvent	  A	   (98.9%	  water,	   1%	  acetonitrile,	  
0.1%	   formic	   acid)	   and	   solvent	   B	   (99.9%	   acetonitrile	   and	   0.1%	   formic	   acid)	   in	   the	   following	  
sequence:	  from	  0	  to	  4%	  B	  in	  1	  min,	  from	  4	  to	  40%	  B	  in	  40	  min,	  from	  40	  to	  60%	  B	  in	  5	  min,	  from	  60	  
to	  85%	  B	  in	  0.1	  min,	  6	  min	  at	  85%	  B,	  from	  85	  to	  0%	  B	  in	  0.1	  min	  and	  9	  min	  at	  0%	  B.	  The	  nanoUPLC	  
system	  was	  coupled	  online	  to	  an	  LTQ	  Orbitrap	  XL	  mass	  spectrometer	  (Thermo	  Scientific).	  Data	  was	  
acquired	  by	  scan	  cycles	  of	  one	  FTMS	  scan	  with	  a	  resolution	  of	  60,000	  at	  m/z	  400	  and	  a	  range	  from	  
300	  to	  2000	  m/z	   in	  parallel	  with	  six	  MS/MS	  scans	   in	  the	   ion	  trap	  of	  the	  most	  abundant	  precursor	  
ions.	   Instrument	   control,	   data	   acquisition	   and	   peak	   integration	   were	   performed	   using	   Xcalibur	  
software	  2.1	  (Thermo	  Scientific,	  Bremen,	  Germany).	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Database	  searches	  were	  performed	  with	  the	  human	  SwissProt	  database	  using	  the	  MASCOT	  search	  
engine	  (Matrix	  Science;	  version	  2.2.2).	  Peptide	  mass	  tolerance	  for	  database	  searches	  was	  set	  to	  5	  
ppm	   and	   fragment	   mass	   tolerance	   was	   set	   to	   0.4	   Da.	   Significance	   threshold	   was	   p<0.01.	  
Carbamidomethylation	   of	   cysteine	  was	   set	   as	   fixed	  modification.	   Variable	  modifications	   included	  
oxidation	  of	  methionine	  and	  deamination	  of	  asparagine	  and	  glutamine.	  One	  missed	  cleavage	  site	  in	  
case	  of	  incomplete	  trypsin	  hydrolysis	  was	  allowed.	  
5.2.2. Cytokine	  antibody	  array	  
Unprocessed	  cell	   culture	   supernatant	  of	  MSC	  and	  SEC	   fractions	  of	   interest	  were	  analyzed	   for	   the	  
presence	  of	  cytokines	  acting	  as	  potential	  chemoattractants.	  The	  membrane	  based	  c-­‐series	  antibody	  
arrays	   ‘Human	   Angiogenesis	   Antibody	   Array	   C1000’	   and	   ‘Human	   Chemokine	   Antibody	   Array	   C1’	  
(RayBiotech)	   are	   based	   on	   a	   sandwich	   immunoassay	   principle	   and	   allowed	   for	   simultaneous	  
detection	   of	   70	   cytokines	   with	   high	   sensitivity.	   Antibody	   arrays	   were	   used	   according	   to	  
manufacturer	   protocol.	   In	   short,	   samples	   were	   incubated	   on	   the	   nitrocellulose	   membranes	  
featuring	   a	   panel	   of	   capture	   antibodies	   printed	   on	   the	   solid	   support.	   This	   was	   followed	   by	  
incubation	  with	  biotinylated	  antibodies	  and	  finally	  horseradish	  peroxidase-­‐labeled	  Streptavidin.	  All	  
incubation	   steps	   were	   conducted	   under	   gentle	   rocking	   motion	   and	   followed	   by	   washing	   steps.	  
Finally,	  the	  chemiluminescence	  based	  read-­‐out	  was	  visualized	  on	  x-­‐ray	  film.	  	  
For	  each	  sample	  tested	  a	  corresponding	  negative	  control	  was	  also	  analyzed	  to	  avoid	  false	  positive	  
results,	  due	  to	  unspecific	  binding.	  These	  included	  fresh	  cell	  culture	  medium	  for	  SN	  MSC	  as	  well	  as	  
fresh	  cell	  culture	  medium	  undergoing	  FPLC	  for	  FPLC	  fractions	  of	  interest.	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7. Appendix	  
7.1. List	  of	  abbreviations	  
bFGF:	   Basic	  fibroblast	  growth	  factor	  
BMP:	   Bone	  morphogenetic	  protein	  
BMSEC:	  Bone	  marrow	  sinusoidal	  endothelial	  cells	  
ECM:	   Extracellular	  matrix	  
EGF:	   Epidermal	  growth	  factor	  
FCS:	   Fetal	  calf	  serum	  
FPLC:	   Fast	  performance	  liquid	  chromatography	  
HGF:	   Hepatocyte	  growth	  factor	  
HSC:	   Hematopoietic	  stem	  cell	  
ITGB:	   Integrin	  β-­‐subunit	  
M-­‐CSF:	   Macrophage	  colony-­‐stimulating	  factor	  
MSC:	   Mesenchymal	  stem	  cell	  
PGF:	   Platelet-­‐derived	  growth	  factor	  
qPCR:	   Quantitative	  real-­‐time	  PCR	  
RANKL:	  Receptor	  activator	  of	  NF-­‐κB	  ligand	  
TGF-­‐β:	   Transforming	  growth	  factor	  β	  
SCF:	   Stem	  cell	  factor	  
SN:	   Supernatant	  
VEGF:	   Vascular	  endothelial	  growth	  factor	  
7.2. List	  of	  figures	  
Figure	  1:	  Steps	  in	  cancer	  progression	  and	  bone	  metastasis	  formation.	   6	  
Figure	  2:	  Cellular	  components	  of	  the	  bone	  marrow	  niche.	   10	  
Figure	  3:	  Workflow	  to	  identify	  secreted	  proteins	  inducing	  migration	  of	  cancer	  cells	  towards	  
mesenchymal	  stem	  cells.	   14	  
Figure	  4:	  MSC	  induce	  rapid	  migration	  of	  cancer	  cells	  able	  to	  form	  bone	  metastasis.	   17	  
Figure	  5:	  Size	  exclusion	  chromatography	  yields	  highly	  reproducible	  fractionation	  despite	  
heterogeneity	  of	  primary	  MSC.	   19	  
Figure	  6:	  High-­‐molecular-­‐weight	  proteins	  induce	  prostate	  cancer	  cell	  migration.	   22	  
Figure	  7:	  High-­‐molecular-­‐weight	  proteins	  induce	  breast	  cancer	  cell	  migration.	   23	  
Figure	  8:	  Ion	  exchange	  chromatography	  yields	  reproducible	  fractionation	  of	  high-­‐molecular-­‐	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   weight	  proteins	  isolated	  from	  MSC	  cell	  culture	  supernatant.	   27	  
Figure	  9:	  Proteins	  of	  distinct	  ionic	  strength	  show	  elevated	  migration-­‐inducing	  activity	  towards	  
prostate	  cancer	  cells.	   29	  
Figure	  10:	  Prostate	  cancer	  cells	  do	  not	  migrate	  towards	  recombinant	  chemokines.	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7.6. Cytokine	  arrays	  
	  
Supplementary	  figure	  1:	  Antibody	  array	  exposures	  and	  positioning	  of	  spotted	  antibodies.	  	  
Detected	  chemokines	  (A)	  and	  angiogenic	  cytokines	  (B,C)	  in	  samples	  of	  the	  cell	  culture	  supernatant,	  1000	  kDa	  
SEC	   fraction	   and	  100	  kDa	   SEC	   fraction	  of	  MSC	  donors	   1	   and	  2.	  All	   three	   antibody	   arrays	   (A	  –	  C)	  were	   also	  
tested	  with	  fresh	  DMEM	  F12	  medium	  as	  negative	  control	  as	  well	  as	  tris-­‐buffer	  (*)	  as	  an	  additional	  negative	  
control	  in	  the	  case	  of	  the	  chemokine	  antibody	  array	  (A).	  Exposure	  time	  of	  all	  blots	  is	  120s.	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Supplementary	   table	  1:	   List	  of	  all	   cytokines	   tested	   for	   their	  presence	   in	  cell	   culture	  supernatant	   and	  SEC	  
fractions	  of	  cultured	  MSC	  by	  antibody	  array.	  	  
Detection	   of	   low	   (*)	   and	  medium	   (**)	   expressed	   and	   secreted	   cytokines	   potentially	   hampered	   by	   present	  
background	  signal	  detected	  in	  neg.	  ctrl.	  samples.	  
	  
Chemokine	  array	   Angiogenic	  cytokine	  arrays	  1	  &	  2	  
Chemokine	  symbol	   Name	   Cytokine	  symbol	   Name	  
CCL1	  (I-­‐309)	   T	  lymphocyte-­‐secreted	  
protein	  I-­‐309	  
ANG	   Angiogenin	  
CCL2	  (MCP1)	   Monocyte	  chemotactic	  
protein	  1	  
ANGPT-­‐1	   Angiopoietin-­‐1	  
CCL3	   Macrophage	  
inflammatory	  protein-­‐1α	  
ANGPT-­‐2	   Angiopoietin-­‐2	  
CCL4	  (MIP-­‐1α)	  **	   Macrophage	  
inflammatory	  protein-­‐1β	  
bFGF	  	   Basic	  fibroblast	  growth	  
factor	  
CCL5	  **	   RANTES	   CCL1	   T	  lymphocyte-­‐secreted	  
protein	  I-­‐309	  
CCL7	  (MCP3)	   Monocyte	  chemotactic	  
protein	  2	  
CCL13	   Monocyte	  chemotactic	  
protein	  3	  (MCP-­‐3)	  
CCL8	  (MCP2)	   Monocyte	  chemotactic	  
protein	  3	  
CCL2	   Monocyte	  chemotactic	  
protein	  1	  (MCP-­‐1)	  
CCL11	  (Eotaxin	  -­‐1)	   Eotaxin	   CCL5**	   Rantes	  
CCL13	  (MCP4)	   Monocyte	  chemotactic	  
protein	  4	  
CCL7	   Monocyte	  chemotactic	  
protein	  2	  (MCP-­‐2)	  
CCL14	   HCC-­‐1	   CD309	  antigen	  	   Vascular	  endothelial	  
growth	  factor	  receptor	  2	  
CCL15(MIP-­‐1δ)	   Macrophage	  
inflammatory	  protein	  5	  
COL18A1	  **	   Endostatin	  





CCL17	  (TARC)	   Thymus	  and	  activation-­‐
regulated	  chemokine	  
CXCL1,2,3	   Growth-­‐regulated	  
protein	  α,β,γ	  
CCL18	  (PARC)	   Macrophage	  
inflammatory	  protein	  4	  
CXCL11	   Interferon-­‐inducible	  T	  
cell	  α	  chemoattractant	  
CCL19	  (MIP-­‐3β)	   Macrophage	  
inflammatory	  protein	  3	  β	  
CXCL5	   Epithelial	  neutrophil-­‐
activating	  protein	  78	  
CCL20	  (MIP-­‐3α)	   Macrophage	  
inflammatory	  protein	  3	  
EGF	   Epidermal	  growth	  factor	  	  
CCL22	  (MDC)	   Macrophage-­‐derived	  
chemokine	  
FIGF	  	   Vascular	  endothelial	  
growth	  factor	  D	  
CCL23	  (MPIF-­‐1)	  *	   Myeloid	  progenitor	  
inhibitory	  factor-­‐1	  
GCSF	   Granulocyte-­‐colony	  
stimulating	  factor	  
CCL24	  (Eotaxin-­‐2)	  *	  
	  
Eotaxin-­‐2	  	   IFNG	   Interferon	  γ	  
CCL25	  	  (TECK)	   Thymus-­‐expressed	  
chemokine	  




Eotaxin-­‐3	  	   IL10	   Interleukin	  10	  
CCL27	  (CTACK)	  *	   Cutaneous	  T-­‐cell-­‐
attracting	  chemokine	  
(CTACK)	  
IL1A*	   Interleukin-­‐1	  α	  
CCL28	   Mucosae-­‐associated	  
epithelial	  chemokine	  
(MEC)	  
IL1B	   Interleukin-­‐1	  β	  
CXCL1	  (Gro	  α)	   Growth-­‐regulated	   IL2	   Interleukin	  2	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α	  protein	  
CXCL2	  (Gro)	   Growth-­‐regulated	  
protein	  β	  
IL4	   Interleukin	  4	  
CXCL3	  (Gro)	   Growth-­‐regulated	  
protein	  γ	  
IL6	   Interleukin	  6	  
CXCL5	  (ENA	  78)	   Epithelial	  neutrophil-­‐
activating	  protein	  78	  
IL8	   Interleukin	  8	  
CXCL6	  (GCP-­‐2)	   Granulocyte	  chemotactic	  
protein	  2	  
LEP	   Leptin	  
CXCL7	  (NAP2)	  **	   Neutrophil-­‐activating	  
peptide	  2	  




Interleukin	  8	   MMP1	  **	   Interstitial	  collagenase	  
CXCL9	  (MIG)	   Monokine	  induced	  by	  γ	  
interferon	  (MIG)	  
PDGFB	   Platelet-­‐derived	  growth	  
factor	  subunit	  B	  
CXCL10	  (IP-­‐10)	   Interferon-­‐inducible	  
protein-­‐10	  
PECAM-­‐1	  	   Platelet	  endothelial	  cell	  
adhesion	  molecule	  
CXCL11	  (I-­‐TAC)	   Interferon-­‐inducible	  T	  
cell	  α	  chemoattractant	  
PGF	   Placenta	  growth	  factor	  
CXCL12α	  (SDF-­‐1α)	   Stromal	  cell-­‐derived	  
factor	  1α	  
PLAUR	   Urokinase	  plasminogen	  
activator	  surface	  
receptor	  
CXCL12β	  (SDF-­‐1	  β)	   Stromal	  cell-­‐derived	  
factor	  	  
1β	  
PLG	   Angiostatin	  	  
CXCL13	  (BLC)	   B-­‐lymphocyte	  
chemoattractant	  	  
TEK	   Angiopoietin-­‐1	  receptor	  
CXCL14	   Chemokine	  BRAK	   TGFB1	   Transforming	  growth	  
factor	  β-­‐1	  
CXCL16	   Transmembrane	  
chemokine	  CXCL16	  
THPO	   Thrombopoietin	  
CX3CL1	  (Fractalin)	  
	  




Lymphotactin	  	   TIMP-­‐2	  	   Metalloproteinase	  
inhibitor	  2	  
	   	   TNF	   Tumor	  necrosis	  factor	  
	   	   VEGF	  R3	  	   Vascular	  endothelial	  
growth	  factor	  receptor	  3	  
	   	   VEGFA	  	   Vascular	  endothelial	  
growth	  factor	  A	  
Appendix	  
	  
	   99	  
7.7. Images	  of	  prostate	  cancer	  cells	  undergoing	  RNAi	  treatment	  
Supplementary	  figure	  2:	  Phase	  contrast	  images	  of	  untreated	  PC3	  cells.	  	  
Cells	  were	   seeded	  72	  h	  post	   reverse	   siRNA	   transfection	   in	  96-­‐well	   tissue	  culture	  plates	  and	   imaged	  at	  10	  x	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Supplementary	  figure	  3:	  Phase	  contrast	  images	  of	  siRLUC	  treated	  PC3	  cells.	  
Cells	  were	   seeded	  72	  h	  post	   reverse	   siRNA	   transfection	   in	  96-­‐well	   tissue	  culture	  plates	  and	   imaged	  at	  10	  x	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Supplementary	  figure	  4:	  Phase	  contrast	  images	  of	  siITGB1	  treated	  PC3	  cells.	  
Cells	  were	   seeded	  72	  h	  post	   reverse	   siRNA	   transfection	   in	  96-­‐well	   tissue	  culture	  plates	  and	   imaged	  at	  10	  x	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Supplementary	  figure	  5:	  Phase	  contrast	  images	  of	  siITGB3	  treated	  PC3	  cells.	  
Cells	  were	   seeded	  72	  h	  post	   reverse	   siRNA	   transfection	   in	  96-­‐well	   tissue	  culture	  plates	  and	   imaged	  at	  10	  x	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Supplementary	  figure	  6:	  Phase	  contrast	  images	  of	  siITGB6	  treated	  PC3	  cells.	  
Cells	  were	   seeded	  72	  h	  post	   reverse	   siRNA	   transfection	   in	  96-­‐well	   tissue	  culture	  plates	  and	   imaged	  at	  10	  x	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Supplementary	  figure	  7:	  Phase	  contrast	  images	  of	  siITGB7	  treated	  PC3	  cells.	  
Cells	  were	   seeded	  72	  h	  post	   reverse	   siRNA	   transfection	   in	  96-­‐well	   tissue	  culture	  plates	  and	   imaged	  at	  10	  x	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Supplementary	  figure	  8:	  Phase	  contrast	  images	  of	  siITGB8	  treated	  PC3	  cells.	  
Cells	  were	   seeded	  72	  h	  post	   reverse	   siRNA	   transfection	   in	  96-­‐well	   tissue	  culture	  plates	  and	   imaged	  at	  10	  x	  
magnification	  2	  h	  (A),	  4	  h	  (B),	  8	  h	  (C)	  and	  12	  h	  (D)	  after	  seeding.	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